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Abstract 
The increasing emergence of drug-resistant pathogens poses a major threat to public health. 
Although influenced by multiple factors, resistance is often associated with mutations in 
drug target-encoding or associated genes. The potential fitness cost of such resistance 
mutations is, in turn, a key determinant of the spread of drug-resistant strains. Rifampicin 
(RIF) is a frontline anti-tuberculosis agent that targets the rpoB-encoded β-subunit of the 
DNA-dependent RNA polymerase (RNAP). RIF resistance (RIFR) maps primarily to mutations 
in rpoB that might be expected to affect transcription and so the ability of the organism to 
cause disease. Accordingly, numerous studies have assessed the impact of RIFR on key 
fitness indicators in pathogens including Mycobacterium tuberculosis (MTB). In contrast, the 
specific consequences of RIFR for bacterial physiology remain poorly understood. Notably, 
previous studies of the effects of RIFR-associated rpoB mutations on mycobacterial 
physiology have been conducted using strains generated by RIF exposure, without 
accounting for the potential impact of second-site mutations that may compensate for 
fitness costs or contribute to drug resistance. In this study, site-directed mutagenesis and 
allelic exchange were employed to generate a panel of M. smegmatis (MSM) strains 
containing clinically-relevant RIFR-associated point mutations. Importantly, this 
methodology enables the introduction of rpoB mutations into defined strain backgrounds in 
the complete absence of RIF. Using this approach, we constructed “RIF naive” MSM rpoB 
mutant strains carrying either an S531L or H526Y mutation. The resulting mutants were 100-
fold less susceptible to RIF than the isogenic, parental strain. Notably, the inclusion of 
selected efflux inhibitors in susceptibility assays had little impact on mutant susceptibility to 
RIF. In contrast, restoration of the wild-type allele returned the observed susceptibility to 
parental levels, thereby providing strong evidence of the sufficiency of a single rpoB 
mutation for clinical RIFR in mycobacteria. Competitive growth assays utilizing the S531L 
mutant and the parental strain exposed a growth defect for the S531L mutant. However, 
discriminating between wild-type and mutant rpoB strains proved a significant technical 
challenge, again highlighting the difficulties associated with inferring in vivo fitness from in 
vitro assays conducted under a limited number of different conditions. In summary, our 
results suggest the benefit of a deeper exploration of the physiological and fitness 
implications of RIFR-associated mutations. In addition, in coupling a system which enables an 
evaluation of the physiological consequences of drug resistance-associated mutations with 
evolutionary analyses, we provide preliminary evidence of the benefits of a multipronged 
approach to elucidating the physiological implications of drug resistance in MTB. 
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A scientist in his/her laboratory is not only a technician: (s)he is 
also a child placed before natural phenomena which impress 
him/her like a fairy tale. 
- Marie Curie 
 
It’s not courage if you’re not scared; it’s not faith if you don’t 
doubt 
- Anonymous 
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1. Introduction 
1.1 Tuberculosis 
Tuberculosis (TB) is responsible for 1.8 million deaths annually (WHO, 2009). The causative 
agent of this devastating disease, Mycobacterium tuberculosis (MTB), is a gram positive, 
facultative anaerobe that is dependent on its human host for survival (Daffe & Etienne, 
1999). The obligatory requirement for the human host means that physiological processes 
important for survival are also essentially virulence properties. Remarkably, it is estimated 
that up to one third of the world’s population is infected by this highly successful pathogen 
(Zhang, 2005), however not all of these infections result in active disease. The risk of 
developing active disease in infected individuals is fundamentally dependent on the immune 
status of the individual and is distinguished by intricate interactions between MTB and host 
immune cells (Peyron et al., 2008). Most immunocompetent individuals are able to control 
infection successfully, but this does not always result in complete clearance of MTB cells and 
the bacilli can persist in a poorly understood dormant state for extended periods (Stewart et 
al., 2003).  
 
MTB is inhaled into the lungs and, once in the alveoli, internalized by lung macrophages 
(Peyron et al., 2008). An accumulation of macrophages, dendritic cells and lymphocytes is 
triggered, which results in granuloma formation (Peyron et al., 2008). In healthy individuals, 
the interplay between MTB and host cellular and adaptive immune cells results in 
asymptomatic infection as granulomas separate MTB cells from the surrounding tissue 
(Peyron et al., 2008), and a state of latency ensues (Stewart et al., 2003). The ability of MTB 
to interact with – and manipulate – host immune functions allows latent infection to 
endure. Traditionally it was thought that granulomas were protective against TB, but a 
recent report indicates that MTB may actually recruit immune cells to form granulomas, 
wherein the bacilli are able to persist in a protected environment until conditions are 
favorable for reactivation (Davis & Ramakrishnan, 2009). The precise physiological state of 
bacilli in latent TB infection (LTBI) is unknown. Latency describes TB with no symptoms of 
active disease and MTB cells during this state are often referred to as dormant (Rustad, 
2008), or existing in a non-replicative state. However, a recent study indicates that 
replication is in fact taking place during latent stages of MTB infection, at least in a mouse 
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model (Gill et al., 2009). It is thought that host immune functions keep dormant 
mycobacteria in a state of slow growth and reduced metabolism (Boshoff, 2008). 
Conceivably, a kind of equilibrium is attained (Scanga & Flynn, 2010). Reactivation of MTB 
infection can occur if the host immune system is suppressed and the granuloma structure is 
compromised, thus allowing MTB cells to escape and begin actively replicating. 
Immunocompetent individuals infected with MTB have a 10 % chance of developing active 
TB within their lifetime however co-infection with HIV increases this risk to 10 % per year 
(Rustad, 2008). Developing countries bear the brunt of the TB burden, with overcrowding, 
malnutrition, and HIV as the biggest risk factors for MTB infection. Unfortunately, these 
regions have the fewest resources to manage this treatable, but deadly disease. 
 
1.2 Drug resistance in mycobacteria 
The serendipitous discovery of penicillin, and subsequently other classes of antibiotics, 
revolutionized treatment of infectious diseases (Cars et al., 2008). Of great consequence 
was the ability to manage TB which was once the blight of industrialized nations (Zumla et 
al., 2009). Microbes have developed resistance to almost every antibiotic that has reached 
mainstream use and in recent times, there has been a notable increase in the prevalence of 
antibiotic resistant pathogens (Cars et al., 2008, Martinez et al., 2009). Unfortunately, TB is 
no exception, and the sharp increase in the emergence of drug-resistant MTB strains 
threatens to thwart progress made by chemotherapeutic control.  
 
According to The World Health Organisation (WHO) almost 500 000 people develop 
multidrug-resistant TB (MDR-TB) every year (WHO, 2009). This form of TB is highly resistant 
to conventional front-line drugs and places additional strain on public health care systems. 
MDR-TB is defined as disease resulting from MTB infection by strains that are resistant to 
frontline TB drugs, isoniazid (INH) and rifampicin (RIF) (Gagneux, 2006c). Treatment for drug 
sensitive TB is less than optimal, partly because the onerous 6 month treatment period 
leads to noncompliance, especially as patients start feeling better. MDR-TB treatment 
regimens are even longer, and the drugs used more expensive and associated with 
extensive side-effects. Interruption of treatment is one of the factors which allow for the 
development and maintenance of drug-resistant MTB strains; however, biological factors 
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are likely to play a significant role as well (Warner & Mizrahi, 2006). Worryingly, extensively 
drug-resistant TB (XDR-TB) cases are at their highest levels ever (Jassal & Bishai, 2009). 
These strains are resistant to INH, RIF, one of the flouroquinolones, and at least one of the 
injectable second line antibiotics (Jassal & Bishai, 2009). The load is especially devastating in 
countries where the burden of TB is highest and health care systems are already struggling 
to manage drug-susceptible TB, as well as other infectious diseases such as HIV and malaria. 
XDR-TB gained notoriety after a deadly outbreak in the Tugela Ferry region in KwaZulu-
Natal, South Africa (Gandhi et al., 2006). South Africa reported 16 000 cases of MDR-TB in 
2007 (WHO, 2009). A recent study at a separate KwaZulu-Natal hospital revealed that 50 % 
of decedents had culture positive TB at the time of death, 94 % were HIV+ and, alarmingly, 
17 % of TB cases were classified as MDR (Cohen et al., 2010). These numbers illustrate the 
deadly co-association between TB and HIV and emphasize the need for a better 
understanding of the factors that contribute to the spread of MDR-TB with a view, 
ultimately, to the development of better HIV/TB management strategies (Kaufmann & 
Walker, 2009). 
 
Many organisms possess intrinsic features that reduce their susceptibility to antibiotics, 
such as the ability to form biofilms (Donlan & Costerton, 2002) or permeability barriers 
(Nikaido, 1994, Nikaido, 2001, Martinez et al., 2009). However, these are tolerance 
mechanisms and should be differentiated from antibiotic resistance which instead denotes 
the heritable acquisition (by horizontal gene transfer or mutations in target or related genes 
(Martinez et al., 2009)) of the ability to withstand exposure to antibiotics at therapeutic 
concentrations. In many bacteria, drug resistance determinants are carried on mobile 
genetic elements. In contrast, the emergence of drug resistance in MTB is distinctive in that 
resistance is associated with point mutations and chromosomal rearrangements (Mariam et 
al., 2004, Gillespie, 2002, Gagneux, 2009, Gagneux et al., 2006c), a feature that results in 
part from the ecological isolation of MTB (within granulomas) during host infection 
(Gillespie, 2002). Contrary to some other bacterial and mycobacterial species (Stinear et al., 
2004), MTB does not possess plasmids (Derbyshire & Bardarov, 2000): very little, if any, 
evidence exists for horizontal gene transfer in the MTB complex (Smith et al., 2009), and 
genetic drift is primarily responsible for diversification and adaptation of this group of 
organisms (Hershberg et al., 2008). Although the absence of gene transfer is a defining 
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characteristic of MTB, the propensity to develop chromosomal mutations associated with 
drug resistance is not limited to mycobacteria and, in several common pathogens high level 
resistance is associated with mutations in target genes. 
 
Various factors contribute to the spread of MDR disease (Borrell & Gagneux, 2009) and 
public health and socio-economic issues have been relatively well explored. In contrast, 
information on the intrinsic biological aspects is lacking.  We are particularly interested in 
the physiological effects of drug resistance-associated mutations in mycobacterial species. 
In this project we focus on RIF, a frontline anti-tubercular agent whose target is a global 
transcriptional regulator, and so might increase the possibility of drug-independent effects 
of resistance-associated mutations. The discussion that follows features the structural and 
physiological consequences of RIF resistance (RIFR) associated rpoB mutations – 
contextualized by what is known about RIFR in MTB and the consequences for TB 
management. 
 
1.3 RIF: Significance and mechanism of action 
RIF diffuses relatively well through tissue and cell membranes which makes it a useful 
antibiotic in the treatment of bacterial infection (Campbell et al., 2001). Many antibiotics 
require active growth and metabolism to kill bacteria (Lipsitch & Levin, 1997). This is 
especially pertinent for MTB, which has a penchant for long-term survival in the host. Within 
the macrophage phagosomal environment bacilli – faced by a myriad of stresses (host 
immune function, nutrient stress and hypoxia (Schnappinger et al., 2003) – adapt to an 
altered, low metabolic state (Connolly et al., 2007). The importance of RIF is therefore 
established by its efficacy in sterilizing slowly metabolising persister populations (Mitchison, 
2000).  
 
RNA transcription is an essential constituent of genetic regulation, and is disrupted by RIF. In 
a tight complementary fit, RIF binds to the β-subunit of RNA polymerase (RNAP), close to 
the DNA/RNA channel (Campbell et al., 2001). Eukaryotic RNAP enzymes comprise up to 14 
subunits with a molecular weight of ~500kDa (Adekambi et al., 2009, Borukhov & Nudler, 
2008, Lane & Darst, 2010a, Lane & Darst, 2010b). Bacteria possess a simpler variant, with a 
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core structure comprising α, β, β’and ω subunits; upon binding of a specific σ factor the 
functional holoenzyme is generated (Adekambi et al., 2009, Campbell et al., 2002, Zhang et 
al., 1999). RNAPs exhibit high levels of conservation, with the large subunits (β and β’; 
encoded by rpoB and rpoC respectively) the most highly conserved among organisms in all 
divisions of life (Adekambi et al., 2009, Lane & Darst, 2010a, Lane & Darst, 2010b, Werner & 
Grohmann, 2011). The high level of evolutionary relatedness between RNAPs indicates the 
importance of this enzyme for gene expression and establishes bacterial RNAP as a useful 
tool in the study of transcriptional processes (Campbell et al., 2001, Adekambi et al., 2008, 
Adekambi et al., 2009).  
 
The crystal structure of core RNAP from Thermus aquaticus in complex with a RIF molecule 
reveals that the closest RIF gets to the active site of RNAP is 12.1 Å (Campbell et al., 2001). 
Consequently, it appears that RIF does not inhibit transcription by directly binding to the 
RNAP active site. Instead, it is widely accepted that RIF inhibits initial events in transcription, 
although structural studies indicate that RIF does not directly obstruct specific promoter 
binding nor open complex formation nor formation of the first phosphodiester bond 
(Campbell et al., 2001). Results from the T. aquaticus model suggest that RIF creates a steric 
clash between the phosphate group of the subsequent 5’ nucleotide and in this way 
prevents bond formation between the second and third ribonucleotide triphosphates in a 
growing transcript. That is, RIF effectively “plugs” the exit site of the growing RNA strand, 
preventing chain elongation and thereby halting transcription (Campbell et al., 2001). The 
first phosphodiester bond can, however, be formed; therefore RIF does not impede catalytic 
activity, substrate binding or the translocation properties of RNAP. The initial phase of RNA 
synthesis is referred to as abortive transcription, whereby short RNA transcripts are 
synthesized, released and re-synthesized. The precise mechanisms are not well-defined, but 
this process is important for promoter escape and progression to the elongation phase of 
transcription (Werner & Grohmann, 2011, Borukhov & Nudler, 2008, Borukhov & Nudler, 
2003). Notably, when an RNA chain longer than 3 – 5 nt has been formed, RIF is no longer 
able to inhibit transcription – possibly because longer chains prevent RIF binding (Campbell 
et al., 2001). It is therefore possible, that by preventing bond formation in early 
transcription, RIF interrupts the abortive cycling process, thus scuppering another important 
mechanistic transcriptional process.  
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Biochemical evidence indicates that the binding affinity of RIF for T. aquaticus RNAP is much 
lower than to that of Escherichia coli (Campbell et al., 2001), which results in higher RIF 
concentrations being required to inhibit T. aquaticus RNAP. Furthermore, a recent analysis 
of the sequence – and, in a related study, the structure – of almost all available bacterial 
RNAPs revealed that small, lineage-specific insertions have important consequences for 
RNAP regulation and function (Lane & Darst, 2010a, Lane & Darst, 2010b). Therefore while 
RNAP is highly conserved among prokaryotes, structural and functional comparisons of 
RNAPs from different organisms must be made with prudence (Kuznedelov & Severinov, 
2009). Given the global increase in MDR-TB, it is critical that the precise mechanisms of 
interaction between RIF and MTB RNAP are identified. This may yield insights into how RIF 
can be derivitised to improve activity against MTB.  
 
An RNAP holoenzyme is formed – and transcription is initiated – when an appropriate σ 
subunit binds the core enzyme and induces significant conformational changes (Murakami 
et al., 2002a; Murakami et al., 2002b). By directly binding to promoter elements, σ factors 
guide transcription initiation from appropriate DNA templates. Double stranded DNA at the 
σ binding site is melted, and a transcriptional bubble is formed (Murakami et al., 2002a; 
Murakami et al., 2002b; Borukhov et al., 2003). To accomplish this, the housekeeping σ 
factor of E. coli, σ70, uses free energy and thermal fluctuations that accumulate during RNAP 
conformational shifting (Borukhov et al., 2008). Interestingly, eukaryotic and some 
alternative bacterial σ factors use energy released by ATP hydrolysis to facilitate the 
process. As a result of DNA unwinding, a stable open promoter complex is formed which 
allows initial RNA synthesis to begin (Borukhov et al., 2003). Although direct interactions 
with core RNAP primarily occur via the β’ subunit, the β subunit is also important for σ 
factor binding (Murakami et al., 2002b; Nickels et al., 2005). The initial phase of RNA 
synthesis is referred to as abortive transcription, whereby short RNA transcripts are 
synthesized, released and re-synthesized (Murakami et al., 2002a; Nickels et al., 2005; 
Borukhov et al., 2008; Goldman et al., 2009). Competition for chemical space between the σ 
subunit and the newly synthesised RNA chain facilitates σ dissociation from the core RNAP 
enzyme, which is generally – but not always – required for progression to elongation phase 
(Murakami et al., 2002b; Nickels et al., 2005; Borukhov et al., 2008). Principle σ factors 
regulate the expression of housekeeping genes, and show significant homology to the E. coli 
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σ70 subunit – in mycobacteria this σ factor is encoded by sigA (Wu et al., 2004). Bacteria 
have varying numbers of alternative σ factors, which selectively bind to promoters to 
express genes important for adaptation to a particular set of environmental stimuli 
(Campbell et al., 2002; Borukhov et al., 2003). 
 
Traditionally, studies examining transcriptional processes made use of RIF as a 
transcriptional inhibitor. These studies revealed that mutations associated with RIFR result in 
differential σ unit binding, as well as distinct promoter binding (Glass et al., 1986a, Glass et 
al., 1986b, Nomura et al., 1984). Furthermore, in E. coli higher concentrations of RIF are 
needed to inhibit transcription from σ70- versus σ32- dependent promoters (Wegrzyn et al., 
1998). Alternative σ factors may induce different conformational changes upon RNAP 
binding (Scott et al., 2000, Wegrzyn et al., 1998), therefore it is intriguing to consider the 
implications of these changes for RIF binding and transcriptional inhibition. A recent 
investigation in MTB indicates that RIF-mediated inhibition of transcription is similar for σA 
and σF containing RNAP, and that over-expression of σF does not contribute to tolerance of 
RIF (Hartkoorn et al., 2010). However, increased expression of σE was observed in a clinical 
MTB strain carrying an S531L mutation. Moreover, increased σE expression correlated with 
increased ability to grow in the presence of INH. Upon σ factor binding, the β subunit region 
containing the RRDR is proximal to several parts of the σ factor (Owens et al., 1998; 
Murakami et al., 2002a; Nickels et al., 2005). It is plausible that RIFR-associated mutations 
may mediate binding of alternative σ factors that increase expression of genes involved in 
INHR and in this way facilitate INHR (Evans et al., 2011, submitted). This highlights the 
possibility that specific rpoB mutations may encourage INH resistance (INHR), and may 
explain why RIF mono-resistance is infrequently observed in the clinical setting (Evans et al., 
submitted). 
 
1.4 RIF resistance:  RIFR-associated mutations in rpoB 
RIFR-associated mutations were originally mapped in E. coli and provided a means for 
examining mechanistic aspects of transcription (Jin & Gross, 1988). These mutations are 
found in cluster I, II and III of the rpoB gene (Campbell et al., 2001). In all bacterial species 
examined, a large proportion of RIFR-associated mutations occur in the RIF Resistance 
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Determining Region (RRDR) – a 81bp region which forms part of cluster I of the rpoB gene 
(Ramaswamy & Musser, 1998, Jin & Gross, 1988) (Figure 1). Nonetheless, mutations in other 
regions of the rpoB gene have been observed (Heep et al., 2001, Heep et al., 2000a). Not all 
RIFR MTB strains contain mutations in rpoB (Telenti et al., 1993, Ramaswamy & Musser, 
1998), and some organisms have additional mechanisms of RIFR (Quan et al., 1997, Newell et 
al., 2006).  Hence, throughout this document, these mutations are referred to as “RIFR-
associated” mutations, or equivalent. Unambiguous genetic analysis of the role of rpoB 
mutations in RIFR represents one of the primary aims of this project; in particular, the need 
to address definitively the sufficiency of rpoB mutations for RIFR. 
 
Alternative mechanisms of resistance to common anti-TB chemotherapeutics have immense 
impact for public health strategies to control MDR-TB. Recently, the WHO approved the use 
of molecular diagnostic kits for diagnosis of MDR-TB. These kits rely on detection of a 
limited number of common drug resistance-associated mutations, particularly those 
associated with RIFR. The tests are not exhaustive, and only the most frequently observed 
RIFR-associated mutations are incorporated in the test. There may be other mutations in 
rpoB (or the RRDR) that contribute to RIFR (Heep et al., 2001, Heep et al., 2000b), or other 
physiological mechanisms that contribute to RIFR. A strain that is resistant to RIF but does 
not carry the specific mutations detected by the test, could be misdiagnosed and spread in 
the community. Cognizance of mechanisms of drug resistance, other than common point 
mutations, is essential when diagnosing drug-resistant TB, and developing public health 
control strategies.  
 
Examination of clinical MTB isolates from various geographical regions indicates that certain 
RIFR-associated mutations in rpoB occur more frequently than others. Moreover, a thorough 
analysis of the literature reveals the most – as well as the least – common mutations 
associated with both laboratory-derived and clinical RIFR MTB isolates (see Results: section 
3.1). Additionally, a database has been set up to document clinically observed RIFR MTB 
mutations (Sandgren et al., 2009). The RRDRs of four common bacterial pathogens are 
illustrated in Figure 1, which also provides the opportunity to compare this region. The 
RRDR was originally defined in E. coli, therefore, as per standard practice amino acid 
numbering corresponds to that of the E. coli sequence (Telenti et al., 1993). The most 
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common mutation associated with RIFR in MTB is a mutation at codon 531 of the rpoB gene 
(Sandgren et al., 2009). In RIFS strains, a serine residue is encoded at position 531; in RIFR 
strains, a transition mutation (tcg→ttg) results in a leucine in this site (Ramaswamy & 
Musser, 1998). Notably this and another common mutation, H526Y (cac→tac), are both 
cytosine to thymine transitions (Mokrousov, 2004). Spontaneous cytosine deamination to 
uracil occurs readily in all cells; however, MTB is thought to be especially susceptible to 
deamination (Warner, 2010) as a result of exposure to reactive oxygen and nitrogen 
intermediates (ROI and RNI) which form part of the host defence against TB infection 
(Mokrousov, 2004).  
 
Of twelve amino acids that surround the RIF binding pocket, eleven mutate in association 
with RIFR – albeit at different frequency. The RRDR is highly conserved between bacteria, but 
shows lower levels of relatedness to archaebacterial and eukaryotic RNAP; this and the fact 
that RIFR-associated mutations are common in this region, imply that this region is not 
essential for RNAP function, but that only certain changes might be tolerated (Campbell et 
al., 2001). The only amino acid which interacts with RIF but for which RIFR-associated 
mutations have not been observed is E565, which lies outside the RRDR. This residue is 
highly conserved across all orders of life, therefore mutations at this site may not be viable 
(Campbell et al., 2001). Since examination of RIFR-associated rpoB sequence is often limited 
to the RRDR, it’s possible that mutations at the E565 site may have been overlooked 
(Campbell et al., 2001). M. smegmatis (MSM) strains containing a 30 bp deletion within the 
RRDR have been isolated on multiple occasions at the MMRU in response to UV treatment 
and starvation (Digby Warner, unpublished work). In a separate study, RNAP from an 
analogous MSM strain was found to be highly recalcitrant to RIF-mediated inhibition 
(Malshetty et al., 2010). Viability of MSM strains with a large deletion in rpoB supports the 
notion that this region is dispensable for RNAP function. Nevertheless, there may be 
significant physiological consequences for the loss of this region. Interestingly, RIFR-
associated substitutions always involve a change from a residue with a compact side chain 
to an amino acid with a more cumbersome one – or involve the addition or removal of a 
proline residue (Campbell et al., 2001). The frequently isolated S531 and H526 residues are 
directly involved with hydrogen bonding to RIF (Campbell et al., 2001).  
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Siddiqi et al. (2002) identified silent mutations in a fraction of clinical strains isolated in 
India. These mutations are noteworthy since they do not result in amino acid substitutions 
but were associated with RIFR (Siddiqi et al., 2002). Only the RRDR was sequenced; 
therefore, it is possible that factors other than mutations in the RDDR region contributed to 
RIFR in these strains. Moreover, if this mutation were also found in susceptible strains, it 
would indicate that it is a phylogenetic marker and is not involved in RIFR. However, if silent 
mutations are in fact associated with high level RIFR, it is a fascinating and important area 
that warrants further study. 
 
Using the crystal structure of T. aquaticus RNAP (Campbell et al., 2001) as a modelling 
scaffold, the structural consequences of RIFR-associated mutations in Staphylococcus aureus 
(O'Neill et al., 2006) and, more recently, MSM (Malshetty et al., 2010) were elucidated. 
These studies reveal that structural determinants and perturbations of RNAP structure as a 
result of RIFR-associated mutations are generally consistent with experimental evidence 
(O'Neill et al., 2006, Malshetty et al., 2010). However, in silico modelling data must be 
interpreted with caution, since the quality of the model is dependent on the crystal 
structure upon which it is built. In E. coli RIFR-associated mutations are known to have 
pleiotropic consequences for transcriptional mechanisms of elongation, pausing and 
termination (Jin et al., 1988, Jin & Gross, 1991). For example, in Bacillus subtilis, a mutation 
to a basic residue at the Q513 position increases auto(de)regulation of NusG, and 
consequently increases termination (Ingham et al., 2000). NusG is an important 
transcriptional elongation factor and deletion of this gene in E. coli is lethal. Early reports 
revealed accelerated elongation when NusG was over-expressed in E. coli, leading to the 
suggestion that NusG acts by suppressing termination (Burova et al., 1995a; Burova et al., 
1995b). However, NusG has been shown to enhance transcriptional pausing in B. subtilis 
(Yakhnin et al., 2008). NusG can have differential effects on transcription when examined in 
vitro, and this presents a difficulty for defining the nature of NusG function and regulation 
(Yakhnin et al., 2008). On the whole, the specific function of NusG is dependent on the 
organism; the specific operon under investigation and it’s interaction with other 
transcriptional factors (Borukhov et al., 2005). In B. subtilis transcription of the nusG operon 
is regulated by the NusG protein. Mutations in rpoB analogous to those found in RIFR 
mycobacteria promoted NusG-mediated repression of nusG transcription, thus decreasing 
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the availability of NusG for resolution of paused RNAP complexes (Ingham et al., 2000) 
Given the importance of all the aforementioned processes for cell functionality, the 
implications of rpoB mutations are likely to be broader than merely inhibition of RIF binding. 
If RIFR-associated mutations trigger severe impairments to RNAP structure and function, one 
would be compelled to consider whether and what mutations in associated genes are 
alleviating these costs, given that fitness costs are negligible in some clinical isolates 
(Gagneux et al., 2006b).   
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1.5 Additional mechanisms of RIFR 
A variety of distinct point mutations have been documented which, in most cases, result 
in single amino acid substitutions that are associated with widespread RIFR. Culture-based 
susceptibility testing techniques can yield highly discordant results (Van Deun et al., 
2009) and susceptibility breakpoints, the concentration of a drug above which a strain is 
defined as drug-resistant, may be too low (Gumbo, 2010). Therefore the WHO has 
approved the use of rapid diagnostic tests based on molecular identification of common 
RIFR-associated mutations (Uys et al., 2009). Although the majority of clinical RIFR MTB 
isolates contain mutations in the RRDR region, it has been estimated that 5% exhibit high 
level RIFR without evidence of mutations in the RRDR or the rest of the rpoB gene 
(Ramaswamy & Musser, 1998, Telenti et al., 1993). If a strain that is resistant to RIF does 
not have any mutations in the RRDR, its susceptibility profile will be misinterpreted, 
which may lead to elevated dissemination of this strain. It is crucial that we gain a better 
understanding of just how tightly rpoB point mutations are associated with RIFR. For 
other anti-TB drugs, the proportion of strains without identifiable target mutations is 
even higher (for example, only 30 – 68 % of ethambutol resistant (EMBR) isolates contain 
target-associated mutations (Safi et al., 2010)) and molecular diagnostics for other anti-
TB drugs may therefore be even more inefficient. The ability of isolates without 
Figure 1.1 The RRDR of a selection of pathogenic bacteria.  
Mutations in the RRDR of distinct bacterial species were ascertained from relevant clinical 
and lab based publications (indicated in brackets after organism names). Wild-type 
sequences were downloaded from the NCBI protein database 
(http://www.ncbi.nlm.nih.gov/guide/proteins/) and are indicated in caps. There were 
some discrepancies between codon numbering as stated in specific publications and 
numbering as indicated in the NBCI protein database, however sequences were aligned, 
and numbered according to the publication. In text amino acid numbering is referred to as 
defined in E. coli (Telenti et al., 1993) however, species specific numbering is shown in the 
figure for comparison. Organism abbreviations and NCBI accession numbers are as follows 
ECO: E. coli K12 subtr. MG1655 (NP_418414.1) (Jin & Gross, 1988, Garibyan et al., 2003, 
Reynolds, 2000); MTB: M. tuberculosis H37Rv (GenBank: AAA20242.2) (Telenti et al., 1993, 
Ramaswamy & Musser, 1998, Williams et al., 1998); SAU: S. aureus subsp. aureus ED98 
(YP_003281434.1) (O'Neill et al., 2006, O'Neill et al., 2000, Wichelhaus et al., 2002); BSU: 
B. subtilis ssubsp. Subtilis str 168 (ZP_03589766.1) (Nicholson & Maughan, 2002, Inaoka et 
al., 2004). 
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identifiable target mutations to remain viable under high concentrations of RIF calls for a 
deeper understanding of the mechanisms involved.  
 
Like most bacterial species, mycobacteria have intrinsic mechanisms by which to 
generate drug resistance. The waxy cell wall of mycobacteria confers a barrier to influx of 
toxic compounds, and provides a significant challenge to the development of new TB 
chemotherapeutics (Louw et al., 2009). One inherent resistance mechanism in MSM to  
RIF was shown to be a result of ribosylation of RIF (Quan et al., 1997) and certain Bacillus 
and Nocardia species also have enzymatic mechanisms that deactivate RIF by modifying 
its chemical structure (Tupin et al., 2010). Moreover, proteins that bind to RNAP, such as 
RpbA in Streptomyces coelicolor and MsRpbA in MSM, confer some levels of RIFR 
(Malshetty et al., 2010, Newell et al., 2006). However, MTB is killed at 100-fold lower 
concentrations of RIF than MSM (Alexander et al., 2003, Changsen et al., 2003, Piddock et 
al., 2000), and there is little evidence of the same drug detoxifying mechanism in this 
pathogen. Interestingly, a recent investigation of the mutational profile of MTB to 
TMC207 (one of the most promising new TB therapeutic in the last 40 years) revealed 
that only 28 % of resistant isolates had mutations in the known target (Huitric et al., 
2010). The lack of mutations in the known target may indicate that there is more than 
one target for this drug, or that alternative mechanisms are involved in resistance 
development. A better understanding of alternative mechanisms for drug resistance is 
crucial if the efficacy of new (and old) chemotherapeutic regimens is to be preserved. 
 
1.5.1 Efflux-mediated drug resistance 
Analysis of the mycobacterial genome indicates that there are several putative drug 
exporters (Louw et al., 2009), none of which has been thoroughly characterized 
(Reviewed in (Louw et al., 2009) and (Viveiros et al., 2003)). A recent model which 
considers the development of drug resistance suggests that efflux systems may “prime” 
bacteria to acquire resistance-associated mutations (Fange et al., 2009). Indeed, some of 
features of this model have been demonstrated experimentally using the macrolide 
antibiotic, erythromycin (ERM) (Lovmar et al., 2009, Moore & Sauer, 2008). The authors 
of the latter report offer a different explanation, however: specifically, that erythromycin 
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resistance (ERMR)-associated ribosomal mutations alter translation of cell wall proteins, 
thereby reducing the intracellular concentration of ERM (Moore & Sauer, 2008). 
Nevertheless both studies imply that the acquisition of target mutations that decrease 
drug-target binding affinity is not enough to confer high level drug resistance that is 
observed in clinical settings. Notably, a clinical MTB strain belonging to the W Beijing 
family was shown to have increased efflux in response to RIF and INH (Jiang et al., 2008). 
Phenothiazine compounds, chlorpromazine and thioridazine, are suggested to have 
clinically relevant anti-mycobacterial possibilities. It has been proposed that these 
compounds function by inhibiting bacterial efflux (Amaral et al., 2008, Viveiros et al., 
2003); however, transcriptional responses of MTB to these compounds indicate that 
respiratory systems are inhibited (Boshoff et al., 2004, Weinstein et al., 2005, Yano et al., 
2006). The interplay between efflux and target mutations is of great relevance to 
elucidating the mechanisms of drug resistance and for contemporary TB control 
measures. For example, recent experimental evidence demonstrates that mutations 
commonly observed in clinical EMBR MTB strains to confer lower levels of resistance 
when introduced to susceptible strains via homologous recombination (Safi et al., 2010). 
This recapitulates the idea that target mutations, on their own, are unable to generate 
the high level resistance seen in clinical environments. 
 
1.5.2 Compensatory mutation? 
A compensatory mutation could be broadly defined as a mutation which reverses the 
deleterious effect of a distinct mutation or restores some functional or structural 
characteristic (Wilke et al., 2003).  Genetic background can have significant effects on 
observed fitness of strains containing drug resistance-associated mutations (Gagneux et 
al., 2006a, Gagneux et al., 2006b). Off-site mutations that distinguish one bacterial strain 
from another may be neutral without any implication for physiology or resistance. If 
these mutations restore function or repair the deleterious effects of a separate mutation, 
they could be referred to as compensatory. It’s important to note, that development of a 
compensatory mutation (as defined above) does not necessarily happen after the 
development of a resistance-associated mutation. Mutations may exist that predispose 
the development of drug resistance, by compensating for the structural or functional 
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consequence the target mutation might have, or by acting synergistically to increase 
resistance. Physiological effects of pre-existing mutations may result in the association of 
strain lineages with distinct drug resistance-associated mutations. 
 
Compensatory mutation also has a bearing on the reversibility of drug resistance-
associated mutation (Trindade et al., 2009, Weinreich et al., 2005). Streptomycin 
resistant (STRR) Salmonella typhimurium strains develop secondary mutations that 
ameliorate functional disadvantages that result from the original mutation (Bjorkman et 
al., 1998, Bjorkman et al., 1999). Moreover, the type of compensatory mutation observed 
was subject to the infection model used; that is, growth in a mouse model produced a 
different spectrum of compensatory mutations than in vitro growth (Bjorkman et al., 
1998, Bjorkman et al., 1999). Recently, Barrick et al. (2010) showed that, in E. coli, the 
advantage of a beneficial mutation is much greater for rpoB mutants in which fitness is 
already attenuated. That is, the lower the fitness, the more advantageous a beneficial 
mutation. Moreover, evolvability is in turn increased in rpoB mutants compared to an 
isogenic reference strain.  Although this evolution does not always restore fitness to wild-
type levels, some form of compensatory mutation is occurring; notably, reversion to wild-
type rpoB was not observed after 640 generations in RIF free medium (Barrick et al., 
2010). These experimental findings support theoretical models by Levin et al. (2000) 
which postulate that, if compensatory mutations occur during pathogen infection, and 
are fixed, an “adaptive valley” will result which will make reversion to susceptibility 
almost impossible – even if antibiotics are completely removed. However, a more recent 
theoretical framework proposed by Schulz Zur Weisch et al. (2010) suggests it may not be 
so simple. This model predicts that persistence of both antibiotic resistance and 
compensatory mutations depends on the advantages (and disadvantages) they confer in 
the presence or absence of drug. Furthermore, that the rate at which bacteria are killed is 
a key parameter in the probability of reversion – bacteria that are more easily killed 
(either as a result of fitness defects or of antibiotic action) are more likely to revert to 
susceptibility (Schulz Zur Wiesch et al., 2010).  
 
A recent investigation into the epistatic effects of sequential antibiotic resistance 
mutations in E. coli uncovered alarming degrees of positive epistasis between genes 
 17 
 
associated with resistance to STR, RIF and Nalidaxic acid (Trindade et al., 2009). 
Interestingly, epistasis was allele-specific, rather than gene specific (Trindade et al., 
2009). Predating the abovementioned study, Chakrabarti et al. (1977) observed 
physiological effects conferred by RIFR-associated mutations that are dependent on 
corresponding STRR-associated mutations (Chakrabarti & Gorini, 1975, Chakrabarti & 
Gorini, 1977). Further evidence for possible epistatic effects of drug resistance-associated 
mutations comes from a recent study which shows that sublethal concentrations of 
ribosome inhibiting agents, STR and chloramphenicol, reduce fitness costs associated 
with RIFR-associated mutations in Pseudomonas aeruginosa, while treatment with drugs 
that have other targets did not (Hall et al., 2011). The authors suggest that transcription 
and translation are linearly related and therefore decreased requirements for RNAP 
diminishes fitness costs that may be incurred by RIFR-associated mutations. A STRR-
associated mutation in rpsL that diminishes ribosome functionality may have similar 
effects (Hall et al., 2011). It would be interesting however to examine whether inhibition 
of RNAP lessens fitness costs that may be associated with STRR-associated mutations. 
Epistasis has significant consequences for drug design, particularly because enzymes in 
these key pathways are common targets for drug development. If the target of a novel 
drug is known, and the spectrum of mutations that may cause resistance are modelled 
(Cao et al., 2005), the level of epistasis between these alleles and existing resistance 
alleles could be examined. If high levels of positive epistasis are observed, the usefulness 
of the new drug in treating resistant disease is diminished. Compensation of the fitness 
costs associated with a RIFR-associated mutation by, for example, a STRR-associated 
mutation would have devastating consequences for MDR-TB control. If this is occurring in 
natural populations, mutant combinations of alleles that are positively epistatic should be 
more frequently observed in clinical settings. 
 
Recently, two independent groups sequenced and comparatively analyzed MTB strains 
implicated in the infamous Tugela Ferry XDR-TB outbreak (Motiwala et al., 2010, Ioerger 
et al., 2009). The results of one study (Ioerger et al., 2009) show that the XDR 
transmission in KZN is due to clonal strain expansion. Even with mutations in multiple 
essential genes, this strain remained highly virulent and transmissible (Ioerger et al., 
2009). Compensatory evolution may be one mechanism by which fitness costs of the 
 18 
 
aforementioned mutations could be ameliorated. However, the subsequent study 
compared XDR strains from the Tugela Ferry region to a phylogenetically comprehensive 
panel of drug-resistant and susceptible MTB strains, and found little evidence for 
compensatory mutations (Motiwala et al., 2010). This poses critical questions 
surrounding the ability of this and other drug-resistant MTB strains to successfully infect 
and cause disease, while harbouring mutations in more than one essential gene. One 
possibility is that in a host population with compromised immunity, the physiological 
requirements for MTB are somewhat different and therefore fitness of resistant strains 
less attenuated (Motiwala et al., 2010). Since TB is the biggest killer of HIV positive 
individuals (WHO, 2009), these findings are especially important in developing countries 
where the burden HIV/TB co-infection is highest.  
 
1.5.3 Drug resistance and increased mutagenesis 
Bacterial populations are not homogeneous, and it has been proposed that exposure to 
antibiotics selects for resistant clones that exist in a population before antibiotic contact 
(Livermore, 2003). However, there is significant debate surrounding the ability of bacteria 
to induce a state of adaptive mutagenesis under stressful conditions (Wrande et al., 2008, 
Roth, 2010). One of the mechanisms for bacterial adaptation – including development of 
drug resistance – is the induction of error prone DNA repair systems (Boshoff et al., 2004, 
Friedberg et al., 2001). The enzymes involved are best characterized in E. coli [Reviewed 
in (Friedberg et al., 2001)] however, analogous pathways are thought to contribute to the 
emergence of drug resistance in an assortment of pathogens (Oliver et al., 2000, 
Bjorkholm et al., 2001, Boshoff et al., 2003, Boshoff et al., 2004). Moreover, it is likely 
that exposure to antimicrobials induces reactive oxygen species (ROS) production, and 
oxidative damage is likely to be involved in antibiotic mediated cell death (Dwyer et al., 
2009). Furthermore, ROS production leads to activation of the SOS response, and recently 
Kohanski et al. (2010) suggested that, as a consequence of ROS-mediated mutagenesis, 
treatment with one antibiotic can encourage resistance to other unrelated antibiotics 
(Kohanski et al., 2010). However, opinions diverge when it comes to the reasons for the 
observed increase in mutants in stressful microenvironments – can harsh conditions 
select for a heightened state of mutability? Alternatively, a small pool of mutants that 
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already exist in the population may be selected for by the conditions to which they confer 
beneficial capabilities (Roth, 2010, Wrande et al., 2008). Some researchers have proposed 
that an increase in rpoB mutations under slow or non-growing conditions indicates that 
some organisms have the ability to increase their mutational rate under these conditions 
(Karunakaran & Davies, 2000, Bjedov et al., 2003, Cairns et al., 1988, Rosenberg & 
Hastings, 2004). Wrande et al. (2008) offer another explanation based on classic 
selection. Specifically, these authors suggest that pre-existing rpoB mutants are selected 
during stationary phase growth because the rpoB mutation confers some physiological 
benefit, based on the following evidence. A logarithmic increase in rpoB mutations was 
observed in ageing E. coli colonies: this suggests expansion of a single clone. For 
increased mutagenesis to be responsible, mutagenic rates would have to have increased 
104-fold, which has never been observed even for lab-induced mutagenesis. Moreover, 
this kind of increase in mutagenesis would likely induce lethal mutation and lead to loss 
of viability. Clones containing rpoB mutations were clustered within sectors of a plate, 
and moreover, strains within these clusters contained the same rpoB mutation. Increased 
mutagenesis would have resulted in spatially distributed colonies with a range of rpoB 
mutations. Finally, competition assays between strains carrying RIFR-associated rpoB 
mutations, and the wild-type strain revealed that mutants had increased growth by day 
seven of the assay (Wrande et al., 2008). Not only do these findings have important 
implications for adaptive mutagenesis but they also support the idea that rpoB mutations 
have considerable consequences for the physiological outcomes of RIFR populations. 
 
Lesions in DNA which hinder RNAP progress pose a risk to both RNA and DNA fidelity. 
Transcription coupled repair (TCR) is an important subclass of nucleotide excision repair, 
and functions to maintain DNA fidelity at genes which are actively transcribed (Roberts et 
al., 2004). Transcription-repair coupling factor (TRCF) plays a pivotal role in this process 
and is encoded by the mfd (mutation frequency decline) gene in E. coli (Park et al., 2002). 
When sufficient nucleotides are present, TRCF reactivates stalled RNAP complexes 
(Borukhov et al., 2005). However, RNAPs that are stuck at a lesion can also be dislodged 
by TRCF pushing forward in an ATP dependent manner (Park et al., 2002). In this case 
DNA repair is initiated by TRCF binding to UvrA (Park et al., 2002; Roberts et al., 2004; 
Westblade et al., 2010). The RNAP interaction domain (RID) of TRCF interacts with the N-
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terminus of the β subunit of RNAP. In E. coli residues 19-142 within the β1-lobe are 
sufficient for mfd interaction and point mutations in this region prevent Mfd-RNAP 
interaction (Trautinger et al., 2002). This region is not commonly associated with RIFR, but 
lies next to the RRDR in RNAP tertiary structure (Ganesan et al., 2007). An investigation of 
E. coli strains exposed to RIF and selected for both RIFR and a defect in TCR revealed that 
only one mutation, R529C, diminished TCR. Neither TRCF-RNAP interaction nor the 
stability of the RNAP-DNA complex were affected, therefore the loss of TCR activity in 
these strains was as a result of an undefined mechanism (Ganesan et al., 2007).   
 
Collisions between RNAP and DNA replication complexes also present an obstacle for 
DNA replication and threaten DNA fidelity. Although not a formal component of TCR, 
other replisome-associated proteins play a key role in resolution of replisome-protein 
blocks – of which RNAPs constitute the most common type (Guy et al., 2009). In E. coli 
UvrD, Rep and DinG helicases share some functional redundancy in that they are all able 
to remove protein blocks during replication (Guy et al., 2009; Boubakri et al., 2010; 
Baharoglu et al., 2011). Mutants that lack either UvrD or Rep are viable however deletion 
of both proteins is lethal. Increased levels of (p)ppGpp and mutations in rpoB which 
mimic the stringent response, can suppress the viability defect of rep uvrD double 
mutants (Guy et al., 2009). Some stringent response mutations are found in the RRDR, 
and may also be associated with decreased levels of RIF susceptibility. Mutations in this 
region, specifically H447R and D444G, minimise replisome blockage by stalled RNAP and 
diminish the need for the aforementioned helicases (Baharoglu et al., 2011). Moreover, 
mutations in the RRDR that mimic the stringent response also decrease susceptibility to 
UV damage in cells lacking functional RecBCD and RuvABC enzyme complexes, and in 
strains lacking mfd (Trautinger et al., 2002). These mutations lie next to the DNA-RNAP 
channel, and decrease stability of RNAP-DNA interactions (Trautinger et al., 2002; 
Baharoglu et al., 2011). These findings are important for maintenance of DNA fidelity in 
strains which lack important DNA repair-associated enzymes and for understanding the 
function of these enzymes. However, the effect of these mutations on DNA fidelity in 
wild-type cells has not been full characterised. Moreover, decreased stability of 
transcriptional complexes could have significant consequences for gene expression.  
Amelioration of DNA repair by RIFR-associated rpoB mutations provides an advantage for 
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cells containing these mutations. If DNA repair is disrupted, the extent of disruption and 
how other DNA repair mechanisms compensate for this disruption would be important in 
determining the outcome for physiology. Increased mutation may provide a favourable 
environment for compensatory mutation or for the development of resistance to other 
drugs. However, if DNA repair is severely compromised, there may be an accumulation of 
mutations that is lethal to the cell. 
 
1.6 The implications of RIFR-associated mutations for fitness: molecular 
epidemiology and evolutionary analyses 
In combination, the high level of evolutionary conservation between RNAPs and the 
importance of this enzyme for expression, suggests that changes in this gene would result 
in fitness costs. However, several studies that have investigated the fitness cost of RIFR-
associated mutations in the rpoB gene indicate that this may not be the case (Reviewed 
in (Borrell & Gagneux, 2009) and (Andersson, 2006)). Studies have generally reported 
that the fitness of strains with distinct rpoB mutations varies relative to their isogenic, 
drug-susceptible parents according to the specific strain background, as well as the 
nature of the in vitro assay (Mariam et al., 2004, Gagneux et al., 2006a, Gagneux et al., 
2006b, Billington et al., 1999). Considering the structural implications for amino acid 
changes in the β-subunit of RNAP, these data provide evidence that different rpoB point 
mutations influence fitness in different ways. The frequency of RIFR-associated mutations 
at certain loci of the RRDR differs between different organisms, despite high similarity in 
the surrounding sequence (Kim et al., 2004, Garibyan et al., 2003, Zeibell et al., 2007). 
The spectrum of observed mutations in rpoB may represent the functional or structural 
constraints for rpoB mutability. However, Zeibell et al. (2007) show that at nucleotide 
position C1576 (which is the base where a change occurs to confer an H526Y mutation 
(cac → tac) E. coli has a mutation rate (µ – mutation rate per replication) of 0.91, while B. 
anthracis only has a mutation rate of 0.47. This indicates that within the limits of rpoB 
mutability, hotspots occur at diverse sites in different organisms. Distinct physiological 
and therefore fitness requirements for individual species may result in a different set of 
mutations being selected for (Jenkins et al., 2009). 
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Sequence variation between MTB strains is conventionally thought of as being 
exceptionally low. However, recent studies provide compelling evidence that MTB 
sequences differ more than initially thought (Hershberg et al., 2008, Gagneux & Small, 
2007, Nicol & Wilkinson, 2008, Niemann et al., 2009). Distinct MTB strains may have 
varying virulence properties as a consequence of relative clonality of the MTB complex 
(Niemann et al., 2009, Gagneux & Small, 2007). This is supported by several indications 
that distinct MTB strains behave differently in models of disease (Gagneux & Small, 
2007). Furthermore, Hershberg et al. (2008) suggest the evolution of distinct 
phylogeographic lineages has occurred in close alliance with the human populations they 
infect. Intriguingly, subsequent work from the same group indicates that in contrast to 
the newly described MTB strain diversity, genomic regions involved in recognition of the 
bacillus by the host immune system are highly conserved (Comas et al., 2010). This 
conservation of antigenic regions is counter-intuitive to the antigen variation found in 
other common pathogens. Dynamics between various biological factors, which translate 
into a complex network of evolutionary pressures, play an enormous role in the 
adaptation and fitness of MTB. In addition to providing tools to investigate outbreak of TB 
disease, molecular genotyping and epidemiological studies provide a means to 
investigate the implications of particular mutations for fitness. This is especially useful 
when examining the fitness implications of drug resistance-associated mutations. Strains 
containing mutations with higher fitness costs should, in principle, result in fewer 
secondary cases. Although this approach is useful, biases – such as selective conditions 
imposed during strain isolation – may be present, and therefore extrapolation of fitness 
effects of certain mutations from epidemiological data may not be straight-forward. From 
a phylogenetic analysis of INHR-associated mutations, Hazbon et al. (2008) suggested that 
assessment of convergent evolution may be a tool to determine levels of selective 
advantage conferred by SNP’s. Phylogenetic and further evolutionary analysis of drug 
resistance-associated mutations, and other SNP’s, may therefore provide a vehicle to 
examine the biological significance of drug resistance mutations.  
 
As molecular genotyping techniques became available, an association between W Beijing 
strains and drug-resistant TB outbreaks were observed (reviewed in (Parwati et al., 
2010)). This could indicate that these strains have a greater propensity to adapt to 
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environmental conditions (van der Spuy et al., 2009) or that there is a general increase in 
dissemination of both susceptible and resistant variants of this strain. A rare variant of 
the W Beijing lineage is differentiated by a small change in its IS6110 fingerprint (Strauss 
et al., 2008). These atypical strains are thought to be less fit, since they are infrequently 
observed in clinical settings. Interestingly, a RIFR clinical isolate of this variation sustained 
transmission in a community with high levels of HIV. Accordingly, a recent article 
describes a RIFR MTB isolate with uncommon rpoB mutations, and unusually high 
virulence and transmission in an HIV positive background (Malhotra et al., 2010). This 
indicates that, against a background of elevated HIV prevalence, RIFR-associated 
mutations can be tolerated without compromising community transmissibility even in a 
strain with already attenuated fitness, (Strauss et al., 2008). Recent whole-genome 
sequencing and subsequent phylogenetic analysis of drug resistance isolates from the 
Western Cape indicate that drug resistance is acquired rather than transmitted (Ioerger 
et al., 2010). However, similar analysis of the XDR strains in the Tugela Ferry region of 
KZN, shows that strains exhibit a definite pattern of clonality (Ioerger et al., 2009). These 
contrasting patterns of spread of drug-resistant strains within the same country affirm 
the importance of considering environmental conditions when evaluating fitness. 
 
1.7 The effect of rpoB mutations on global transcriptional regulation: 
Changes in physiology 
It has been postulated that the natural antibiotics function to limit the growth of 
competitor organisms in resource-poor environments (Goh et al., 2002). Contemporary 
models propose a subtle modification of this hypothesis, holding that antibiotics operate 
instead as low-concentration effector molecules in other ecological processes such as 
signalling and transport mediation (Davies, 2009, Martinez et al., 2009). It follows, 
therefore, that mutations which arise in response to excessive concentrations of 
signalling or regulatory molecules might have profound consequences for bacterial 
physiology. In support of this idea, transcription in Mycobacteria and Salmonella species 
is modulated by sub-inhibitory concentrations of RIF and STR and, furthermore, that 
resistance-associated mutations weaken the level of transcriptional regulation induced by 
each drug (Goh et al., 2002, Yim et al., 2006, Boshoff et al., 2004). 
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In combination with small proteins such as DksA in E. coli (Potrykus & Cashel, 2008) and 
CarD in mycobacteria (Stallings et al., 2009), guanosine tetraphosphate (ppGpp) is a 
central modulator of the bacterial response to environmental stress (Chatterji & Ojha, 
2001, Traxler et al., 2006, Traxler et al., 2008). In addition, it is well established that 
antibiotic production by Streptomyces sp. is fundamentally dependent on ppGpp-
activated pathways (Xu et al., 2002, Hu et al., 2002, Ochi, 1987). In S. coelicolor antibiotic 
producer strains, , for example, RIFR-associated mutations corresponding to those found 
in clinical MTB isolates are associated with increased antibiotic production (Xu et al., 
2002, Hu et al., 2002, Hosaka et al., 2009), as well as the inducing the production of novel 
antibiotics in defined non-producer strains (Hosaka et al., 2009). Moreover, mutations in 
rpoB increase secondary metabolism in relA/relC mutants that are defective in antibiotic 
production owing to an inability to generate ppGpp (Hu et al., 2002). In addition to their 
enormous utility in the pharmaceutical industry, these findings imply that rpoB mutations 
have significant consequences for secondary metabolism in Streptomyces species.  
Interestingly, some Nonomuraea and Nocardia species encode two paralogues of the 
rpoB gene. In these strains, the alternative rpoB gene confers RIFR and its activation 
induces the expression of dormant genes (Tala et al., 2009, Vigliotta et al., 2005, Ishikawa 
et al., 2006). Notably, the sequence variations that differentiate the alternative rpoB gene 
from the “wild-type” correspond to common rpoB mutations in clinically isolated RIFR 
MTB strains. Moreover, in S. lividans expression of the Nonomuraea rpoB(R) gene induces 
antibiotic biosynthesis (Tala et al., 2009, Vigliotta et al., 2005). In B. subtilis, dormant 
antibiotic production is activated by RIFR-associated rpoB mutations (Inaoka et al., 2004), 
while RIFR-associated mutations in the E. coli rpoB gene resulted in RNAP behaving as if it 
was under ppGpp regulation (Zhou & Jin, 1998). Together, these data point to the ability 
of RIFR-associated rpoB mutations to mimic functionally the actions of ppGpp (Hu et al., 
2002, Xu et al., 2002), possibly by modifying promoter specificity. Considering these 
observations, as well as the complexity of transcriptional regulation, it is likely that RIFR-
associated mutations alter mechanisms of transcription (Tupin et al., 2010). 
 
More than two decades ago, researchers began investigating the effect of rpoB mutations 
on transcriptional pausing and termination (Jin & Gross, 1991, Landick et al., 1990, Singer 
et al., 1993). In E. coli, certain mutations were found to increase termination while others 
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resulted in decreased termination; moreover compensatory mutations within rpoB itself 
were found to restore the wild-type phenotype (Singer et al., 1993). Jin et al. (1988) 
observed that RIFR-associated mutations in E. coli resulted in a range of phenotypic 
effects including temperature sensitivity and phage susceptibility which they suggested 
might result from the effect of RIFR-associated mutations on transcriptional pausing and 
termination. In a 2002 report, Nicholson et al. (2002) showed that the spectrum of RIFR-
associated mutations in B. subtilis differs significantly, depending on whether cells are in 
a vegetative state or not (Nicholson & Maughan, 2002). Notably, this study demonstrated 
that B. subtilis spores exhibit mutations in the RDDR that are similar to those commonly 
found in clinically isolated RIFR MTB strains, prompting the suggestion that the DNA in 
dormant MTB cells may be in a state analogous to that of DNA in B. subtilis spores 
(Nicholson & Maughan, 2002). Further investigation of the effect of rpoB mutations on B. 
subtilis physiology revealed that single amino acid changes in rpoB resulted in major 
changes in physiological processes such as sporulation, germination and competence. For 
example, a mutant carrying a H526Y was not able to form spores efficiently at 48 ˚C, 
while a mutant carrying the S531L had enhanced spore forming capacity (Maughan et al., 
2004). Moreover, RIFR-associated mutations altered the metabolic capability of B. subtilis 
– allowing the organism to utilize substrates that had not previously been identified as 
suitable for B. subtilis (Perkins & Nicholson, 2008). Analogously, an S. aureus strain with 
low level RIFR was better able to establish biofilms on catheters in mice than parental 
strains (Yu et al., 2005). This RIFR-associated mutation, S509P, was most commonly 
isolated during murine infection, whereas during in vitro biofilm growth, the mutations 
occurred at position 516 more frequently (Yu et al., 2005).  This phenomenon has 
recently been investigated in MTB: particularly, adjusting the pH of a chemostat culture 
of MTB resulted in a widely varied spectrum of rpoB mutations. At pH 7.0, 89 % of all 
strains isolated contained the S531L mutation. Although the majority of strains still 
contained the S531L mutation when the pH was lowered to pH 6.0, the absolute number 
had dropped to 50 % (Jenkins et al., 2009). This finding is particularly important given that 
a key environmental niche for MTB is the acidic macrophage phagosomal compartment 
(Schnappinger et al., 2003). 
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Mutations in the rpoB gene that are associated with RIFR are likely to have drug-
independent consequences for bacterial physiology. The biological implications of drug 
resistance-associated mutations have a substantial role to play in determining the fitness 
of resistant bacteria (Borrell & Gagneux, 2009), which has critical bearing on the type of 
treatment and control measures for MDR disease. The assay system used to measure 
these effects is not trivial. For MTB in particular, most assays examining the relative 
fitness of RIFR mutants are conducted under conditions using a sugar as the primary 
carbon source (Billington et al., 1999, Gagneux et al., 2006b). The MTB genome encodes a 
sophisticated repertoire of enzymes to facilitate lipid metabolism when glucose is limited 
(Savvi et al., 2008, McKinney et al., 2000) and microarray studies have shown that many 
of these genes are up-regulated during infection (Schnappinger et al., 2003). These (and 
other) studies suggest mycobacteria favour lipid metabolism during infection, where 
nutrient levels may be low (Pandey & Sassetti, 2008, Brzostek et al., 2009, Yang et al., 
2009, Yam et al., 2009).  Recent studies in E. coli indicate that adaptation to growth in 
nutrient limited environments is facilitated by rpoB mutation, some of which are 
analogous to those found in clinical MTB strains (Conrad et al., 2010). Moreover, fitness 
of P. aeruginosa strains containing RIFR-associated mutations varies depending on the 
carbon source applied (Hall et al., 2011). These studies support the idea that carbon 
source (and other environmental conditions) can have a major impact on the observed 
fitness of strains containing RIFR-associated mutations, and that these factors must be 
considered during fitness assay. 
 
In an effort to understand the fitness consequences of RIFR in MTB, many lab-based 
studies have isolated spontaneous mutants derived from exposure to RIF. A potential 
limitation of this approach is that it almost certainly fails to replicate adequately the 
complex conditions that MTB is expected to encounter in vivo. In addition, it does not 
take into account the potential for (undetected) compensatory mutations to ameliorate 
fitness costs. Clinical strains harbouring mutations that confer the lowest fitness cost in 
lab-derived mutants containing the identical rpoB mutation are most commonly isolated 
from patients with MDR-TB disease (Borrell & Gagneux, 2009, Gillespie et al., 2002, 
Shcherbakov et al., 2010). However, caution must be exercised when making these kinds 
of inferences (Mariam et al., 2004, Andersson, 2006). There may be selective pressures 
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which act during the isolation of clinical strains, from sputum collection through strain 
propagation, storage, and re-growth in vitro. Although the S531L mutation is frequently 
observed in clinical isolates, mutations at other sites in rpoB may not be observed 
because they negatively impact the “culturability” of the strain at each of these stages. 
These pressures may be imposed by the kind of media used during culture of clinical 
strains – which may not always be representative of conditions during host infection. 
Usually similar media are used during fitness assays, and in this way a “selection bias” 
could be imposed. This has potentially far reaching implications for the reliability of these 
data to inform about the fitness cost of clinical resistance.  
 
A thorough understanding of the impact that chemotherapeutic measures (as well as 
resistance to these measures) have on microbial physiology is a key component in 
answering the many questions surrounding microbial drug resistance. In addition to 
preventing spread of MDR and XDR disease, the global effects of resistance mechanisms 
provide an exciting space for a deeper understanding of microbial physiology. 
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1.8 Specific aims of for this project 
1.8.1 Overall objective 
The overall objective of this project is to determine the extent to which common 
mutations associated with RIFR in clinical MTB isolates impact mycobacterial physiology, 
primarily carbon source metabolism. Given that physiology and fitness cannot be 
uncoupled an understanding of the impact of these mutations for physiology will be 
especially useful for evaluating the fitness, and ultimately transmissibility, of MTB. In this 
dissertation, we utilize MSM as surrogate for MTB: specifically, we describe the 
construction of a panel of MSM mutant strains containing RIFR-associated point 
mutations that are equivalent to the corresponding mutations in clinically RIFR MTB 
strains. Importantly, our methodology ensures that rpoB mutants are generated without 
exposure to RIF, such that the ability of single point mutations to confer high-level RIF 
resistance could be evaluated. 
 
1.8.2 Hypothesis 
The central hypothesis informing this project is that clinically-relevant rpoB mutations 
impact the capacity of MTB to metabolize different carbon sources and, further, that such 
mutations arise, and are maintained, in the population in the absence of RIF exposure.  
 
1.8.3 Specific aims 
a) Construction of a panel of MSM mutants containing point mutations in rpoB that are 
equivalent to the corresponding mutations in clinically RIFR MTB strains 
b) Evaluation of the fitness of the MSM mutants in comparison with the otherwise 
isogenic parental strain during growth on various carbon sources. 
  
 29 
 
2. Methods 
 
2.1 Selection of rpoB mutations to include in the study 
An analysis of the literature and preliminary data generated at the MMRU informed the 
selection of RIFR-associated mutations to be included in the project. Recent literature was 
broadly analyzed to determine the most commonly observed rpoB mutations in clinically 
isolated and laboratory-derived RIFR MTB strains. The terms “rpoB” AND “mutations” 
AND “Mycobacterium tuberculosis” were included in a search on the NCBI Pubmed 
database (http://www.ncbi.nlm.nih.gov/pmc/). The analysis was by no means exhaustive, 
nor was it intended to be a complete meta-analysis of the literature. Rather, the purpose 
of the literature search was to gain a sense of common rpoB mutations in RIFR isolates 
from a variety of geographical regions. Therefore, restrictions relating to study size or the 
technique applied in strain isolation, were not imposed. A list of papers included in the 
analysis can be found in Appendix 5.1.  
 
The observation that a silent mutation (L521L) was associated with relatively high levels 
of RIFR in a clinical isolate (Siddiqi et al., 2002) suggested this allele for inclusion in the 
study. The remaining three mutations were included owing to their potential significance 
as established by previous work at the MMRU (Table 3.1). The TH526TY mutation is 
commonly associated with error prone DNA polymerase activity, in particular DnaE2 
(Boshoff et al., 2003). In preliminary experiments at the MMRU, a MSM rpoB mutant 
containing a Q513V mutation displayed differential growth on OADC (oleic acid-albumin-
dextose-catalase) vs. Glucose-NaCl (Glucose Salt; GS) containing 7H10 media (D Warner 
and Susan Puckett, unpublished results). The 30 bp deletion has been isolated at the 
MMRU in response to DNA damaging agents and nutrient stress, and has also been 
studied in an independent study (Malshetty et al., 2010). 
 
2.2 Bioinformatic analysis of rpoB  
Nucleic acid and protein sequence of the MSM and MTB rpoB gene were downloaded 
from The Comprehensive Microbial Resource database of the J. Craig Venter (JCVI CMR; 
http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi) (Peterson et al., 2001). Analysis 
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of the similarity of the nucleotide and amino acid sequences of the rpoB genes from 
these two organisms was accomplished using the Blast2seq tool available on the NCBI 
website  
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&PROG_DEF=blastn&BLA
ST_PROG_DEF=megaBlast&BLAST_SPEC=blast2seq). Fasta format files containing the 
respective rpoB gene sequences were uploaded onto the online program and the option 
to optimise the program for highly similar sequences was selected. Algorithm parameters 
were maintained as default settings. Default settings for scoring parameters were as 
follows: mismatch/match scores: 1,-2; gap costs: linear. The algorithm used for the 
blast2seq are similar to those used for standard BLASTn queries (Altschul et al., 1990). 
ClustalX 2.0.12 software allowed for additional analysis and visualisation of the similarity 
of RpoB protein sequence MSM and MTB (Thompson et al., 1997). Finally, genomic 
context information for the rpoB gene in mycobacterial species was obtained from the 
JCVI CMR (Peterson et al., 2001). 
 
2.3 General Microbiological and DNA manipulation techniques 
All DNA manipulations were performed as described previously (Sambrook et al., 1989; 
Sambrook & Russell, 2001). All mycobacterial culture and molecular cloning techniques 
were performed as described in Jacobs et al. (1991), Larsen (2000), and Parish & Stoker 
(2001). 
 
2.3.1 General bacterial growth conditions 
2.3.1.1 Growth media, reagents and solutions 
Growth media, reagents, solutions and buffers used in this study are described in detail in 
Appendices 5.2. 
 
2.3.1.2 MSM growth conditions 
Unless otherwise described, MSM strains were cultured on Middlebrook 7H9 (liquid 
medium) or Middlebrook 7H10 medium (solid medium) (DifcoTM, USA) supplemented 
with oleic acid-albumin-dextrose-catalase (Beckton Dickinson, USA), 0.05 % tween80 
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(Sigma Aldrich, USA), 0.02 % glycerol (Merck, Germany) for liquid media (0.05 % glycerol 
for solid media), supplemented with antibiotics as required. Liquid cultures were 
incubated in Erlenmeyer flasks at 37 °C, with shaking at 120 rpm, in a New Brunswick 
Scientific Innova 400 incubator shaker (New Brunswick Scientific Co; Inc, USA). Strains 
cultured on solid media were incubated at 37 ˚C in an Incotherm incubator (Labotec, 
South Africa). MSM strains to be cultured from freezer stocks were cultured in liquid 
media for 48 hours to allow for sufficient recovery. Subsequently, an aliquot was sub-
cultured into fresh media and strains were grown to the appropriate optical density (OD) 
for further analysis.  
 
2.3.1.3 E. coli growth conditions 
The E. coli DH5α (Promega, USA) host strain was used in this study. E. coli strains were 
grown in Luria Bertani (LB) broth or on Luria Bertani agar plates (LA), supplemented with 
appropriate antibiotics (Appendix 5.2). Liquid cultures were incubated in Erlenmeyer 
flasks with shaking at 120 rpm, at 37 °C or 30 °C in the New Brunswick Scientific Innova 
400 incubator shaker. Strains cultured on solid media were incubated at 37 ˚C or at 30 ˚C 
in an Incotherm incubator.  
 
2.3.1.4 Medium supplements 
Appropriate compounds were included in growth media to select for strains containing 
the desired plasmids. Details of plasmid and strain selection conditions can be found in 
Tables 2.1 and 2.2. Antibiotics were used at the following concentrations: (1) E. coli: 
ampicillin (AMP), 200 μg/ml (AMP200); hygromycin (HYG), 200 μg/ml (HYG200); kanamycin 
(KAN) 200 μg/ml (KAN200) (2) MSM: HYG, 50 μg/ml (HYG50); KAN 20 μg/ml (KAN20). RIF 
concentrations ranging from 50 μg/ml to 4000 μg/ml were included in media to evaluate 
RIFR of MSM strains. Selection of double cross over (DCO) strains required sucrose 
supplementation which was at 5 % (w/v) for E. coli, and 2 % (w/v) for MSM. Where 
plasmids or strains contained the lacZ gene, 5-bromo-4-chloro-3-indolyl- β-galactoside (X-
gal) was included at 40 µg/ml for E. coli and MSM. Details of supplements can be found in 
Appendix 5.2. 
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2.3.1.5. Bacterial strains and plasmids 
Strains and plasmids used in this study are listed in Table 2.1. Strains were stored at -70 
°C in 66 % glycerol (v/v). Strains for storage were prepared as follows. Strains were grown 
to logarithmic phase (OD of 600 nm (OD600) = 0.6 – 1.0), and 500 μl of the strain added to 
1.5ml microfuge tubes (Whitehead Scientific, South Africa) containing 500 µl 66 % (v/v) 
glycerol. Glycerol was prepared by diluting 66 ml of glycerol in 44 ml of sterile distilled 
water (dsH20); and autoclaved for 15 min using the Speedy Autoclave (Huxley, Taiwan).  
 
Table 2.1 Bacterial strains used in this study 
Strain Details Reference 
E. coli DH5α Host E. coli strain used in this study. Promega 
(USA) 
Mycobacterium 
smegmatis mc2155 
High frequency transformation strain. (Snapper et 
al., 1990) 
rpoBS531L MSM mutant containing S531L mutation in the rpoB 
gene. 
This study 
rpoBS531L→WT MSM mutant wherein the wild-type allele was 
restored in the S531L mutant strain. 
This study 
rpoBH526Y MSM mutant containing H526Y mutation in the rpoB 
gene. 
This study 
rpoBL521L MSM mutant containing L521L mutation in the rpoB 
gene. 
This study 
rpoBscoS531L/WT MSM up-stream SCO mutant containing rpoB with 
S531L mutation and wild-type rpoB; contains KANR; 
HYGR; LacZ and SacB markers. 
This study 
rpoBscoWT/H526Y MSM SCO (down-stream) containing rpoB with 
H526Y mutation and wild-type rpoB; contains KANR; 
HYGR; LacZ and SacB markers. 
This study 
rpoBscoL521L/WT MSM SCO (up-stream) mutant containing rpoB with 
L521L mutation and wild-type rpoB; contains KANR; 
HYGR; lacZ and sacB markers. 
This study 
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rpoBscoQ513V MSM SCO mutant (orientation not determined) 
containing rpoB with Q513V mutation and wild-type 
rpoB; contains KANR; HYGR; lacZ and sacB markers. 
This study 
rpoBscoWT/WT MSM SCO mutant containing two copies of wild-type 
rpoB; contains KANR; HYGR; lacZ and sacB markers. 
This study 
rpoBscoTH526TY MSM SCO mutant (orientation not determined) 
containing rpoB with TH526TY mutation and wild-
type rpoB; contains KANR; HYGR; lacZ and sacB 
markers. 
This study 
rpoBsco30del MSM SCO mutant (orientation not determined) 
containing rpoB with a 30 bp deletion and wild-type 
rpoB; contains KANR; HYGR; lacZ and sacB markers. 
This study 
 
 
Table 2.2 Plasmids used in this study 
Strain Details Reference 
p2NIL Core vector used in this study. E. coli-
Mycobacterium shuttle vector, KANR 
(Parish & 
Stoker, 
2000) 
p2NILAB Modified version of p2NIL where Acc65I and 
BamHI sites had been removed; KANR 
This study 
p2rpoB Template for SDM: p2NILAB with rpoB gene 
inserted; KANR 
This study 
p2rpoBMT constructs 
p2rpoBS531L Suicide vector: p2NILAB with rpoB containing 
an S531L mutation inserted; KANR 
This study 
p2rpoBH526Y Suicide vector: p2NILAB with rpoB containing 
an H526Y mutation inserted; KANR 
This study 
p2rpoBL521L Suicide vector: p2NILAB with rpoB containing 
an L521L mutation inserted; KANR 
This study 
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p2rpoBQ513V Suicide vector: p2NILAB with rpoB containing 
an Q513V mutation inserted; KANR 
This study 
p2rpoBTH526TY Suicide vector: p2NILAB with rpoB containing 
an TH526TY mutation inserted; KANR 
This study 
p2rpoB30del Suicide vector: p2NILAB with rpoB containing a 
30bp del inserted; KANR 
This study 
pOLYG E. coli-Mycobacterium shuttle vector; 
Replicates episomally; HYGR 
(O'Gaora 
et al., 
1997) 
rpoB containing pOLYG constructs (pGrpoB) 
pGrpoBWT This derivative of pOLYG replicates episomally 
in MSM and contains the wild-type rpoB gene; 
HYGR 
This study 
pGrpoBS531L This derivative of pOLYG replicates episomally 
in MSM and contains the rpoB gene with a 
S531L mutation; HYGR 
This study 
pGrpoBH526Y This derivative of pOLYG replicates episomally 
in MSM and contains the rpoB gene with a 
H526Y mutation; HYGR 
This study 
pGOAL 19  Marker gene cassette for allelic exchange was 
isolated from this vector; AMPR for replication 
in E. coli 
(Parish & 
Stoker, 
2000) 
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2.3.2 DNA extractions 
Large scale plasmid extraction from E. coli (Maxi-prep) 
2.3.2.1 Extraction of DNA 
An E. coli culture (100 ml) was grown to stationary phase (8 – 12 hours). Cells were 
harvested by centrifugation (3500 rpm; 10 min) in a Beckmann J2-21 centrifuge. Pellets 
were re-suspended in 1 ml Solution I by aspiration and vortexing. EDTA in Solution I 
inhibits any DNase activity that may be present in the unpurified sample, and glucose 
maintains osmotic pressure. An aliquot (2 ml) Solution II was added, and tubes were 
inverted twice to allow for cell lysis to occur before the addition of 1.5 ml Solution III. 
Solution II contains NaOH which increases the pH of the sample, and facilitates lysis. By 
adding Solution III, which contains sodium acetate, the pH of the sample is restored to 
approximately 7.0. Details of the composition of Solutions I, II and III can be found in 
Appendix 5.3  Mixing by vortexing was avoided from this stage onwards to prevent any 
shearing of DNA. Aliquots of 800 µl each of the lysed cell mixture were decanted into 1.5 
ml microfuge tubes, and centrifuged in the Eppendorf 5415 benchtop centrifuge 
(Eppendorf, Germany) at 13000 rpm for 10 min. The supernatant was decanted into fresh 
microfuge tubes, and the pellet containing protein and genomic DNA was discarded. An 
aliquot of 100 μg RNase A (Roche Applied Science, Germany) was added to each 
microfuge tube and samples were incubated at 42 °C for 1 hour to allow for RNA 
degradation. After incubation, 700 µl of 100 % isopropanol (Merck, Germany) was added, 
and microfuge tubes were left to stand at room temperature for 10 min to allow for DNA 
precipitation. Thereafter, tubes were centrifuged at 13000 rpm for 10 min, to sediment 
the DNA. The DNA pellet was washed with 70 % ethanol (Merck, Germany) and excess 
ethanol was removed by drying in a vacuum centrifuge (SpeedVac, USA) at 45 ˚C for 20 
min. DNA pellets were re-suspended in 100 µl dsH20. From an initial 100 ml culture of E. 
coli, ten samples of 100 µl each should be obtained. The compositions of the relevant 
solutions are provided in Appendix 5.3. 
 
2.3.2.2 Plasmid DNA purification 
Sodium acetate, which provides sufficient salt for subsequent precipitation of DNA, was 
added to each sample to a final concentration of 0.05 M. An aliquot (700 µl) phenol-
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chloroform solution (Appendix 5.3) was added to solution, and inverted repeatedly. DNA 
is water soluble and remains in the aqueous phase, while proteins accumulate in the 
organic phase. Therefore, after centrifugation for 10 min at 13000 rpm, the supernatant 
was removed cautiously, and added to a fresh microfuge tube. Upon addition of 350 µl of 
chloroform-isoamyl alcohol solution (Appendix 5.2), the mixture was centrifuged for 
another 10 min. Chloroform-isoamyl alcohol provides an initial clean up step, and 
minimises phenol carry over. The supernatant was removed, and placed in fresh 
microfuge tubes.  
 
2.3.2.3 DNA precipitation 
An aliquot (1 ml) of cold (-20 °C) 100 % ethanol was added to each sample. Samples were 
incubated at -20 °C for 1 hour to allow for DNA precipitation. After precipitation a stringy 
mass of DNA was often visible in the sample. Subsequently, samples were centrifuged for 
20 min to allow for sedimentation of DNA. The supernatant was discarded and the DNA 
pellet was washed with 70 % ethanol, and dried for 20 min at 45 °C for 20 min. DNA was 
re-suspended in 30 µl dsH20.  
 
2.3.2.4 Quantification and analysis of DNA purity 
The NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, USA) was used to assess 
the concentration and quality of plasmid DNA. Pure DNA is required for all molecular 
biological techniques as impurities in the DNA can interfere with down-stream processes 
such as enzymatic treatment and PCR. Although different nucleotides comprising the 
DNA sample have slightly different absorbance, optimal absorbance of light for nucleic 
acids is at 260 nm. Owing to the presence of the aromatic amino acids, tryptophan and 
tyrosine, protein predominately absorbs light at 280 nm. Therefore, spectrophotometric 
measurement of the extracted DNA sample is taken at 260 nm and 280 nm. The 260:280 
ratio gives some indication of the relative levels of DNA and protein in the sample. If a 
ratio of 1.8 is obtained DNA is considered pure, if the ratio is 2.0 DNA is considered very 
pure. Given that EDTA, carbohydrates and phenol have absorbance close to 230 nm the 
absorbance of the sample at this wavelength is also measured. There should be little of 
these compounds in the sample, and therefore a 260:230 ratio of 2.0 – 2.2 is considered 
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acceptable. Nanodrop measurement of DNA concentration and purity are generally 
reliable, but can vary depending on the composition of DNA (linear versus plasmid, 
chromosomal versus PCR fragment, etc.), and the calibration status of the machine.  
 
2.3.2.5 Small-scale plasmid extraction from E. coli (Mini-prep) 
Culture and reagent volumes were reduced appropriately for small-scale plasmid 
extraction. This method was especially useful when large numbers of colonies had to be 
screened. An E. coli culture of 2 ml was grown to stationary phase in 2 ml microfuge 
tubes. The cultures were centrifuged for 10 min at 13000 rpm, and the supernatant was 
discarded. Pellets were re-suspended in 100 µl Solution I. An aliquot (200 μl) of Solution II 
was added, samples were inverted, and 150 µl Solution III was added. Samples were 
centrifuged for 5 min at 13000 rpm, and the supernatant decanted to fresh microfuge 
tubes. Thereafter 10 μl of a 10 mg/ml solution of RNase was added, and samples 
incubated for 15 min at 42 °C. After incubation, 350 µl of 100 % isopropanol was added to 
each sample, which were left to stand at room temperature for 5 min. Samples were 
centrifuged at 13000 rpm for 10 min, and the supernatant discarded. The pellet 
containing the DNA was washed with 70 % ethanol, and dried in the vacuum centrifuge. 
The dried DNA was re-suspended in 20 µl of dsH20.  
 
Chromosomal DNA extraction from MSM 
2.3.2.6 Cetyltrimethylammoniumbromide (CTAB) isolation of chromosomal DNA  
To obtain pure, concentrated chromosomal DNA from mycobacterial cells, the CTAB 
method of DNA extraction was employed. MSM cultures were grown to logarithmic 
phase, and decanted into 2 ml microfuge tubes. Samples were centrifuged for 5 min at 
13000 rpm, and the supernatant discarded. Cell pellets were re-suspended in 500 µl tris-
EDTA (TE) (Appendix 5.3) buffer. Cells were heat killed by incubation at 65 °C for 20 min, 
500 µg of lysozyme (Roche Applied Sciences, Germany) was added to samples, and 
samples were incubated overnight at 37 °C with shaking. Following incubation, 70 µl 10 % 
sodium dodecyl sulphate (SDS) (Fluka, Switzerland) and 10 µl of proteinase K (10 mg/ml) 
(Roche Applied Sciences, Germany) were added to samples. SDS and lysozyme facilitate 
breakage of the mycobacterial cell wall and proteinase K degrades protein contaminants. 
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An aliquot (100 μl) of 5 M NaCl (Merck, Germany) was added to each sample, and 
inverted repeatedly to mix. Thereafter, 80 µl pre-warmed CTAB was added to samples, 
which were then incubated 65 oC for 10 min. CTAB binds proteins, polysaccharides and 
other impurities in the sample, thereby facilitating purification. An equal volume of 
chloroform-isoamyl alcohol was added, and samples were centrifuged for 5 min at 13000 
rpm. The supernatant was removed to fresh microfuge tubes, and precipitation 
continued as described in Section 2.3.2.3.  
 
2.3.2.7 Colony boil 
The colony boil method was applied to facilitate genotypic screening of large numbers of 
MSM transformants following electroporation. Colonies were picked and re-suspended in 
100 µl TE buffer. Samples were incubated for 10 min at 65 °C to kills cells and allow 
disruption of the cell wall. An aliquot (100 μl) of chloroform-isoamyl alcohol was added 
for limited purification of samples, which were then left to stand at room temperature for 
10 min, with periodic mixing by inverting. Samples were centrifuged for 10 min at 13000 
rpm. DNA contained in the supernatant was used for subsequent PCR screening or 
processing.  
 
2.3.2.8 DNA storage 
DNA is generally stable at room temperature; however, to prevent degradation or 
damage, extracted chromosomal and plasmid DNA were stored in dsH2O at -20 °C. 
 
2.3.3 Agarose electrophoresis 
Agarose is a seaweed-based polymer that forms a gel that inhibits passage of DNA 
through a polymer matrix when an electric current is applied. DNA is negatively charged, 
and will therefore migrate from the negative to the positive electrode in an electric field. 
Depending on the concentration of agarose used in preparation, different sized “pores” 
are obtained which allow for separation of DNA of different sizes. The more concentrated 
the agarose, the smaller the cross-linked pores, and the harder it is for large DNA 
fragments to migrate across the gel. In this way, larger fragments of DNA become 
trapped closer to the negative electrode, while smaller fragments migrate further down 
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the gel as they move towards the positive electrode. Addition of ethidium bromide, 
which intercalates between nucleotides and fluoresces under UV light, allows for 
visualisation of DNA. Agarose gel electrophoresis was invaluable for separation, 
visualisation and purification of DNA fragments.  
 
2.3.3.1 Preparation of agarose gels 
For general DNA separation, 1 % agarose gels were employed. However, the size of allele 
specific PCR (AS-PCR) products required the higher resolution of small (100 – 200 bp) PCR 
fragments; therefore, 2 % gels were utilised. Appropriate amounts of agarose were added 
to 1 X tris-acetate-EDTA (TAE) buffer (Appendix 5.4). The mixture was weighed and dsH2O 
equivalent to 10 g was added. The mixture was heated, to allow for melting of agarose 
powder, until the weight of the solution was the same as before dsH2O was added. 
Addition of dsH2O, and subsequent weight measurement maintained TAE buffer 
concentration, and ensured that only excess water evaporated during heating. The 
mixture was allowed to cool, and 0.5 µl of ethidium bromide per 30 ml geL was added. 
Gels were allowed to set in casting trays at 4 °C for 1 hour.  
 
2.3.3.2 Electrophoresis 
Cold (4 °C) 1 X TAE buffer was added to tanks prior to running. The buffer stabilises the 
pH and provides ions for conductivity. A 2 µl sample of loading dye was added for every 4 
µl DNA sample to be run. Loading dye was added to all DNA samples including DNA 
ladders, and contains bromophenol blue which is negatively charged, and therefore runs 
in the same direction as DNA. This facilitates evaluation of the migration distance of DNA. 
Additionally, the loading dye mixture contains glycerol which facilitates loading of the 
DNA into liquid-filled wells. For most gels, Molecular Weight Marker III was used (Roche 
Applied Science, Germany); however, to quantify accurately the smaller fragments 
generated by AS-PCR, Molecular Weight Marker V (Roche Applied Science, Germany) was 
used. Tanks were attached to a power pack (BIO-RAD, UK) and gels were run at 100 mV 
for the appropriate time.  
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2.3.3.3 Purification of DNA from agarose gels  
Following separation of DNA by agarose gel electrophoresis, the required bands were 
excised from gels, and added to 1.5 ml microfuge tubes. To extract DNA, the QIAquick Gel 
Extraction KitTM (QIAGEN, USA) was used according to manufacturer’s instructions. 
Appropriate amounts of the QG BufferTM were added to the gel slices, and samples were 
incubated at 65 °C until agarose had completely melted. The QG BufferTM contains 
chaotropic agents which facilitate dissociation of DNA strands. Single-stranded DNA 
(ssDNA) binds to silica based columns in the presence of high salt concentrations, and in 
this way DNA is purified. The solution was then added to the QIAquik Spin ColumnTM, and 
centrifuged for 1 min at 13000 rpm. The flow-through was discarded and 800 µl of PE 
BufferTM added to facilitate flow-through of impurities. After addition of the PE buffer the 
sample was centrifuged for 1 min at 13000 rpm, and the flow through discarded. The 
column was centrifuged again to remove any excess PE BufferTM. The column was then 
placed in a fresh 1.5 ml microfuge tube, and 30 µl pre-warmed dsH20 was then added to 
column and DNA was eluted by centrifugation for 1 min at 13000 rpm. Before DNA 
elution the sample was left to stand for 2 min.  It was observed that warming of dsH20 
significantly improved final DNA yield from the column. 
 
2.3.4 DNA manipulation and cloning 
Construction of vectors was accomplished using the E. coli DH5α host strain, and final 
vector products were used to transform MSM strains. Broadly, vector construction and 
cloning involved three core steps. The appropriate plasmid vector was used to facilitate 
insertion of the gene of interest, for this study the rpoB gene or gene fragments were 
inserted. After extraction, plasmid DNA, or PCR product were digested with the 
appropriate restriction endonuclease. If the same enzyme is used to cleave two distinct 
DNA fragments, the ends of the fragments will have the same nucleotide overhangs, and 
will therefore be complimentary. This facilitates the ligation step, in which the two 
fragments are covalently bound. Once the required construct was generated, E. coli cells 
were transformed with the plasmid and extracted DNA was used to genetically 
manipulate MSM.  
 
 41 
 
2.3.4.1 Restriction endonuclease digests 
For construct screening, and generation of appropriate fragments for cloning, restriction 
endonuclease digestion was utilized. Restriction enzymes have high levels of specificity, 
and cleave defined sequences of DNA at the sugar phosphate backbone. These enzymes 
are found in bacterial and archaeal species, and form part of an innate defence system 
protecting against bacteriophage attack. Restriction endonucleases commonly recognise 
4 – 8 bp palindromic nucleotide sequences, and often cleave close to (or within) the 
recognition site. The high specificity of restriction enzyme recognition sites make them 
very useful for molecular cloning techniques. One unit of the appropriate enzyme was 
added to 10 µg of required DNA, and incubated overnight without shaking. Unless 
otherwise described, optimal incubation temperature for restriction digests was 37 °C. 
Different restriction enzymes require different buffer conditions, and some enzymes 
require bovine serum albumin (BSA) to stabilise the enzyme during reaction.  In general, 1 
X buffer/BSA is included in the reaction mixture. A list of restriction enzymes that were 
frequently used in this study, and the corresponding buffer conditions, is provided in 
Appendix 5.3. Fragments containing the required DNA were isolated from agarose gels as 
described in Section 2.3.3.  
 
2.3.4.2 Removal of 5’ ends from vector DNA 
To minimise vector re-ligation during cloning, 5’ phosphate groups are removed after 
restriction digestion. The ligase enzyme requires a 5’ phosphate group to join two DNA 
molecules. Removal of these groups from the vector means that only the insert DNA 
fragment can provide the necessary chemical scaffold, and therefore minimises vector re-
ligation. After digestion, 1 unit of Antarctic Phosphatase (New England Biolabs, USA) was 
added to digested DNA and the sample was incubated for 1 hour at 37 °C. The sample 
was removed and purified using the QIAquick PCR Purification KitTM (QIAGEN, USA) 
purification kit according to manufacturer’s instructions. The principle of DNA purification 
is similar to that of the QIAquick Gel Extraction KitTM (described in Section 2.3.3.3) and 
the protocol is essentially the same, except that melting of agarose is not necessary.  
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2.3.4.3 Ligations 
T4 DNA ligase (Roche Applied Sciences, Germany) was used to join the vector and insert 
DNA of interest to generate the desired plasmid. Depending on DNA fragment sizes, 
different amounts of vector and insert are required. Furthermore, to maximise the 
likelihood of legitimate ligation events, ligation reactions are set up using various 
vector:insert ratios. After estimation of DNA concentration using an agarose gel, the 
amount of insert and vector DNA required is calculated using the following formula: 
[(ng vector x kb size of insert) / kb size of vector] x desired ratio = ng insert 
 
One unit of T4 DNA ligase was added to the mixture of vector and insert DNA together 
with 1 X ligation buffer. The reaction buffer contains ATP, which is an essential cofactor 
for the ligation reaction. The sample was incubated at 4 °C overnight, for sticky ended 
ligations, and at room temperature for blunt ended ligations. 
 
2.3.5 Transformation of cells and electroporation 
2.3.5.1 Transformation of E. coli 
Transformation-competent E. coli DH5α cells were used to efficiently introduce plasmids 
into the E. coli cell. Upon culture and replication of E. coli, larger amounts of the plasmid 
of interest could be extracted. After the ligation reaction had been allowed to proceed, 
the T4 DNA ligase was inactivated by heating at 65 °C for 20 min. Transformation-
competent E. coli cells were thawed on ice, and 100 µl of cells were added to each 
ligation reaction. The mixture was heat shocked at 42 °C for 90 s to allow for DNA uptake, 
and placed on ice. An aliquot of 500 µl of LB broth was added, and cells were incubated at 
37 °C to allow for replication and recovery. After 1 hour of incubation, cells were spread 
on LA plates containing appropriate antibiotics, and incubated to allow for colony growth. 
All vectors contain defined antibiotic-resistance genes; therefore, colonies that grew on 
selective media were likely to contain the vector (Table 2.2) 
 
2.3.5.2 Electroporation of MSM 
To transform MSM with appropriate vector, the electroporation technique as described 
in (Larson, 2000) was employed. A 100 ml culture of MSM cells was grown to logarithmic 
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phase. Cells were chilled at 4 °C and centrifuged at 3500 rpm for 10 min to sediment cells. 
Cells were re-suspended in 30 ml 10 % glycerol that had been chilled to 4 °C and filter 
sterilised. Cells were maintained on ice, and washed three times by centrifugation, each 
time re-suspending in the 10 % glycerol solution. After the third centrifugation step, cells 
were re-suspended in 7 ml 10 % glycerol, and used immediately. DNA was precipitated as 
described in 2.3.2.3 and a 1 µg sample of DNA was added to 0.2 cm electroporation 
cuvettes (BIO-RAD, UK). Electroporations were carried out using the BIORAD gene pulser, 
using the following settings: 2.5 kV; 25 µF and 1000 Ω. After electroporation, cells were 
removed from the cuvette and added to fresh 2 ml microfuge tubes. An aliquot (800 µl) 
7H9 OADC medium was added, and samples were incubated overnight at 37 °C to allow 
for recovery. Thereafter, cells were plated on 7H10 OADC media containing relevant 
selective compounds.  
 
2.3.6 Polymerase chain reaction (PCR) 
PCR was employed to isolate the rpoB gene from the MSM chromosome to construct a 
template for site-directed-mutagenesis (SDM), to introduce point mutations via SDM, and 
to screen for point mutations using AS-PCR. During template construction, as well as 
SDM, it was essential that no additional point mutations were introduced into the rpoB 
gene. The DNA polymerase often used in PCR reactions is isolated from T. aquaticus (Taq) 
and has no 3’ → 5’ proofreading ability. The variant used for this project, FastStart Taq 
DNA PolymeraseTM (Roche Applied Sciences, Germany) results in approximately 1.3 errors 
every 105 bases. To minimise the likelihood of erroneous bases being incorporated during 
PCR, Phusion High Fidelity DNA PolymeraseTM (New England Biolabs, USA) was employed. 
This enzyme has a reduced error rate of approximately 4 errors every 107 bases. During 
PCR screening, large numbers of colonies were screened, and the intrinsic error-rate of 
FastStart Taq DNA PolymeraseTM was acceptable. 
 
2.3.6.1 PCR using Phusion High Fidelity DNA polymeraseTM 
PCR reactions contained the following reaction components: 1 X Phusion High Fidelity 
PCR bufferTM, 1 X Roche GC solutionTM,  1 µM forward primer, 1 µM reverse primer, 100 
ng template DNA and 200 µM of each deoxydribonucleotide phosphate (dNTP): dATP; 
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dCTP; dGTP and dTTP (New England Biolabs, USA). Reactions were made up to 20 µl or 50 
µl with dsH2O. Cycling conditions were modified according to the specific fragment being 
amplified, and are described in relevant Sections.  
 
2.3.6.2 PCR using FastStart Taq DNA PolymeraseTM  
PCR reactions contained the following reaction components: 1 X Roche PCR reaction 
bufferTM, 1 X Roche GC solutionTM, 1 µM forward primer, 1 µM reverse primer, 100 ng 
template DNA and 200 µM of each dNTP: dATP; dCTP; dGTP and dTTP. Reactions were 
made up to 20 µl or 50 µl using dsH20.  Cycling conditions were modified according to the 
specific fragment being amplified, and will be described in relevant Sections.  
 
2.3.6.3 Primer design 
Clone Manager version 6.00 (Scientific & Educational Software, USA) was used to 
facilitate planning of the cloning strategy and primer design. Clone manager allowed 
prediction of product sizes for restriction digestion as well as PCR. As far as possible, 
oligonucleotide primers were designed with the following specifications: 50 % GC 
content, 18 – 20 bp, and an annealing temperature of 60 ˚C. Primers were obtained from 
Integrated DNA Technologies (USA). A list of primers and primer sequences can be found 
in Appendix 5.5. 
 
2.3.6.4 Sequencing 
All sequencing was conducted at the Stellenbosch Sequencing Facility (Stellenbosch, 
South Africa). Plasmids; purified chromosomal and unpurified/purified plasmid DNA at a 
concentration of at least 100 ng/µl was delivered to the facility, together with sequencing 
primers (Appendix 5.5) at a concentration of at least 1.1 µM that had been ordered from 
Integrated DNA technologies.  
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2.4 Specific strategies used in this project 
 
2.4.1 Generation of suicide vectors and plasmid constructs used in this study 
2.4.1.1 Cloning strategy 
A cloning strategy was designed to introduce a selection of RIFR-associated mutations into 
the rpoB gene of MSM via SDM and allelic exchange. The core vector used in this study 
was p2NIL (Parish & Stoker, 2000), which contains KANR genes for selection in E. coli and 
MSM. This vector also has a multiple cloning site, which includes a single PacI site for 
convenient addition of a marker cassette, which facilitates selection of SCO and DCO 
strains during allelic exchange. A template containing the full length rpoB gene was 
constructed so that SDM could be performed. In Figure 2.1, the full length rpoB gene is 
represented in green.  Specific rpoB mutations were introduced into the appropriate 
region in the rpoB gene via SDM. SDM was performed on a smaller fragment of the rpoB 
gene (shown in red in Figure 2.1), which was inserted back into the template to yield a 
vector containing a mutated version of the rpoB gene. For five out of six mutations, SDM 
was used. Cross over (Xover) PCR was used to generate the 30 bp deletion. The term for 
these vectors was p2rpoBMT; where reference is made to a specific mutation, for example 
the S531L mutation, the vector would be called p2rpoBS531L (Table 2.2). The PacI marker 
cassette was added to facilitate selection during allelic exchange.  
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aphC (KANR)
PCR based-SDM
Digestion of p2NIL with Acc65I 
and BamHI and fill in using 
Klenow
p2NIL to be used as core vector, 
Acc65I and BamHI sites need to be 
removed to facilitate cloning of 
mutated rpoB fragment later
Phase 1: Construction of wild-type MSM rpoB template for subsequent SDM 
experiments
Re-ligation of vector 
(now p2NIL AB)
PCR of wild type rpoB using primers with HindIII and ScaI sites 
HindIII ScaIBamHI Acc65I
rpoB gene
Phase 2: SDM to generate RIFR point mutations and cloning of these into p2NILAB yield suicide vector 
for allelic exchange mutagenesis
Cloning of WT rpoB fragment into p2NIL AB to yield template
p2rpoB
(8256 bp)
Reverse ‘outer’ primer
MT
Forward mutagenic ‘inner’ primer
Acc65I
round 1
BamHI
round 2
Forward ‘outer’ primer
Reverse ‘megaprimer’
Standard p2NIL
(4753 bp)
Cloning of mutated rpoB fragment into 
p2NILAB to yield suicide vector
BamHI
Acc65I
BamHI
Acc65I
ScaI
HindIII
PacI
aphC (KANR)
p2rpoBMT
(8256 bp)
BamHI
Acc65I
MT
MT
Figure 2.1 Schematic summary of the cloning strategy used in this project. 
During phase 1 of this strategy, the wild-type rpoB gene (green) was amplified by PCR, 
and inserted into a modified version of the p2NIL vector (p2NILAB) to generate the 
p2rpoB template. PCR-based SDM (or Xover-PCR for the 30 bp deletion) was performed 
on a small region of the rpoB gene (red), and the resultant fragment containing the 
mutation of interest was inserted back into the p2rpoB template to generate the 
p2rpoBMT vector.  
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2.4.1.2 Suicide vector construction 
 
Generation of template for SDM 
a) Modification of p2NIL vector backbone: fill-in using DNA polymerase Large Fragment I 
(Klenow) 
The core vector used to generate the p2rpoB template was p2NIL (Parish & Stoker, 2000). 
However, as indicated in Figure 2.1, Acc65I (New England Biolabs, USA) and BamHI (New 
England Biolabs, USA) restriction sites were used to facilitate cloning of the mutated 
fragment of rpoB back into the full length rpoB gene. Since these sites occur in the rpoB 
gene, and in the p2NIL vector, they had to be removed from the vector to prevent 
digestion at two sites during cloning. Restriction digestion was carried out as described in 
Section 2.3.4.1. After digestion with Acc65I, Klenow enzyme (New England Biolabs, USA) 
was used to fill in the overhangs at each end. The Klenow fragment retains polymerase 
activity as well as 3’ → 5’ exonuclease activity, but has lost 5’ → 3’ exonuclease activity. 
The following components were included in the reaction mixture:  1 µg of DNA; 200 µM 
of each dNTP; 1 X Klenow buffer. The sample was made up to 15 µl with dsH20. The 
reaction was incubated for 13 min at 37 °C. Incubation time was found to be an 
important parameter and it was found that longer incubation times induced excessive 3’ 
→ 5’ exonuclease activity which resulted in failed ligation reactions. After Klenow fill in of 
the Acc65I site, the vector was re-ligated using T4 DNA ligase with reaction conditions as 
described in 2.3.4.3. E. coli was transformed with this modified version of p2NIL (p2NILA) 
and, after screening for removal of the Acc65I site, the BamHI site was removed by the 
same process. The resultant vector had both the Acc65I and BamHI sites removed 
(p2NILAB). The p2NIL vector contains the aphC gene which confers KANR. Removal of 
Acc65I and BamHI sites did not disrupt this gene, and therefore transformed E. coli 
colonies were selected on LA plates containing KAN200.  
 
b) Isolation of full length rpoB gene from MSM chromosome 
The full length wild-type MSM rpoB gene with 300 bp up-stream flanking sequence was 
amplified from wild-type MSM by PCR.  It was important to include 300 bp up-stream 
sequence to ensure the inclusion in the final construct of the (unknown) rpoB promoter 
region. Phusion High Fidelity DNA PolymeraseTM was employed according to 
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manufacturer’s specifications as described in Section 2.3.6.1. Primers used were 
WholerpoBF and WholerpoBR (Appendix 5.5). The following cycling conditions were used: 
Initial denaturation at 98˚ C for 2 min to facilitate denaturation of double stranded DNA 
molecule, 30 cycles of [denaturation at 98 ˚C for 30 s; annealing of 60 ˚C for 30 s, and 
extension at 72 ˚C for 2 min] and a final extension at 72 ˚C for 7 min to ensure all DNA 
molecules had been replicated.  
 
The manufacturer suggests that, when using Phusion High Fidelity DNA PolymeraseTM, 
extension times of 15 – 30 s for every kb of DNA is employed. Given that the rpoB gene is 
3510 bp in length and 300 bp up-stream sequence was included, 2 min extension time 
was used. 
 
c) Cloning of full length rpoB into p2NILAB 
The WholerpoBF and WholerpoBR primers were designed so that HindIII and ScaI 
restriction sites were introduced into the PCR product (Appendix 5.5). The rpoB PCR 
product and the p2NILAB vector were digested with HindIII and ScaI these enzymes as 
described in Section 2.3.4.1. Fragments were separated and purified from an agarose gel 
as described in Section 2.3.3 Digestion of the p2NILAB vector with HindIII and ScaI yielded 
two fragments of 398 bp and 4363 bp. The 4363 bp fragment was required for cloning, 
and was isolated from the agarose gel accordingly. Digestion of the rpoB PCR product 
with HindIII and ScaI shaved a few base pairs off either end of the fragment. A ligation 
reaction was set up as described in 2.3.4.3 and, after overnight incubation, competent E. 
coli cells were transformed as described in 2.3.5.1 and selected on LA plates containing 
KAN200. Colonies were screened for the presence of the correct vector and restriction 
analysis of the correct vector ensured vector integrity. The following enzymes were use 
to check the vector integrity HindIII, ScaI, Acc65I BamHI and BfaI (New England Biolabs, 
USA). In this way a template for SDM was generated (p2rpoB).  
 
2.4.1.4 SDM  
To introduce point mutations into the rpoB gene, a PCR-based SDM method was used 
(Smith & Klugman, 1997). This technique involved two rounds of PCR (Figure 3.4). In the 
 49 
 
first round, a non-mutagenic reverse “outer” primer was used in combination with a 
forward primer designed to introduce the desired point mutation, and amplify the down-
stream sequence. A non-mutagenic forward “outer” primer was used in the second round 
of PCR, while the PCR product of the first round was then used as the reverse primer. In 
this way the entire region of interest was amplified, while introducing a single desired 
point mutation. This method is often referred to as the “megaprimer” method owing to 
the large size of the primer used in the second round of PCR (Smith & Klugman, 1997). 
Following mutagenic PCR, fragments were inserted back into the p2rpoB vector and AS-
PCR was used to confirm the SDM process was successful in introducing the correct point 
mutation. Constructs were also sequenced to ensure that unwanted point mutations had 
not been introduced during PCR.  
 
a) Round one of SDM 
In the first round of PCR for SDM, the megaprimer containing the point mutation of 
interest was generated. A forward mutagenic inner primer was used to introduce the 
point mutation of interest. The SDM outer R primer was used as the reverse primer 
however the forward mutagenic primer for each mutation would be different (Appendix 
5.5). The final size of the megaprimer varied slightly for each mutation. Specific sizes 
were as follows: S531L) 537 bp; H526Y) 553 bp L521L) 568 bp Q513V) 592 bp and 
TH526Y) 554 bp. In this PCR reaction it was of utmost importance that unwanted, off-site 
mutations were not introduced into the PCR product. Therefore, the Phusion High Fidelity 
DNA PolymeraseTM enzyme was employed using reaction component concentrations as 
described in 2.3.6.1. The following cycling conditions were utilised:  Initial denaturation at 
98 ˚C for 2 min; 30 cycles of [98 ˚C for 30 s; 60 ˚C for 30 s, and 72 ˚C for 90 s] and a final 
extension at 72 ˚C for 7 min. Resultant product was visualised, and purified from a 1 % 
agarose gel to be used as the megaprimer in the next round of PCR. 
 
b) Round two of SDM 
The megaprimer contained the point mutation of interest, and its use in the second 
round of PCR facilitated introduction of the mutation into the full-length product (Figure 
3.4). A common outer forward primer (SDM outer F) was used in this reaction (Appendix 
5.5). For the first five cycles of PCR, only the megaprimer, and not the forward primer, 
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was included in the reaction. All other reaction components necessary for High Fidelity 
DNA PolymeraseTM were included in the reaction mixture. As a result of the unusual 
length of the megaprimer, inclusion of only this primer for the first five rounds of PCR 
increased binding of the megaprimer to the template. The cycling conditions of the first 
five rounds of PCR were as follows: Initial denaturation: 98 ˚C for 2 min; 5 cycles of [98 ˚C 
for 30 s and 72 ˚C for 120 s]. Only denaturation and extension were included so that the 
megaprimer was allowed to bind to fragments and extend fragments. Thereafter, the 
forward primer was added and amplification continued for another 25 cycles. The cycling 
conditions for the second half of the reaction were: Initial denaturation: 98 ˚C for 2 min; 
25 cycles of [98 ˚C for 30 s; 60 ˚C for 30 s, and 72˚ C for 120 s]. This strategy produced a 
1578 bp fragment containing the mutation of interest. Fragments were visualised and 
purified from a 1 % agarose gel.  
 
2.4.1.5 Xover-PCR 
The “megaprimer” method could not be used to generate the 30 bp deletion, therefore 
Xover-PCR was used (Link et al., 1997). Two rounds of PCR were necessary to generate 
the final product containing the 30 bp deletion. Moreover, during the first round of PCR 
two separate reactions are set up. To amplify the region up-stream from the deletion, 
reaction A was set up and reaction B was set up to amplify the region down-stream from 
the deletion. The reverse primer used in reaction A is unique in that it contains a “tail” at 
the 3’ end, which is homologous to the 5’ end of the region down-stream from the 
deletion (Figure 3.5 and Appendix 5.5). Products from the first set of PCR were purified 
on a 1 % agarose gel, and used as templates in the second round of PCR. The product 
from reaction A contains a region that is homologous to the product of reaction B. This 
facilitates homologous recombination between the two products. For this reason it was 
important to allow for five rounds of PCR without addition of the outer primers. This 
allowed for recombination and for “fill-in” of the ends by the DNA polymerase. After 
outer primer addition, the full length product was amplified. In this reaction, two general 
outer primers were used (SDM outer F and SDM outer R; Appendix 5.5). 
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a) Round one of Xover-PCR 
During this the first round of Xover-PCR, two separate reactions were set up. In reaction 
A, the region up-stream of the deletion was amplified. This was accomplished using a 
non-mutagenic forward primer (SDM outer F), and a unique reverse primer (Appendix 
5.5). The reverse primer (Xover R inner) was unique in that the 3’ region contained a 
portion that was homologous to the 5’ region of the rpoB region down-stream of the 
deletion (Figure 3.5). In this way, this homologous region was introduced into the product 
of reaction A (2237 bp). In reaction B, both the forward (Xover F inner) and the reverse 
primer (SDM outer R) were non-mutagenic and generated a 1596 bp product. Phusion 
High Fidelity DNA PolymeraseTM enzyme was employed using reaction component 
concentrations as described in 2.3.6.1. The following cycling conditions (for both reaction 
A and B) were utilized:  Initial denaturation at 98 ˚C for 2 min; 30 cycles of [98 ˚C for 30 s; 
63 ˚C for 30 s, and 72 ˚C for 90 s] and a final extension at 72 ˚C for 7 min. Resultant 
product was visualised, and purified from a 1 % agarose gel to be used as the template in 
the next round of PCR. 
 
b) Round two of Xover-PCR 
The products of reaction A and B from the first round of Xover-PCR, were used as a 
template in the second round. The reverse primer from reaction B contained a tail that 
was homologous to the 5’ region of the product of reaction A, and in this way this region 
was introduced into the product of reaction A (Figure 3.5). All reaction components 
necessary for High Fidelity DNA PolymeraseTM were included in the reaction mixture. Due 
to homologous regions in the fragments generated in round 1, recombination should 
occur. Primers were excluded for the first ten rounds of this PCR to maximize 
recombination, and to allow the DNA polymerase to “fill in” ends. Thereafter, non-
mutagenic outer primers were added, and the PCR continued. The cycling conditions of 
the first ten rounds of PCR were as follows: Initial denaturation: 98 ˚C for 2 min; 10 cycles 
of [98 ˚C for 30 s; 60 ˚C for 30 s and 72 ˚C for 55 s]. Thereafter, the forward (SDM outer F) 
and reverse primers (SDM outer R) were added and amplification continued for another 
20 cycles. The cycling conditions for the second part of the reaction were: Initial 
denaturation: 98 ˚C for 2 min; 25 cycles of [98 ˚C for 30 s; 60 ˚C for 30 s, and 72˚C for 155 
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s]. This strategy produced a 1578 bp fragment containing the mutation of interest. 
Fragments were visualised and purified from a 1 % agarose gel.  
 
2.4.1.5 Cloning of SDM and Xover-PCR products into the template 
Once fragments containing the desired rpoB mutation had been successfully generated 
via PCR-based SDM, they were inserted back into the p2rpoB vector to generate 
p2rpoBMT vectors (Figure 2.1).  Acc65I and BamHI were used to digest SDM (or Xover-
PCR) fragments, and the template, using conditions as described in 2.3.4.1. Digested SDM 
(or Xover-PCR) fragments and vector were visualised and isolated from a 1 % agarose gel. 
Digestion of the p2rpoB vector with Acc65I and BamHI yielded fragments of 6676 bp and 
1555 bp. The 6676 bp fragment was required, and was purified from the agarose gel as 
described in 2.3.3. The phosphate groups were removed from the vector as described in 
2.3.4.2, and ligation proceeded as in 2.3.4.3. Vector insert molar ratios of 1:1; 1:2 and 1:3 
were employed. The resultant ligation reactions were used to transform competent E. 
coli cells as described in 2.3.5.1, and colonies were screened for the presence of the 
correct vector. AS-PCR was used to screen for the presence of the specific mutation.  
 
2.4.1.6 PacI cloning 
Upon successful generation of p2rpoB vectors containing the desired mutation, a marker 
gene cassette was added to the vectors to complete suicide vector construction. The 
marker gene cassette contained genes which facilitate selection during allelic exchange in 
MSM. The selection strategy is described in detail in Section 2.4.2. The marker cassette 
was obtained from pGOAL19 (Parish & Stoker, 2000). Both the pGOAL19 vector, and 
p2rpoBMT vectors were digested with PacI under conditions as described in 2.3.4.1. 
Digestion of pGOAL19 vector with PacI resulted in 7939 bp and 2496 bp fragments. The 
7939 bp fragment was isolated from the agarose gel. Digestion of the p2rpoBMT vectors 
with the PacI enzyme linearised the vector, which was purified from an agarose gel to 
ensure any uncut vector was no present. After removal of 5’ phosphate groups from the 
vector, ligation of was accomplished as described in 2.3.4.3, and E. coli cells were 
transformed. Plasmids were extracted using the large scale extraction protocol as 
described in 2.3.2.1, and used for subsequent allelic exchange.  
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2.4.2 Generation of MSM mutants containing RIFR-associated mutations: allelic 
exchange 
Allelic exchange mutagenesis allows introduction of the required mutation into the MSM 
chromosome and is essentially dependent on homologous recombination. The p2NIL 
vector series, which was used for the construction of all suicide vectors, contains an oriE 
site for replication in E. coli, and the aphC gene which confers KANR for selection in both 
E. coli and mycobacteria (Parish & Stoker, 2000). As described in Section 2.4.1.6, the 
marker cassette was added to the p2rpoBMT constructs using the PacI cloning strategy. 
The marker gene cassette comprises Ag85p-lacZ; hsp60p-sacB; and the HYGR gene 
(Gordhan and Parish, 2001). Using the Ag85 promoter, mycobacteria are able to 
constitutively express the lacZ operon and form blue colonies on X-gal (Gordhan and 
Parish, 2001), while cells expressing the sacB gene, express levansucrase and are unable 
to grow in media containing sucrose (Machowski et al., 2005). The use of HYGR as well as 
KANR decreases the likelihood of false positives due to spontaneous mutation (Gordhan 
and Parish, 2001).  The allelic exchange process involves two selection steps. In the 
primary selection step cells are plated onto solid media containing KAN, HYG and X-gal. 
Blue colonies that are able to grow on KAN and HYG indicate that in those cells a single 
cross over (SCO) event has occurred and that the mycobacterial chromosome now 
includes the artificial vector as well as the native gene (Gordhan and Parish, 2001). Blue 
colonies from the primary selection step are streaked onto solid media to allow the 
second, DCO event to occur, and then plated on solid media containing sucrose as well as 
X-gal. White colonies that are sucrose tolerant indicate two possible events. The desirable 
outcome is that a DCO has occurred that has, in essence, “looped out” the vector 
containing the marker genes. If the sacB gene was still present, cells would not be 
tolerant of sucrose, and blue colonies would indicate that lacZ was still present. The 
second possibility is that cells are wild-type revertants that have eliminated the inserted 
DNA through the same process of homologous recombination. The protocol that was 
used was a slight departure from the standard allelic mutagenesis technique in that the 
original was developed to create gene deletion mutants (Gordhan and Parish, 2001). For 
our purposes, it was of utmost importance that the rpoB gene was kept exactly the same 
as (isogenic with) the wild-type, except for the specific RIFR mutation. For this reason, an 
unmarked mutant was engineered. HYGR genes could not be used to mark allele 
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replacement, nor could they be used to selectively drive a DCO event. DNA extracted 
from “white, sucrose resistant, second selection step colonies”, was screened via AS-PCR 
to ensure the point mutation has been successfully cloned into the rpoB gene. This 
system was developed for use in mycobacterial strains by Dr. Bhavna Gordhan, a long-
time member of the MMRU, in collaboration with Dr. Tanya Parish (Gordhan and Parish, 
2001).  
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2.4.2.1 First step of allelic exchange: Generation of SCO strains 
Each suicide vector was introduced into MSM by electroporation as described in Section 
2.3.5.2. After electroporation and cell recovery, cells were plated on 7H10 OADC media 
containing KAN20; HYG50 and X-gal. Blue colonies that were able to grow on 7H10 OADC 
KAN20HYG50X-gal plates indicated that a probable SCO event had occurred. These colonies 
upstream  SCO
suicide vector with  
mutated rpoB
chromosomal DNAWT rpoB
a
MT
MT
downstream SCO
MT
chromosomal DNA
b
KANR
HYGR
85lacZ
sacB
a b
chromosomal DNA chromosomal DNAmutated rpoBMT
Culture in antibiotic free 7H9 OADC 
and screening via AS-PCR
DCO cross over strain containing RIFR
associated mutation in rpoB
WT
WT
Figure 2.2 Schematic representation of allelic exchange process. 
A cross over event mediated by homologous recombination can occur at two sites a) If 
a cross over occurs at site A, an up-stream SCO strain is generated, and the mutant 
(MT) rpoB allele had been inserted up-stream from the wild-type (WT). b) If the cross 
over happened at site B, a down-stream SCO was generated. During the first step of 
allelic exchange, strains were selected on antibiotic containing media (KAN20HYG50). 
During the second step of allelic exchange, SCO strains were cultured in antibiotic-free 
media to allow for a DCO event and loss of marker genes. Resultant strains were either 
wild-type revertants, or mutants containing the RIFR-associated mutation of interest. 
AS-PCR was used to screen for the presence of the mutation. The rpoB gene is 
indicated in green; promoter sequence in yellow and vector sequence in blue. 
 56 
 
were picked, and cultured overnight in 7H9 OADC media containing KAN20HYG50. DNA 
was extracted using the CTAB extraction method and the orientation and presence of the 
mutation was verified as described in 2.4.2.4. 
 
2.4.2.2 PCR strategy to determine orientation of SCOs 
During the first step of allelic exchange, the gene of interest can be inserted into the 
mycobacterial chromosome in one of two orientations. The mutated version of the rpoB 
gene may have been inserted up-stream of the native rpoB gene, or it may have been 
inserted down-stream of the native rpoB gene (Figure 2.3). A PCR strategy, using two 
primer sets, was designed to differentiate the up-stream and down-stream rpoB genes. 
The forward primer for the primer set one, UpOriF (F1 in Figure 2.3), was designed so that 
it would bind chromosomal sequence up-stream of the 300 bp rpoB promoter region. The 
reverse primer for primers set one, UpOriR (R1 in Figure 2.3), was designed to bind within 
the rpoB gene. In this way, only the up-stream gene would be amplified. For the primer 
set two, the forward primer, DownOriF (F2 in Figure 2.3), was designed to bind within the 
rpoB gene, while the reverse primer, DownOriR (R2 in Figure 2.3) (Appendix 5.5), was 
designed to bind in the chromosomal region down-stream of the rpoB gene. Given that 
the two rpoB genes would be separated in the chromosome by vector sequence, primer 
set one would be specific for the up-stream rpoB gene, and primer set two would be 
specific for the down-stream rpoB gene. The presence of the mutation was then checked 
using AS-PCR. If the mutation was present in the up-stream gene, then an up-stream SCO 
had been generated. Conversely, if the mutation was present in the down-stream rpoB 
gene, a down-stream SCO had been generated. This technique served the further 
purpose of confirming that the mutation had, been introduced into SCO strains.  
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To generate up-stream and down-stream rpoB fragments from SCO strains, DNA was 
extracted from SCO colonies using the CTAB method. Given that this was essentially a 
screening technique, and that DNA would not be used for further processing, the 
potential introduction of point mutations into the product was not that important, and 
therefore FastStart Taq DNA PolymeraseTM was used using reaction components as 
described in Section 2.3.6.2. The cycling conditions for this PCR were as follows: Initial 
denaturation at 95 ˚C for 2 min; 30 cycles of [95 ˚C for 30 s; 62 ˚C for 30 s, and 72 ˚C for 
90 s] and a final extension at 72 ˚C for 7 min. The product of the up-stream rpoB gene, 
using primer set one was 3259 bp; and the product for the down-stream rpoB gene, using 
primer set two was 2770 bp. These two product sizes were easily distinguishable on a 1 % 
agarose gel. Products were purified from an agarose gel, and AS-PCR was used to check 
for the presence of the mutations in either of the two fragments.  
 
2.4.2.3 Step two of allelic exchange: Generation of DCOs 
After the orientation of SCO strains and the presence of the mutation of these strains had 
been verified, DCO strains were generated. SCO strains were grown in antibiotic-free 7H9 
OADC media overnight at 37 ˚C with shaking at 120 rpm, to allow for a DCO event to 
occur. Subsequently, a serial dilution series of cells was prepared, and plated in duplicate 
on 7H10 OADC containing 2 % sucrose, and standard 7H10 OADC media. White colonies 
that were able to grow on sucrose indicated that the marker genes (lacZ and sacB) had 
been lost. DNA was extracted from these colonies using the colony boil methodology as 
WT/MT WT/MT
F1
R1 R2
F2
vector sequence
Figure 2.3 PCR strategy to determine orientation of SCO strains.  
Primer set one [F1+R1] is specific for the up-stream variant of the rpoB gene, while 
primer set two [F1+R1] is specific for the down-stream variant of the rpoB gene. AS- 
PCR was employed to determine which fragment contained the mutant (MT) allele and 
which fragment contained the wild-type allele (WT), and the presence of the mutation 
was confirmed by sequencing.  
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described in Section 2.3.2.7, and the presence (or absence) of the mutation was 
determined by AS-PCR. 
 
2.4.2.4 Screening for the presence of a point mutation: AS-PCR 
During the initial planning stages of this project, an allele-specific PCR (AS-PCR) strategy 
was designed to screen both suicide vectors and DCOs. This technique relies on the 
specificity of a particular primer for its complementary template in a PCR reaction, and 
forms the basis of commercially available molecular diagnostic kits for MDR-TB (Makinen 
et al., 2006). In this project, two sets of primers were designed for each mutation – one 
that is specific for the wild-type allele, and another that is specific for the mutant allele. 
Primers were designed so that the variable nucleotide was at the last position at the 3’ 
end of the primer. If the wild-type-specific primer is used in a reaction with a template 
containing the wild-type allele, a PCR product of the correct size should be formed. If the 
wild-type primer is included in a reaction containing a template with a mutant allele, no 
product should be formed. The same principle applies for mutant alleles and mutant 
specific primers (Figure 3.7). The AS-PCR methodology used to screen for mutations in 
plasmid DNA differed slightly from the methodology used to screen for mutation in DCO 
chromosomal DNA in that it required two rounds of PCR. During the first round, general 
outer primers were used to generate a 311 bp fragment that contained the RRDR. In the 
second of PCR, the AS-primer was used, together with a general reverse primer. 
 
a) AS-PCR: Screening for the presence of mutations in suicide vectors 
Once suicide vectors had been successfully generated, AS-PCR was employed to check for 
the presence of a mutation. To screen plasmid DNA two PCR reactions were set up for 
each sample. In each reaction, either wild-type-specific or mutant specific primer was 
used. Naming, and sequence, of mutant- or wild-type-specific primers are dependent on 
the mutation being screened (Appendix 5.5). In addition, in each reaction, a general 
forward and a general reverse primer were used (SDM outer F and SDM outer R). The 
addition of two general primers results in one band being formed for every reaction, 
which acts as a control to ensure successful amplification. If a wild-type-specific primer 
was used with a sample that contained the wild-type allele, an extra band would be 
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visible on the agarose gel. If a wild-type-specific primer was used in a sample containing a 
mutant allele, no extra product would be formed. For screening purposes, FastStart Taq 
DNA PolymeraseTM was employed using components as described in Section 2.3.6.2. The 
product of the general primers, SDM outer F and SDM outer R, was visible as a 1578 bp 
band on a 1 % agarose gel. Expected sizes of the additional (diagnostic) bands were as 
follows: S531L) 546 bp H526Y) 559 bp L521L) 576 bp Q513V) 597 bp TH526TY) 559bp 
30bp del) 597 bp. Annealing temperature of primers is important for AS-PCR therefore a 
gradient PCR was performed to ensure that binding of primers was specific (Figure 3.8). If 
the annealing temperature was too low, primers would bind to sequence non-specifically. 
If the primer specificity was reduced, a wild-type specific primer could bind to a mutant 
allele, and vice versa. This would have generated false results. If the annealing 
temperature was too high, primers would not have bind at all. Gradient AS-PCR 
conditions were as follows: Initial denaturation: 95 ˚C for 2 min; 30 cycles of [95 ˚C for 30 
s; (55 °C; 56.9 °C; 61.1°C or 64.2°C) for 30 s, and 72 ˚C for 2 min] and a final extension at 
72 ˚C for 7 min. Based on results from gradient AS-PCR an annealing temperature of 60 °C 
was selected for subsequent AS-PCR based screening of suicide vectors.  
 
2.4.2.5 AS-PCR: screening for the presence of mutations in DCOs 
The strategy to screen for the presence of a mutation in chromosomal DNA from possible 
MSM DCOs required considerable optimisation. Only MSM mutants containing S531L, 
H526Y, and L521L alleles were generated in this study; therefore, AS-PCR was only 
adapted for these mutations. In this version of the AS-PCR, two separate PCR steps were 
required. Instead of using three primers in one reaction, a fragment of the rpoB gene was 
amplified from the MSM genome using general primers. This PCR product was used in the 
next PCR as a template, with an AS-forward primer and a general reverse primer. If a 
band was formed in the second reaction, the correct AS-primer had been used with the 
correct allele. Positive controls used for this PCR included wild-type MSM chromosomal 
DNA, and chromosomal DNA from MSM strains with known rpoB mutations (generated 
by UV exposure, Digby Warner, unpublished results). FastStart Taq DNA PolymeraseTM 
was used for this screening technique with components as described in Section 2.3.6.2. 
SeqF RRDR and SeqR RRDR primers were used to 311 bp fragment from MSM 
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chromosomal DNA (Appendix 5.5). Cycling conditions for the first round of PCR were as 
follows: Initial denaturation 95 ˚C for 2 min; 20 cycles [95 ˚C for 30 s; 62 ˚C for 30 s, and 
72 ˚C for 30 s] and final extension at 72 ˚C for 7 min. 
 
The 311 bp product from reaction one was used as a template in the second round of 
PCR, where the AS-primer was used as the forward primer, and the Whole R3 primer was 
used as the reverse primer. Cycling conditions for this PCR were as follows. Initial 
denaturation: 95 ˚C for 2 min; 20 cycles of [95 ˚C for 15 s; 62 ˚C for 15 s, and 72 ˚C for 15 
s] and a final extension at 72 ˚C for 7 min. Given the short product formed by this round 
of PCR, only 15 s of extension time was required. Specific sizes of mutant bands are as 
follows: S531L) 109 bp H526Y) 122 bp L521L) 139 bp. A 2 % agarose gel was required to 
view these products. 
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2.4.3 Construction of rpoB containing pOLYG plasmids and electroporation into MSM 
The pOLYG vector is a HYGR–containing vector that replicates episomally in MSM 
(O'Gaora et al., 1997) and exists in multicopy at up to 23 copies per cell (Huff et al., 2010). 
Insertion of the rpoB gene into this vector allowed evaluation of the implication of over-
expression of rpoB in MSM. Wild-type and S531L and H526Y mutant versions of rpoB 
were inserted on the pOLYG vector. The rpoB containing pOLYG constructs were 
generated by digesting the pOLYG vector and the p2rpoB template with AclI and HindIII 
under conditions described in 2.3.4.1. The enzymes have the same buffer conditions and 
could therefore be used simultaneously in a single reaction. Digestion of the pOLYG 
backbone with AclI and HindIII resulted in 55 bp and 5260 bp fragments; the 5260 bp 
fragment was purified from the gel. Digestion of p2rpoB with AclI and HindIII yielded 4107 
bp and 4124 bp fragments, and the 4124 bp fragment was isolated from the gel. A 
ligation reaction was set up under conditions described in 2.3.4.3, and molar ratios of 
vector:insert of 1:1, 1:2 and 1:3 were used. The resultant ligation was transformed into 
competent E. coli cells, and plated on LA media containing HYG200. The pOLYG backbone 
contains resistance genes for HYG, and therefore only cells containing the vector grow on 
HYG200 LA plates. DNA was extracted using the small-scale extraction protocol, and 
screened for the presence of the correct vector. Cells containing the correct vector were 
inoculated into a larger scale culture, and a large-scale DNA extraction performed. AS-
PCR was used to confirm the presence of the mutation, where mutated versions of rpoB 
had been inserted into the pOLYG vector. Resulting constructs were transferred into 
MSM via electroporation as described in 2.3.5.2. Cells were selected on 7H10 OADC 
Figure 2.4 Generation MSM strains containing RIFR-associated mutations in rpoB.  
During the first phase, Acc65I, and BamHI sites were removed from the p2NIL vector 
(Section 2.4.1.2) to generate p2NILAB. The wild-type rpoB gene was isolated from MSM 
via PCR, and cloned into p2NILAB to generate p2rpoB (Section 2.4.1.2). SDM was 
performed on a portion of the wild-type rpoB gene to introduce RIFR-associated point 
mutations, (or Xover-PCR for the 30 bp deletion) into the rpoB gene. This fragment was 
cloned back into the p2rpoB vector, to generate p2rpoBMT (Section 2.4.1). These suicide 
vectors were electroporated into MSM, to allow for allelic exchange (Section 2.4.2). 
During the first step of SCO strains were selected on KAN20HYG50X-gal containing 7H10 
OADC plates. SCO strains were cultured in antibiotic free media to antibiotic free media 
to allow for generate DCO strains. The presence of a mutation was determined using AS-
PCR (Section 2.4. 2. 5) and confirmed by sequencing. The rpoB gene is indicated in 
green; promoter sequence in yellow and vector sequence in blue. 
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media containing HYG50. The HYG
R gene is expressed at higher levels in E. coli than it is in 
MSM, therefore higher concentrations of HYG are used to select for E. coli cells 
containing the pOLYG constructs than MSM cells.  
 
2.4.3.1 Electroduction 
The pOLYG constructs containing rpoB were isolated from putative MSM transformants 
after electroporation and selection by electroduction into E. coli. A single MSM colony 
containing the construct was re-suspended in 50 µl cold (4 ˚C) 10 % glycerol and 
incubated on ice for 10 min, and 70 µL of the electrocompetent E. coli cells were added. 
The sample was transferred to a 0.1 cm electroporation cuvette and cells were pulsed 
with the following conditions: 1.8 kV, 25 µF and 200 Ω.  A 500 µl aliquot of LB media was 
added to electroporated cells, which were incubated for 1 hour at 37 °C to allow for 
recovery. Cells were plated on LA plates containing HYG200. DNA was isolated from 
resultant colonies as described in 2.3.2.1.  
 
2.4.3.2 Toxicity evaluation and restriction analysis 
Re-arrangement of a plasmid after electroporation suggests that expression of the 
plasmid is toxic to the host cell. A restriction analysis of rpoB containing pOLYG plasmids 
was conducted to check for re-arrangement of the plasmid. DNA from cells obtained 
during electroduction experiments was extracted using the large-scale DNA extraction 
protocol (Section 2.3.2.1). The following restriction enzymes were applied to check the 
integrity of the plasmids AatII, EcoRI, NaeI and NspI (New England Biolabs, USA) under 
conditions described in 2.3.4.1 with buffers as described in Appendix 5.3. Standard 
pOLYG, as well as samples of the plasmids before electroporation, were also digested as 
controls.  
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2.4.5 RIF susceptibility (RIFS ) analyses 
2.4.5.1 RIFS on solid media 
Strains to be tested on RIF-containing solid media were grown to logarithmic phase and 
serial dilutions were prepared in un-supplemented 7H9 liquid medium. Aliquots (20 µl) of 
serial log-fold dilutions (100 – 10-6) were spotted on 7H10 OADC media containing 50 
µg/ml; 100 µg/ml; 200 µg/ml or 400 µg/ml RIF (RIF50; RIF100; RIF200; RIF400 respectively). 
Strains were also plated on standard OADC to measure growth, as well as 7H10 
KAN20HYG50Xgal plates to determine cross over status 
 
2.4.5.2 Mycobacterial Alamar Blue Assay (MABA) 
To assess the sensitivity of MSM strains containing RIFR associated mutations, the MABA 
technique was employed. This assay has been shown to detect drug resistance in clinical 
MTB isolates, and was modified from published standards to assay RIFS in MSM strains 
(Collins & Franzblau, 1997, Franzblau et al., 1998, Palomino et al., 2002). The utility of this 
assay resides largely in its use of 96-well plates which allow evaluation of MSM growth 
across a variety of MSM concentrations.  
 
The functionality of the microtitre plate derives from its ability to allow different 
concentrations of a compound(s) to be tested to be generated down the rows, while 
different kinds of growth analysis can be accomplished across the plates in the columns. 
A 50 µl sample of appropriate liquid media was added to all wells, except the upper-most 
wells. The compounds to be tested were then added to the upper-most row. The outer-
most columns served as controls to ensure that normal growth had occurred; therefore 
100 µl of media was added to those wells at the top of the outer-most columns. The next 
two inner columns served as controls to assay whether the RIF diluent had any effect on 
cell growth; therefore, 100 µL of the dimethyl sulphoxide (DMSO) diluent was added to 
the top most wells in the second outer-most column. The 4 innermost columns contained 
decreasing concentrations of RIF, and therefore 100 µL of an appropriate starting 
concentration of RIF was added to the upper-most well of the four inner columns of the 
plate. Initially a starting concentration of 1000 µg/ml of RIF was added, however when 
growth in higher concentrations of RIF were to be assayed a starting concentration of 
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4000 µg/ml of RIF was used.  Using a Research Pro 8 multichannel pipette (Eppendorf, 
Germany) 50 µL from the upper-most well was added to the second row, and then 50 µl 
was removed from this row and added to the next row. In this way a serial dilution of the 
contents in the upper-most wells (media, diluents and RIF) was achieved. 
 
Strains to be tested were grown to logarithmic phase in 7H9 OADC media, and diluted to 
and OD600 of 0.05 in un-supplemented 7H9 media. An aliquot (50 µl) of cells were added 
to all wells except the upper-most well. It is worth mentioning here that this halved the 
concentration of drug or diluents present in the wells after serial dilution. For example, if 
a 1000 µg/ml starting concentration of RIF was used, and serially diluted, the next row 
would contain a 50 µl of RIF at 500 µg/ml. However, when 50 µL of cells were added the 
concentration of RIF in this row was halved to 250 µg/ml. Moreover, by added cells to 
wells already containing 50 µl of liquid, the concentration of cells was halved to an OD600 
of 0.025.  
 
Plates were incubated for 48 hours at 37 ˚C without shaking. After 48 hours of incubation, 
10 µL Alamar Blue (Invitrogen, USA) was added to each well, and plates were incubated 
for a further 24 hours. The active compound in Alamar Blue, resazurin, changes colour 
upon reduction. A change from blue to pink indicates that growth has occurred. Given the 
deep red colour of RIF, there were some instances where a resazurin colour change could 
not be used to evaluate growth. In these cases, pellets from a selection of wells were 
plated on standard 7H10 OADC media to ensure that pellets were representative of cell 
growth, and not of cell debris due to cell death. 
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Figure 2.5 Schematic representation of preparation of MABA 96-well plates.  
Media is added to every well except the uppermost well. Diluent or RIF is added to the 
uppermost well, and a dilution series is prepared. At this point each well contains a 100 
µL solution. Thereafter, cells are added to every well, except the topmost well, which 
serves as a positive control. The final volume is each well is 150 µL 
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2.4.6 Evaluation of the physiological effects of RIFR-associated mutations: competition 
assays 
Competition assays were used to evaluate competitive growth between MSM strains 
containing an S531L mutation, and parental MSM strains. Each strain was grown in 
parallel in axenic culture as a control. Competition experiments were performed using 
7H9 OADC media, based on a modified version of Gagneux et al. (2006b). Strains were 
grown to logarithmic phase, and diluted to an OD600 of 0.05. Equal amounts of cells were 
added into a 250 ml Erlenmeyer flask. Cultures were incubated at 37 ˚C with 120 rpm 
shaking. For the first day, 1 ml samples were taken at 0 hours; 4.5 hours and 9 hours. For 
the next 6 days, samples were taken at 24 hour intervals, and every seven days 
thereafter. Samples (1 ml) were serially diluted in 0.5 % tween80. For measurements 
from the first day, 400 µl aliquots from dilutions 10-4 – 10-7 were plated on standard 7H10 
plates, and 400 µl were plated on plates containing RIF200. For all following 
measurements dilutions of 10-6 – 10-8 were plated. Plates were incubated for seven days, 
and colonies enumerated. An average of CFU/ml from at least two plates was used, and 
experiments were conducted in triplicate up until week 3. Two sets of cultures became 
contaminated after week three, therefore subsequent results describe a single 
experiment and so constitute preliminary data. The number of colony forming units 
(CFU/ml) was calculated using the following formula: 
 
[(number of colonies) X (dilution factor) X 2.50] = CFU/ml 
 
The relative fitness of strains was determined using the formula:  
 
W = ln (RF/R0)/ln (SF/S0) 
 
R0 and S0 indicate cell concentration of resistant (R) and susceptible (S) strains at the 
beginning of the experiment, and RF and SF indicate the final cell concentration of the 
same strains (Gagneux et al., 2006b).  
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3. Results  
3.1 Selection of rpoB mutations to study in this project 
A number of different rpoB mutations have been identified in clinical MTB strains that are 
resistant to RIF. These mutations have been associated with varied levels of RIFR and have 
been found to impose heterogeneous fitness costs (Gagneux et al., 2006b, Mariam et al., 
2004, Gillespie et al., 2002). At the onset of this study, we conducted an analysis of 
published literature to generate an inventory of RIFR-associated rpoB alleles identified in 
MTB in both clinical and in vitro studies. Our analysis revealed a set of mutations that are 
most commonly identified in both clinical and laboratory-generated RIFR MTB mutants 
(Table 3.1). More recently, Sandgren et al.  (2009) established the TBDReaMDB to 
document RIFR mutations in MTB (Sandgren et al., 2009), that became available 
subsequent to the completion of our analysis. Comparison of their results with ours 
reveals minor differences in reported mutation frequencies. However, these 
discrepancies are readily ascribed to the fact that Sandgren et al. (2009) used very 
specific inclusion criteria (for example, only clinical studies with more than 100 samples, 
that describe the proportion of both sensitive and resistant strains with an associated 
mutation were included) and were far more exhaustive in their analysis (Sandgren et al., 
2009). The TBDReaDB was not available at the start of this project, and therefore our 
literature analysis was intended to give some indication of commonly occurring 
mutations in clinical and lab-derived MTB isolates. Consequently, our literature analysis 
was by no means exhaustive, and we did not impose strict inclusion criteria.  
 
Based on the results of our analysis (Appendix 5.1), we selected five rpoB alleles for 
further study. Table 3.1 provides a list of the alleles selected for introduction into MSM, 
as well as the rationale for the investigation of these particular RIFR-associated mutations. 
It should be noted that, since the RRDR was initially defined in E. coli (Jin & Gross, 1988), 
mutations are conventionally referred to using the numbering of the E.coli rpoB gene 
(Telenti et al., 1993). 
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The observation that a silent mutation (L521L) was associated with relatively high levels 
of RIFR in a clinical isolate (Siddiqi et al., 2002) suggested this allele for inclusion in the 
study. The remaining three mutations were included owing to their potential significance 
as established by previous work at the MMRU (Table 3.1). The TH526TY mutation is 
commonly associated with error prone DNA polymerase activity, in particular DnaE2 
(Boshoff et al., 2003). In preliminary experiments at the MMRU, a MSM rpoB mutant 
containing a Q513V mutation displayed differential growth on OADC (oleic acid-albumin-
dextose-catalase) vs. Glucose-NaCl (Glucose Salt; GS) containing 7H10 media (D Warner 
and Susan Puckett, unpublished results). The 30 bp deletion has been isolated at the 
MMRU in response to DNA damaging agents and nutrient stress, and has also been 
studied in an independent study (Malshetty et al., 2010). 
Table 3.1 RIFR
Mutationa 
-associated mutations to be examined in this project 
Reason for study 
S531L (tcg→ttg) Most frequently isolated RIFR mutation in both clinical 
isolates as well as lab-derived RIFR strains (Appendix 
5.1) 
H526Y (cac→tac) Another common RIFR conferring mutation  (Appendix 
5.1)  
L521L (ctg→ttg) Silent mutation observed in clinical RIFR MTB strains 
(Yang et al., 1998, Siddiqi et al., 2002)  
Q513V (cag→gtg) In preliminary research at the MMRU, the equivalent 
mutation incurs no obvious growth phenotype in MSM 
cells cultures in different media in vitro; for this reason, 
the Q513V allele was identified as a potentially useful 
negative control. 
T-H526T-Y (acccac→acttac) A double transition mutation that is commonly 
associated with DnaE2 activity in both MTB and MSM. 
DnaE2 is an important error-prone DNA repair enzyme 
(Boshoff et al., 2003).  
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aMutations have been numbered according to the standard system based on the E. coli genome as per 
standard practise (Telenti et al., 1993) 
 
3.2 The use of MSM as a study organism  
There has been significant debate regarding the use of MSM as a model for answering 
questions pertinent to control of TB (Barry, 2001, Reyrat & Khan, 2001). There are 
significant differences in genome composition and biology between these two organisms 
(Barry, 2001) and moreover, there are important disparities in RIF metabolism. MSM has 
intrinsic RIF detoxifying mechanisms, and can tolerate much higher concentrations of RIF 
than MTB (Quan et al., 1997, Alexander et al., 2003, Dey et al., 2010). In spite of these 
important differences, several factors make MSM a useful study organism. The feasibility 
of introducing point mutations conducting this study in MSM or MTB was evaluated and 
it was clear that the use of MSM was preferable.  
 
Several physiologically significant and clinically relevant mycobacterial functions have 
been uncovered while studying MSM. For example, the characterisation of two proteins 
that form part of a damage-induced mutagenesis system in MTB was accomplished using 
an MSM based system (Warner et al., 2010). This enzymatic machinery plays an 
important role in MTB adaptation and the development of drug resistance, and is 
therefore an attractive drug target. The ability of MTB to modulate its growth is a key 
factor for virulence and survival under stress. Much of this growth modulation is 
dependent on rRNA synthesis (Stallings et al., 2009). Using MSM, Stallings et al. (2009) 
revealed by binding to RpoB, CarD regulates rRNA synthesis, and went on to show that 
CarD was essential for both replicative and persistent phases of MTB infection in mice. In 
a study more directly relevant to this project, genetic engineering of MSM was used to 
suggest a model for evolution of aminoglycoside resistance in MTB (Shcherbakov et al., 
A 30 bp deletion in the rpoB 
gene (Q512 – S522) 
 (cagttcatggacca 
gaacaacccgctgtcg) 
During studies at the MMRU, this deletion was isolated 
on more than one occasion, in response to exposure to 
UV irradiation, starvation, and treatment with 
replication inhibitors (Digby Warner, unpublished). This 
deletion has also been isolated in a separate study 
(Malshetty et al., 2010). 
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2010). Moreover, TMC207 – a promising new chemotherapeutic that inhibits both drug 
sensitive and drug-resistant TB – was initially isolated in a screen against MSM (Andries et 
al., 2005). These studies exemplify the usefulness of MSM for elucidating important 
physiological mechanisms, and how this information can be applied to clinical problems. 
 
Several practical considerations also informed the use of MSM. MSM is non-pathogenic, 
which allows use of this organism in a BLS2 laboratory, whereas any work involving MTB 
culture requires strict BSL3 conditions. MTB has an approximate generation time of 24 
hours as established in our lab, and colonies can take up to a month to be visible on a 
plate. In contrast, MSM has a generation time of 3 – 4 hours (Snapper et al., 1990), and 
growth can be elucidated after 2 – 3 days. Given the time constraints for a Masters 
research project, both biosafety and culture characteristics favoured MSM as a study 
organism. In addition, MSM is more amenable to genetic manipulation than MTB. SDM 
and allelic exchange were the methods of choice to introduce rpoB mutations into the 
chromosome of MSM. Although this kind of genetic manipulation was more time 
consuming, it was preferred as mutations could be introduced in the complete absence of 
RIF. We were firm on this, because any exposure to RIF may have introduced second-site 
mutations which would confound any assay of drug resistance, or physiological change. It 
is worth mentioning here, that this strategy fashioned the dual nature of this project. 
Generation of strains containing RIFR-associated mutations in the absence of RIF provided 
an opportunity to investigate the role of these mutations in RIFR, without second-site 
mutations. Had this been the primary aim, MTB might have been a more suitable model. 
However, the driving aim of this project was to investigate the implications of point 
mutations in rpoB for mycobacterial physiology, so for this purpose MSM was suitable.  
 
Recombineering has been used to introduce point mutations into the mycobacterial 
genes without the need for selection (van Kessel & Hatfull, 2008, van Kessel & Hatfull, 
2007). However, when this technique was applied to RIFR-associated mutations, RIF was 
used to select for mutants (van Kessel & Hatfull, 2008). Although it was technically 
feasible to use recombineering to generate point mutants without selection (van Kessel & 
Hatfull, 2008), mutagenesis and screening techniques would still have required 
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optimisation. Moreover, our laboratory has extensive experience in generating mutants 
via allelic exchange. For these reasons the combinatorial process of SDM and allelic 
exchange was therefore the preferred method for this project. Until this study, allelic 
exchange had never been used to introduce RIFR-associated mutations into the 
chromosome of a mycobacterial strain. Given the essentiality of rpoB for bacterial 
function, there was no certainty that this kind of genetic manipulation was viable in 
mycobacteria. The allelic exchange procedure requires two selection steps and the only 
difference between the wild-type gene, and the mutated version of rpoB (rpoBMT) was a 
point mutation. Therefore, screening for mutants after allelic exchange was accomplished 
using AS-PCR. The use of MSM provided the opportunity to assess the feasibility of this 
process in mycobacteria, within the time constraints of an MSc. After consideration of the 
aforementioned factors, we were confident that study of MSM would not only facilitate a 
proof-of-concept experiment that could be repeated in MTB, but also inform important 
issues relevant to mycobacterial physiology.  
 
3.3 Genomic context, sequence and structural similarity of MSM RpoB and 
MTB RpoB: A bioinformatic analysis 
The use of MSM to investigate drug resistance is expected to yield interesting insights 
into mycobacterial physiology. However, the clinical importance (and therefore clinical 
relevance) of this project demanded that all “proof-of-principle” work be applicable, as 
far as possible, to MTB in terms of the techniques developed as well as the implications 
for fundamental mycobacterial physiology. For this reason it was important to examine 
the similarities between the MSM and MTB rpoB genes – at the sequence level, and in 
terms of genomic context. Moreover, this information was essential for designing 
efficient cloning and allelic exchange strategies. The JCVI CMR (http://cmr.jcvi.org/tigr-
scripts/CMR/CmrHomePage.cgi) (Peterson et al., 2001) was used to examine the rpoB 
gene in both organisms.  
 
As shown in Figure 3.1, the genomic context of rpoB is conserved in mycobacteria: 
although the genes occurring up-stream of rpoB vary between species, in all cases rpoC is 
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located down-stream of rpoB. For allelic exchange, it was important to include sufficient 
promoter sequence in the suicide construct, (as discussed in Section 3.5.2) however, the 
sequence and co-ordinates of the rpoB promoter region in mycobacteria have not been 
defined. The gene map from the JCVI CMR indicates that in both MTB and MSM the rpoB 
gene is separated from the up-stream gene (Rv0666 in MTB; MSMEG_1366 (a putative 
ATP binding protein) in MSM,) by a large intergenic region. In MTB, the region is 498 bp in 
size, in MSM the region is 600 bp (Figure 3.1). In E. coli, rpoB occurs in a gene cluster that 
includes the rplKALJ operon which encodes the ribosome large-subunit (Passador & Linn, 
1989). Expression of rpoB and rpoC in E. coli is driven by strong promoters up-stream of 
rpLK and rpLJ. In contrast, the genetic organisation and transcriptional regulation of rpoB 
differs in B. subtilis (Boor et al., 1995). In this gram positive organism, an additional open 
reading frame (ORF) is present, which encodes a 22513 Da protein that is essential for B. 
subtilis viability (Boor et al., 1995). The rpoBC promoter element overlaps with the 3’ end 
of this ORF therefore expression of rpoBC is not dependent on promoter sequence up-
stream of the rplK and rplJ genes. If the mycobacterial rpoB gene arrangement is 
comparable to B. subtilis (Boor et al., 1995), the region up-stream of the rpoB gene is 
expected to contain the rpoB promoter. For this reason, the conservative decision was 
taken to retain at least 300 bp up-stream sequence in all MSM rpoB mutation alleles. 
Subsequent results (see Section: 3.5.2) provided strong evidence to suggest that the 
promoter was located in this region. 
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When MSM and MTB rpoB genes were compared using the BLASTn algorithm (Altschul et 
al., 1990) they were found to be 87 % similar.  When just the RRDR region was compared 
90 % similarity was reported. At the amino acid level the full length rpoB gene from these 
two organisms was 91 % similar. Most notably, the RRDR regions of both MTB and MSM 
RpoB proteins display perfect identity (Figure 3.2). To gain a sense of the position of 
important structural domains in RpoB, and how rpoB mutations may affect them, 
structural domains were mapped onto a multiple sequence alignment (MSA) generated in 
PROMALS3D (http://prodata.swmed.edu/promals3d/promals3d.php) (Pei et al., 2008). 
The PSI-BLAST (Altschul et al., 1997), and PSIPRED (Jones, 1999) databases are then 
scanned for secondary structure determination, and Hidden Markov Models are 
employed to examine the probabilities of the matches (Pei & Grishin, 2007). The 
conservation index is then determined, which indicates the level of functional or 
structural significance of conservation at a particular site (Pei & Grishin, 2001).  
Figure 3.1 The genomic context of rpoB is conserved in mycobacteria.  
The genomic context of rpoB in all mycobacterial genomes available on the JCVI CMR 
database (http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi) (Peterson et al., 2001) 
was retrieved on 03 January 2010. The E. coli and B. subtilis rpoB gene context is included 
at the top of the figure. The rpoB gene is indicated in the centre of the figure in black, and 
genes occurring immediately up- or down-stream are shown on either side. 
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Structural domains as defined by Lane and Darst (2010) were mapped onto the 
PROMALS3D alignment (Figure 3.2). Although it is beyond the scope of this discussion to 
describe structure-function relationships in detail, particularly interesting and pertinent 
features are summarized below. It is important to note that structural information comes 
from crystal structures of T. thermophilus (Vassylyev et al., 2007) and T. aquaticus (Zhang 
et al., 1999), and structural domains may not be precisely the same in other organisms. 
The β-lobe 1 domain contains the active site channel and covers the RNA/DNA hybrid 
(Lane & Darst, 2010b), and makes extensive interactions with the β’ subunit (Zhang et al., 
1999). In addition, β-lobe 1 contains a site important for interactions with transcription-
repair coupling factor (TRCF), and is therefore important for resolution of stalled RNAP 
(Westblade et al., 2010). The β-lobe 2 domain covers down-stream DNA during 
transcription and a large insertion in the E. coli sequence of this domain alters promoter 
specificity (Lane & Darst, 2010b). Together β-lobe 1 and 2 may have a role for opening 
and closing of the main RNA channel, which is important for maintenance of the 
transcription bubble during elongation, and for σ factor binding and release (Borukhov & 
Nudler, 2008). The fork loop 2 region is important for unwinding DNA during elongation, 
and maintaining the transcription bubble in the transcriptional elongation complex (TEC) 
(Lane & Darst, 2010b), and may play an important role in RNAP translocation (Borukhov 
& Nudler, 2008). Domains β-a10 – 14 contain key components of the RNAP active site and 
the β-flap contained within these domains is an important constituent of the RNA exit 
channel during elongation (Lane & Darst, 2010b), and for interactions with the β’ subunit 
(Darst, 2001). This region also undergoes significant alteration during σ factor binding 
(Vassylyev et al., 2002), and directly interacts with RNA during exit, which has 
implications for pausing and termination (Borukhov & Nudler, 2008). Within the flap tip, a 
short region termed the flap tip helix (not shown in Figure 3.2, but coordinates are listed 
in the Figure legend) is important for hairpin induced pausing (Lane & Darst), and for σ 
factor interaction (Vassylyev et al., 2002). The β-clamp region continues in the β’ primer 
subunit, and forms an important structural unit for elongation (Lane & Darst, 2001b). 
 
The RRDR region is mapped, and residues that directly interact with RIF are indicated in 
Figure 3.2 (hydrogen bonds: orange; van der Waals interactions: purple). The crystal 
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structure of core T. aquaticus RNAP enzyme, in complex with RIF, indicates that RIF binds 
close to the DNA/RNA channel, but only comes within 12 Å of the active site (Campbell et 
al., 2001). Six amino acids are able to form hydrogen bonds with RIF, and another six are 
likely to partake in van der Waals interactions. Of these 12 amino acids, 11 mutate in 
association with RIFR (I572, E. coli numbering, is just outside the RRDR). The 12th (E565, E. 
coli numbering) is highly conserved, and mutations at this site might be lethal (Campbell 
et al., 2001). However, this residue falls outside of the RRDR and therefore, mutations 
here may not have been detected in studies of RIFR isolates. Studies have shown that 
RIFR-associated mutations can have pleiotropic effects for transcriptional mechanisms (Jin 
& Gross, 1989, Jin & Gross, 1991, Landick et al., 1990). Looking at the map in Figure 3.2, it 
would not seem that the RRDR sits completely in any structural domain. However folding 
to form tertiary structures can greatly influence domain interactions, and therefore the 
RRDR is likely to intereact with structurally important regions. RIFR-associated mutations 
have long been studied for their effect of mechanistic aspects of transcription (Jin & 
Gross, 1989). Given the importance of RpoB for genetic expression, it is likely that the 
potential functional consequences of rpoB mutations have physiological implications.  
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ECO            101  RLVIYEREAPEGTVKDIKEQEVYMGEIPLMTDNGTFVINGTERVIVSQLHRSPGVFFDSDKGKTHSSGKV  170 
SAU             97  RLIIKE-------TGEVKEQEVFMGDFPLMTDTGTFVINGAERVIVSQLVRSPSVYFNEKIDK--NGREN  157 
BSU             97  RLINKE-------TGEVKDQDVFMGDFPIMTDTGTFIINGAERVIVSQLVRSPSVYFSGKVDK--NGKKG  157 
MSM            129  EFINNN-------TGEIKSQTVFMGDFPMMTEKGTFIINGTERVVVSQLVRSPGVYFDETIDK--STEKT  189 
MTB            138  EFINNN-------TGEIKSQTVFMGDFPMMTEKGTFIINGTERVVVSQLVRSPGVYFDETIDK--STDKT  198 
Consensus_aa:       phI.pp.......TGblKpppVFhGchPhMT-pGoFlINGh-RVlVSQlhRSPtVYFs.p.....ssc.s 
Consensus_ss:       eeee           eeeeeeeeeeeeeee   eeeeee   eeeeeehhh   eeeee          e 
 
 
Conservation:          6 69  9 99 966 6 6  6 6 66666 96 9 6 696696   66   66               
TTH            157  RYIASIIPLPKRGPWIDLEVEPNGVVSMKVNK-RKFPLVLLLRVLGYDQETLARELG-------------  212 
TAQ            157  RYIASIIPLPKRGPWIDLEVEASGVVTMKVNK-RKFPLVLLLRVLGYDQETLVRELS-------------  212 
ECO            171  LYNARII--PYRGSWLDFEFDPKDNLFVRIDRRRKLPATIILRALNYTTEQ-ILDLFFEKVIFEIRDNKL  237 
SAU            158  -YDATII--PNRGAWLEYETDAKDVVYVRIDRTRKLPLTVLLRALGFSSDQEIVDLL-------------  211 
BSU            158  -FTATVI--PNRGAWLEYETDAKDVVYVRIDRTRKLPVTVLLRALGFGSDQEILDLI-------------  211 
MSM            190  LHSVKVI--PGRGAWLEFDVDKRDTVGVRIDRKRRQPVTVLLKALGWTNEQ-IVERF-------------  243 
MTB            199  LHSVKVI--PSRGAWLEFDVDKRDTVGVRIDRKRRQPVTVLLKALGWTSEQ-IVERF-------------  252 
Consensus_aa:       .@.hplI..P.RGsWl-h-h-.pshV.h+ls+.R+bPlhlLL+hLG@sp-p.l.-............... 
Consensus_ss:       eeeeeeeee    eeeeeee    eeeeeeee ee  eeeeeee    hhhhhhhh               
 
 
Conservation:                                                                              
TTH                 ----------------------------------------------------------------------      
TAQ                 ----------------------------------------------------------------------      
ECO            238  QMELVPERLRGETASFDIEANGKVYVEKGRRITARHIRQLEKDDVKLIEVPVEYIAGKVVAKDYIDESTG  307 
SAU                 ----------------------------------------------------------------------      
BSU                 ----------------------------------------------------------------------      
MSM                 ----------------------------------------------------------------------      
MTB                 ----------------------------------------------------------------------      
Consensus_aa:       ...................................................................... 
Consensus_ss:                                                                              
 
 
Conservation:                                                 66           96  66  6999699 
TTH            213  ----------------------------------AYGELVQGLMDESVFAMRPEEALIRLFTLLRPGDPP  248 
TAQ            213  ----------------------------------AYGDLVQGLLDEAVLAMRPEEAMVRLFTLLRPGDPP  248 
ECO            308  ELICAANMELSLDLLAKLSQSGHKRIETLFTNDLDHGPYISETLRVDPTNDR-LSALVEIYRMMRPGEPP  376 
SAU            212  ----------------------------------GDNEYLRNTLEKDGTENT-EQALLEIYERLRPGEPP  246 
BSU            212  ----------------------------------GENEYLRNTLDKDNTENS-DKALLEIYERLRPGEPP  246 
MSM            244  ----------------------------------GFSEIMMGTLEKDTTSGT-DEALLDIYRKLRPGEPP  278 
MTB            253  ----------------------------------GFSEIMRSTLEKDNTVGT-DEALLDIYRKLRPGEPP  287 
Consensus_aa:       ..................................t.s-hhpshL-cssh..p.-pALlcl@p.LRPG-PP 
Consensus_ss:                                           hhhhhhhhhh      hhhhhhhhhhhh       
 
 
Conservation:       6 6 9  6   6 6 6 9999  69969 6 696             6     6    6            
TTH            249  KRDKAVAYVYGLIADPRRYDLGEAGRYKAEEKLGIR------LSGRTLARFEDGEF--KDEVFL------  304 
TAQ            249  KKDKALAYLFGLLADPKRYDLGEAGRYKAEEKLGVG------LSGRTLVRFEDGEF--KDEVFL------  304 
ECO            377  TREAAESLFENLFFSEDRYDLSAVGRMKFNRSL----------LREEI---EGSGILSKDDII-------  426 
SAU            247  TVENAKSLLYSRFFDPKRYDLASVGRYKTNKKLHLKHRLFNQKLAEPIVNTETGEIVVEEGTVLDRRKID  316 
BSU            247  TVENAKSLLDSRFFDPKRYDLANVGRYKINKKLHIKNRLFNQRLAETLVDPETGEILAEKGQILDRRTLD  316 
MSM            279  TKESAQTLLENLFFKEKRYDLARVGRYKVNKKLGLN-------AGKPI----TSSTLTEEDVV-------  330 
MTB            288  TKESAQTLLENLFFKEKRYDLARVGRYKVNKKLGLH-------VGEPI----TSSTLTEEDVV-------  339 
Consensus_aa:       p.-pAbshlbs.hhc.+RYDLtphGRYKhpcKL.lp........tcsl....stph..c-.hh....... 
Consensus_ss:        hhhhhhhhhhh          hhhhhhhhhhhhhh      hhhhhh           hhhhh       
 
 
 
β-lobe 1 
β-lobe 1 
β-lobe 1 β-lobe 2 
β-lobe 2 
β-lobe 2 
β-lobe 2 
β-lobe  
2 
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Conservation:                           6      6                  969                      
TTH            305  -------------------PTLRYLFALT---------------AGVPGH--------------------  320 
TAQ            305  -------------------PTLRYLFALT---------------AGVPGH--------------------  320 
ECO            427  -------------------DVMKKLIDIR-----------------------------------------  436 
SAU            317  EIMDVLESNANSEVFELHGSVIDEPVEIQSIKVYVPNDDEGRT-TTVIGNAFPDSEVKCITPADIIASMS  385 
BSU            317  KVLPYLENGIGFRKLYPNGGVVEDEVTLQSIKIFAPTDQEGEQVINVIGNAYIEEEIKNITPADIISSIS  386 
MSM            331  -------------------ATIEYLVRLH----------EGQTSMTVPGGVEVPV---------------  356 
MTB            340  -------------------ATIEYLVRLH----------EGQTTMTVPGGVEVPV---------------  365 
Consensus_aa:       ...................shlcbbh.lp...............hsV.G..................... 
Consensus_ss:                          hhhhhhhhhh               hh                         
 
 
Conservation:                  699999699996969996  6969696 9 69 96996  66   6696 669 69  9 
TTH            321  ----------EVDDIDHLGNRRIRTVGELMTDQFRVGLARLARGVRERMLMGSEDSLTPAKLVNSRPLEA  380 
TAQ            321  ----------EVDDIDHLGNRRIRTVGELMADQFRVGLARLARGVRERMVMGSPDTLTPAKLVNSRPLEA  380 
ECO            437  ------NGKGEVDDIDHLGNRRIRSVGEMAENQFRVGLVRVERAVKERLSLGDLDTLMPQDMINAKPISA  500 
SAU            386  YFFNLLSGIGYTDDIDHLGNRRLRSVGELLQNQFRIGLSRMERVVRERMSIQDTESITPQQLINIRPVIA  455 
BSU            387  YFFNLLHGVGDTDDIDHLGNRRLRSVGELLQNQFRIGLSRMERVVRERMSIQDTNTITPQQLINIRPVIA  456 
MSM            357  ----------EVDDIDHFGNRRLRTVGELIQNQIRVGLSRMERVVRERMTTQDVEAITPQTLINIRPVVA  416 
MTB            366  ----------ETDDIDHFGNRRLRTVGELIQNQIRVGMSRMERVVRERMTTQDVEAITPQTLINIRPVVA  425 
Consensus_aa:       ..........-hDDIDHhGNRRlRoVGELhpsQhRlGLtRh.RsVRERMsh.s.-slTP.pLlN.RPl.A 
Consensus_ss:                        hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh    hhh      hhh 
 
 
Conservation:       6 69996 999999696 9996 669999699999999699996 699999 69999 996999996999 
TTH            381  AIREFFSRSQLSQFKDETNPLSSLRHKRRISALGPGGLTRERAGFDVRDVHRTHYGRICPVETPEGANIG  450 
TAQ            381  ALREFFSRSQLSQFKDETNPLSSLRHKRRISALGPGGLTRERAGFDVRDVHRTHYGRICPVETPEGANIG  450 
ECO            501  AVKEFFGSSQLSQFMDQNNPLSEITHKRRISALGPGGLTRERAGFEVRDVHPTHYGRVCPIETPEGPNIG  570 
SAU            456  SIKEFFGSSQLSQFMDQANPLAELTHKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIG  525 
BSU            457  SIKEFFGSSQLSQFMDQTNPLAELTHKRRLSALGPGGLTRERAGMEVRDVHYSHYGRMCPIETPEGPNIG  526 
MSM            417  AIKEFFGTSQLSQFMDQNNPLSGLTHKRRLSALGPGGLSRERAGLEVRDVHPSHYGRMCPIETPEGPNIG  486 
MTB            426  AIKEFFGTSQLSQFMDQNNPLSGLTHKRRLSALGPGGLSRERAGLEVRDVHPSHYGRMCPIETPEGPNIG  495 
Consensus_aa:       tl+EFFtpSQLSQFbDpsNPLt.LpHKRRlSALGPGGLoRERAGh-VRDVH.oHYGRhCPlETPEGsNIG 
Consensus_ss:       hhhh      eeee     hhhhhhhhh        eeeeee              eeee        ee 
 
Conservation:       99 996 99 66  9966999969    6 66  6 9669 996 6669999   6    6    6  9  
TTH            451  LITSLAAYARVDELGFIRTPYRRV--VGGVVTDEVVYMTATEEDRYTIAQANTPLEGN-RIAAERVVARR  517 
TAQ            451  LITSLAAYARVDALGFIRTPYRRV--KNGVVTEEVVYMTASEEDRYTIAQANTPLEGD-RIATDRVVARR  517 
ECO            571  LINSLSVYAQTNEYGFLETPYRKV--TDGVVTDEIHYLSAIEEGNYVIAQANSNLDEEGHFVEDLVTCRS  638 
SAU            526  LINSLSSYARVNEFGFIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRF  595 
BSU            527  LINSLSSYAKVNRFGFIETPYRRVDPETGKVTGRIDYLTADEEDNYVVAQANARLDDEGAFIDDSIVARF  596 
MSM            487  LIGSLSVYARVNPFGFIETPYRKV--ENGVVTDQIDYLTADEEDRHVVAQANSPTDENGRFTEDRVMVRK  554 
MTB            496  LIGSLSVYARVNPFGFIETPYRKV--VDGVVSDGIVYLTADEEDRHVVAQANSPIDADGRFVEPRVLVRR  563 
Consensus_aa:       LIsSLtsYA+Vs.hGFIcTPYR+V...sGhVT-plsYhTAsEEDp@hlAQANo.l-.p.+hhp-pVhhR. 
Consensus_ss:       eehhhhhhhh          hhhe  eeeeee eeeee hhhh   eee       hh hh     eee  
 
 
Conservation:       6 96        66699996 9669  6  9999969969999996999699996    69 969969   
TTH            518  K-GEPVIVSPEEVEFMDVSPKQVFSVNTNLIPFLEHDDANRALMGSNMQTQAVPLIRAQAPVVMTGLEER  586 
TAQ            518  R-GEPVIVAPEEVEFMDVSPKQVFSLNTNLIPFLEHDDANRALMGSNMQTQAVPLIRAQAPVVMTGLEER  586 
ECO            639  K-GESSLFSRDQVDYMDVSTQQVVSVGASLIPFLEHDDANRALMGANMQRQAVPTLRADKPLVGTGMERA  707 
SAU            596  R-GNNTVMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTGMEHV  664 
BSU            597  R-GENTVVSRNRVDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMQPEAPFVGTGMEYV  665 
MSM            555  KGGEVEFVSADQVDYMDVSPRQMVSVATAMIPFLEHDDANRALMGANMQRQAVPLVRSEAPLVGTGMELR  624 
MTB            564  KAGEVEYVPSSEVDYMDVSPRQMVSVATAMIPFLEHDDANRALMGANMQRQAVPLVRSEAPLVGTGMELR  633 
Consensus_aa:       +.GEs.hht.ppV-@MDVSP+QhhShsTshIPFLEpDDtNRALMGtNMQpQAVPLhpspAPhV.TGhE.. 
Consensus_ss:            ee  hheeeeeeee  eee   eeeee        eeeee        eee          hhhh 
 
Conservation:          966        9 6  9    6 6            6    6 6 66 999 696 69 9 9  9   
TTH            587  VVRDSLAALYAEEDGEVAKVDGNRIVV--------RYEDGRLVEYPLRRFYRSNQGTALDQRPRVVVGQR  648 
TAQ            587  VVRDSLAALYAEEDGEVVKVDGTRIAV--------RYEDGRLVEHPLRRYARSNQGTAFDQRPRVRVGQR  648 
ECO            708  VAVDSGVTAVAKRGGVVQYVDASRIVI-KVNEDEMYPGEAGIDIYNLTKYTRSNQNTCINQMPCVSLGEP  776 
SAU            665  AARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSGTCYNQRPIVAVGDV  734 
BSU            666  SGKDSGAAVICKHPGIVERVEAKNVWVRRYEEVDGQKVKGNLDKYSLLKFVRSNQGTCYNQRPIVSVGDE  735 
MSM            625  AAIDAGDVVVADKTGVIEEVSADYITV--------MADDGTRQSYRLRKFARSNHGTCANQRPIVDAGQR  686 
MTB            634  AAIDA-ATSSSQESGVIEEVSADYITV--------MHDNGTRRTYRMRKFARSNHGTCANQCPIVDAGDR  694 
Consensus_aa:       hh.Dt.hhhhtccsG.l.cVpts.IhV...........cGp..pY.L.+@hRSNpGTthsQ.P.VshGp. 
Consensus_ss:       hh     ee      eeeee   eeee        ee    eeeeee                 eeee h 
 
 
 
 
 
Conservation:       9  6  69999    966999 9  966966 96969966  96666  9  9699966 6  6999999 
TTH            649  VRKGDLLADGPASENGFLALGQNVLVAIMPFDGYNFEDAIVISEELLKRDFYTSIHIERYEIEARDTKLG  718 
TAQ            649  VKKGDLLADGPASEEGFLALGQNVLVAIMPFDGYNFEDAIVISEELLKRDFYTSIHIERYEIEARDTKLG  718 
ECO            777  VERGDVLADGPSTDLGELALGQNMRVAFMPWNGYNFEDSILVSERVVQEDRFTTIHIQELACVSRDTKLG  846 
SAU            735  VEYNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERLVKDDVYTSIHIEEYESEARDTKLG  804 
BSU            736  VVKGEILADGPSMELGELALGRNVMVGFMTWDGYNYEDAIIMSERLVKDDVYTSIHIEEYESEARDTKLG  805 
MSM            687  VEAGQVIADGPCTQNGEMALGKNLLVAIMPWEGHNYEDAIILSNRLVEEDVLTSIHIEEHEIDARDTKLG  756 
MTB            695  VEAGQVIADGPCTDDGEMALGKNLLVAIMPWEGHNYEDAIILSNRLVEEDVLTSIHIEEHEIDARDTKLG  764 
Consensus_aa:       Vc.GpllADGPt.-.GbhALGpNlhVthMs@-G@N@EDAIlhSpcLlccDhhTSIHIEc@E.-ARDTKLG 
Consensus_ss:       h                     eeeeeee        eeeeeehhhhh   eeeeeeeeeeeeeee     
 
 
β-lobe 1 
 
β-lobe 1 Fork loop 2 
 
RRDR 
β-flap 
β-a10 
 
β-a11 
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Conservation:       6969969996 66 69  996 966699999  9969996666996 66669969966999999669696 
TTH            719  PERITRDIPHLSEAALRDLDEEGVVRIGAEVKPGDILVGRTSFKGESEPTPEERLLRSIFGEKARDVKDT  788 
TAQ            719  PERITRDIPHLSEAALRDLDEEGIVRIGAEVKPGDILVGRTSFKGEQEPSPEERLLRSIFGEKARDVKDT  788 
ECO            847  PEEITADIPNVGEAALSKLDESGIVYIGAEVTGGDILVGKVTPKGETQLTPEEKLLRAIFGEKASDVKDS  916 
SAU            805  PEEITRDIPNVSESALKNLDDRGIVYIGAEVKDGDILVGKVTPKGVTELTAEERLLHAIFGEKAREVRDT  874 
BSU            806  PEEITRDIPNVGEDALRNLDDRGIIRIGAEVKDGDLLVGKVTPKGVTELTAEERLLHAIFGEKAREVRDT  875 
MSM            757  AEEITRDIPNVSDEVLADLDERGIVRIGAEVRDGDILVGKVTPKGETELTPEERLLRAIFGEKAREVRDT  826 
MTB            765  AEEITRDIPNISDEVLADLDERGIVRIGAEVRDGDILVGKVTPKGETELTPEERLLRAIFGEKAREVRDT  834 
Consensus_aa:       sEcITRDIPplt-.hL.sLD-cGIV.IGAEV+sGDILVG+ho.KG.oE.TsEERLL+tIFGEKAR-V+DT 
Consensus_ss:         hh        hhhh             eee   eeeeee         hhhhhhhh        eeee 
 
 
 
 
Conservation:       99699 9 69 6    66 9                                                   
TTH            789  SLRVPPGEGGIVVRTVRLRRG-------------------------------------------------  809 
TAQ            789  SLRVPPGEGGIVVGRLRLRRG-------------------------------------------------  809 
ECO            917  SLRVPNGVSGTVIDVQVFTRDGVEKDKRALEIEEMQLKQAKKDLSEELQILEAGLFSRIRAVLVAGGVEA  986 
SAU            875  SLRVPHGAGGIVLDVKVFNRE-------------------------------------------------  895 
BSU            876  SLRVPHGGGGIIHDVKVFNRE-------------------------------------------------  896 
MSM            827  SLKVPHGESGKVIGIRVFSRE-------------------------------------------------  847 
MTB            835  SLKVPHGESGKVIGIRVFSRE-------------------------------------------------  855 
Consensus_aa:       SL+VP.G.tGbVlsh..hpR.................................................. 
Consensus_ss:       eeee     eeeeeeeeee                                                    
 
 
Conservation:                                                            6  9 699   9696 6 
TTH            810  ---------------------------------------------------DPGVELKPGVREVVRVYVA  828 
TAQ            810  ---------------------------------------------------DPGVELKPGVREVVRVFVA  828 
ECO            987  EKLDKLPRDRWLELGLTDEEKQNQLEQLAEQYDELKHEFEKKLEAKRRKITQGDD-LAPGVLKIVKVYLA 1055 
SAU            896  ---------------------------------------------------EGDDTLSPGVNQLVRVYIV  914 
BSU            897  ---------------------------------------------------DGDE-LPPGVNQLVRVYIV  914 
MSM            848  ---------------------------------------------------DDDE-LPAGVNELVRVYVA  865 
MTB            856  ---------------------------------------------------DEDE-LPAGVNELVRVYVA  873 
Consensus_aa:       ...................................................-ss..L.sGVpplVRVYlh 
Consensus_ss:                                                                    eeeeeeeee 
 
 
Conservation:       69966  99966699999996 99 9 9999 6 6969696 996699969996996996969  6     
TTH            829  QKRKLQVGDKLANRHGNKGVVAKILPVEDMPHLPDGTPVDVILNPLGVPSRMNLGQILETHLGLAGYF--  896 
TAQ            829  QKRKLQVGDKLANRHGNKGVVAKILPVEDMPHLPDGTPVDVILNPLGVPSRMNLGQILETHLGLAGYF--  896 
ECO           1056  VKRRIQPGDKMAGRHGNKGVISKINPIEDMPYDENGTPVDIVLNPLGVPSRMNIGQILETHLGMAAKGIG 1125 
SAU            915  QKRKIHVGDKMCGRHGNKGVISKIVPEEDMPYLPDGRPIDIMLNPLGVPSRMNIGQVLELHLGMAAKN--  982 
BSU            915  QKRKISEGDKMAGRHGNKGVISKILPEEDMPYLPDGTPIDIMLNPLGVPSRMNIGQVLELHMGMAARY--  982 
MSM            866  QKRKISDGDKLAGRHGNKGVIGKILPVEDMPFLPDGTPVDIILNTHGVPRRMNIGQILETHLGWVAKA-G  934 
MTB            874  QKRKISDGDKLAGRHGNKGVIGKILPVEDMPFLADGTPVDIILNTHGVPRRMNIGQILETHLGWCAHS-G  942 
Consensus_aa:       QKRKlpsGDKhAsRHGNKGVltKIlP.EDMP@LsDGTPlDlhLNshGVPpRMNlGQlLEhHLGhtt.... 
Consensus_ss:       ee    hhhhhhhhh   eeeeeeeehhh        eeeeee          hhhhhhhhhhhhhhh   
 
Conservation:              6                                                  6969999 6 6  
TTH            897  ------LGQR----------------------------------------------YISPIFDGAKEPEI  914 
TAQ            897  ------LGQR----------------------------------------------YISPVFDGATEPEI  914 
ECO           1126  DKINAMLKQQQEVAKLREFIQRAYDLGADVRQKVDLSTFSDEEVMRLAENLRKGMPIATPVFDGAKEAEI 1195 
SAU            983  ------LGIH----------------------------------------------VASPVFDGANDDDV 1000 
BSU            983  ------LGIH----------------------------------------------IASPVFDGAREEDV 1000 
MSM            935  WNIDVAAGVPDWASKLPEELYSA----------------------------PADSTVATPVFDGAQEGEL  976 
MTB            943  WKVDAAKGVPDWAARLPDELLEA----------------------------QPNAIVSTPVFDGAQEAEL  984 
Consensus_aa:       ......hG................................................hhoPVFDGApEs-l 
Consensus_ss:                e                                              e         hhhh 
 
Conservation:         66                                                   66  9699969966  
TTH            915  KELLAQAFEVYFGKRKGEGFGVDKREVEVLRRAEKLGLVTPGKTPEEQLKELFLQGKVVLYDGRTGEPIE  984 
TAQ            915  KELLAEAFNLYFGKRQGEGFGVDKREKEVLARAEKLGLVSPGKSPEEQLKELFDLGKVVLYDGRTGEPFE  984 
ECO           1196  KELLK-------------------------------------------LGDLPTSGQIRLYDGRTGEQFE 1222 
SAU           1001  WSTIE-------------------------------------------EAGMARDGKTVLYDGRTGEPFD 1027 
BSU           1001  WETLE-------------------------------------------EAGMSRDAKTVLYDGRTGEPFD 1027 
MSM            977  AGLLGSTL-----------------------------------PNRDGEVMVDADGKSTLFDGRSGEPFP 1011 
MTB            985  QGLLSCTL-----------------------------------PNRDGDVLVDADGKAMLFDGRSGEPFP 1019 
Consensus_aa:       b.hL............................................b..h..pGKhhL@DGRoGEPF. 
Consensus_ss:       hhhhhhhhhh               hhhhhhhhhh          hhhhh       eeeee     eee 
 
Conservation:        66 99 966 99 969699 9999996996699999999999999999999699669999969999 99 
TTH            985  GPIVVGQMFIMKLYHMVEDKMHARSTGPYSLITQQPLGGKAQFGGQRFGEMEVWALEAYGAAHTLQEMLT 1054 
TAQ            985  GPIVVGQMFIMKLYHMVEDKMHARSTGPYSLITQQPLGGKAQFGGQRFGEMEVWALEAYGAAHTLQEMLT 1054 
ECO           1223  RPVTVGYMYMLKLNHLVDDKMHARSTGSYSLVTQQPLGGKAQFGGQRFGEMEVWALEAYGAAYTLQEMLT 1292 
SAU           1028  NRISVGVMYMLKLAHMVDDKLHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEVWALEAYGAAYTLQEILT 1097 
BSU           1028  NRVSVGIMYMIKLAHMVDDKLHARSTGPYSLVTQQPLGGKAQFGGQRFGEMEVWALEAYGAAYTLQEILT 1097 
MSM           1012  YPVTVGYMYILKLHHLVDDKIHARSTGPYSMITQQPLGGKAQFGGQRFGEMECWAMQAYGAAYTLQELLT 1081 
MTB           1020  YPVTVGYMYIMKLHHLVDDKIHARSTGPYSMITQQPLGGKAQFGGQRFGEMECWAMQAYGAAYTLQELLT 1089 
Consensus_aa:       ..lsVGbM@hhKLhHhV-DKhHARSTGPYShlTQQPLGGKAQFGGQRFGEMEhWAhpAYGAA@TLQEhLT 
Consensus_ss:       eeeee hhhhhhhhhhh   eeeee       ee               hhhhhhhhhh hhhhhhhhhh 
 
 
 
 
 
β-a12 
β-flap 
β-flap 
β-flap 
β-flap tip 
β-a13 
β-a14 
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Conservation:        9999  99 6 9 69669    696 9999 99 996669  66   6                      
TTH           1055  LKSDDIEGRNAAYEAIIKGEDVPEPSVPESFRVLVKELQALALDVQTLDEKDNPVDIFEG---------- 1114 
TAQ           1055  IKSDDIEGRNAAYQAIIKGEDVPEPSVPESFRVLVKELQALALDVQTLDEKDNPVDIFEG---------- 1114 
ECO           1293  VKSDDVNGRTKMYKNIVDGNHQMEPGMPESFNVLLKEIRSLGINIELEDE-------------------- 1342 
SAU           1098  YKSDDTVGRVKTYEAIVKGENISRPSVPESFRVLMKELQSLGLDVKVMDEQDNEIEMTDVDDDDVVEHK- 1166 
BSU           1098  VKSDDVVGRVKTYEAIVKGDNVPEPGVPESFKVLIKELQSLGMDVKILSGDEEEIEMRDLEDEEDAKQAD 1167 
MSM           1082  IKSDDTVGRVKVYEAIVKGENIPEPGIPESFKVLLKELQSLCLNVEVLSSDGAAIEMRDGDDEDLERAAA 1151 
MTB           1090  IKS------------------------------------------------------------------- 1092 
Consensus_aa:       lKSDDh.GRs.hYcsIlcGpp..EPthPESFpVLlKElptLtlslphbsp.................... 
Consensus_ss:            eeeeeeee               hhhhhhhhhhhh     eeee    eee               
 
 
Conservation:                                  
TTH           1115  ---------------------LASKR 1119 
TAQ           1115  ---------------------LASKR 1119 
ECO                 --------------------------      
SAU           1167  -VDLQQNDAPE------TQKEVTD-- 1183 
BSU           1168  GLALSGDEEPEETASADVERDVVTKE 1193 
MSM           1152  NLGINLSRNES--------ASVEDLA 1169 
MTB                 --------------------------      
Consensus_aa:       .......................... 
Consensus_ss:                                  
 
 
 
 
 
 
 
 
 
 
 
 
3.4 Construction of suicide vector plasmids for allelic exchange 
In this study, a cloning strategy was designed to introduce selected rpoB alleles (Table 
3.1) into wild-type MSM using SDM to generate the specific point mutations, and allelic 
exchange for targeted mutagenesis. Although this strategy cannot eliminate the potential 
for second-site mutations, it does allow for the introduction of point mutations 
associated with RIFR into the chromosome of MSM without the need to expose bacilli to 
RIF to select for mutation. The first step in this process involved the construction of 
suicide vectors containing the relevant mutant MSM rpoB allele. E. coli DH5α was used as 
the host organism for vector construction and manipulation, as described (see Materials 
and Methods 2.4.1). 
β-region of clamp 
 
β-region of clamp 
 
Figure 3.2 The structural domains of RpoB.  
PROMALS3D (Pei et al., 2008) was used to align the full rpoB protein between of MTB 
(AAA20242.2), MSM (YP_885753.1), E.coli (ECO) (NP_418414); S. aureus (SAU) 
(YP_003281434.1); B. subtilis (ZP_03589766.1); T. aquaticus (TAQ) (CAB65465) and T. 
thermophilus (TTH) (2A6E_M). In the PROMALS3D alignment, representative sequences 
are coloured in magenta, and residues forming alpha-helix are red and β-strands blue. The 
first and last residues of each block are numbered. Consensus predicted secondary 
structure symbols: alpha-helix: h; beta-strand: e. Structural domains of the β subunit of 
RNAP polymerase, determined using the T. thermophilus ternary elongation complex 
structure (Vassylyev et al., 2007), were mapped as defined by Lane and Darst (2010b). 
Amino acid co-ordinates for each domain are as follows: β-lobe 1) Q22 – G125 and V336 – 
S392; β-lobe 2) R142 – A253; fork loop 2) P415 – E421 and D426 – R428; βa-10) V529 – 
D590; β-a11) F665 – K716; β-a12) A733 – K762; β-a13) D787 – V804; βa14) V823 – G894; β-
flap) I705 – A828; flap tip) G763 – D784; flap tip helix) P769 – G779; β-clamp) D1058 – 
A1116 (continues in the β’);  RRDR) F385 – G417. Residues that can interact with RIF are 
highlighted in orange: hydrogen bonding and purple: van der Waals interactions (Campbell 
et al., 2001). Conservation indices above 4 are shown in the first line above each block. 
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3.4.1 Modification of p2NIL to remove Acc65I and BamHI restriction sites 
The core plasmid vector used in this study was p2NIL (Parish & Stoker, 2000). This vector 
carries an aphC gene which confers kanamycin resistance (KANR), thereby facilitating 
selection of E. coli and MSM transformants. Replication of p2NIL in E. coli begins at the 
oriE site, and no mycobacterium-specific origin of replication is present. Therefore p2NIL 
is a suicide vector for mycobacteria. This vector also has a multiple cloning site, which 
includes a single PacI site for convenient addition of the two-step selection cassette 
developed for use in mycobacteria by Parish and Stoker (Parish & Stoker, 2000). 
Naturally-occurring Acc65I and BamHI restriction sites are located within the wild-type 
rpoB gene in MSM and were used for subsequent cloning (Figure 3.3). Therefore these 
sites were removed from the p2NIL backbone: that is, the vector was digested with 
Acc65I and the resulting 5’ overhangs filled in using the large (Klenow) fragment of E. coli 
DNA polymerase before re-circularization of the plasmid by ligation of the blunt ends. The 
BamHI sites in p2NIL were removed in a similar process. Digestion and fill in of Acc65I and 
BamHI sites, individually, resulted in a small increase (8 bp) in plasmid size. To confirm 
that both sites had been removed, an aliquot of the modified version of p2NIL – 
designated p2NILAB – was exposed to Acc65I and BamHI. After overnight incubation, the 
plasmid remained undigested (Figure 3.3), verifying that these sites had been eliminated. 
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3.4.2 Construction of a template for SDM 
A suitable template for SDM and suicide vector assembly was constructed by cloning 
wild-type MSM rpoB into p2NILAB. Primers were designed to amplify wild-type rpoB 
(Appendix 5.5) including 300 bp up-stream sequence thought to include the promoter 
(see Section 3.5.2). Artificial ScaI and HindIII restriction sites were included in the primer 
sequences to facilitate subsequent cloning into p2NILAB using the corresponding sites. 
The resulting 3893 bp PCR product was cloned into p2NILAB to generate p2rpoB. The 
integrity of the 8256 bp p2rpoB vector was established by restriction analysis and to 
confirm its suitability as a template for the subsequent construction of mutant rpoB 
alleles. Sequencing of the entire rpoB gene on the p2rpoB vector confirmed that no point 
mutations had been introduced into during cloning. Sequencing was of utmost 
importance, so that when SDM was applied, we were sure that the starting rpoB 
sequence was exactly the same as wild-type. 
 
MW 
III
1 2 3 4 5 6 7
21226 bp
5148 bp
4973 bp
Figure 3.3 Acc65I and BamHI sites were removed from p2NIL.  
This figure represents two plasmids that were isolated from separate colonies. lane 1: 
standard p2NIL (undigested); lane 2: standard p2NIL (Acc65I digest); lane 3: p2NILAB 
from colony 2 (Acc65I digest); lane 4: p2NILAB from colony 17 (Acc65I digest); lane 5: 
standard p2NIL (BamHI digest); lane 6: p2NILAB from colony 2 (BamHI digest); p2NILAB 
from colony 17 (BamHI digest). The standard p2NIL vector is 4753bp; removal of Acc65I 
and BamHI sites led to a size of 4761bp. In lanes 3 and 4, uncut DNA indicates that the 
putative p2NILAB vector was not cut with Acc65I. Similarly, in lanes 6 and 7, putative 
p2NILAB plasmid was not cut with BamHI. This verified that the sites had been removed 
from p2NIL, to generate p2NILAB. MW III denotes molecular weight maker III (Roche, 
Germany). Fragments were visualised on a 1% agarose gel. 
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3.4.3 Introduction of RIFR-associated point mutations: SDM 
The p2rpoB construct was used as a template to facilitate introduction of relevant 
mutations into the rpoB gene. A PCR-based SDM strategy was employed to introduce five 
out of six mutations selected (Table 3.1), as described previously (Smith & Klugman, 
1997). A schematic of SDM is presented in Figure 3.4. Briefly, this process involved two 
rounds of PCR. In the first round, a mutagenic primer was designed that contained the 
mutation of interest in the rpoB gene. This mutagenic “inner” primer was applied in a PCR 
reaction containing the p2rpoB template and a reverse “outer” primer to generate  a PCR 
product  that  served  as the “megaprimer”  in the second  PCR reaction, the remainder  
of the rpoB fragment was amplified (Figure 3.4), thereby generating a 1578 bp fragment 
(between Acc65I and BamHI restriction sites). Given the length of the megaprimer used 
(530 bp – 600 bp, exact size depends on the mutation being introduced, see Materials 
and Methods 2.4.1.4).  
 
  
 
 
 
 
 
reverse ‘outer’ primer
MT
forward mutagenic ‘inner’ primer
Acc65I
round 1
BamHI
round 2
forward ‘outer’ primer
reverse ‘megaprimer’
MT
Figure 3.4 Schematic representation of the SDM strategy used to introduce point 
mutations into the rpoB gene. 
The first round PCR generates a megaprimer containing the mutation (MT) of interest in a 
region of rpoB. The megaprimer is 500 – 600 bp (the exact size depends on the mutation 
being generated) and contains the RRDR. During the second round of PCR the 
megaprimer is used to introduce the mutation into a larger fragment of rpoB, which can 
then be cloned back into the p2rpoB vector, using Acc65I and BamHI restriction sites. 
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3.4.4 Introduction of the 30 bp deletion: Xover-PCR 
Five out of six constructs containing target RIFR rpoB mutations were generated using the 
aforementioned SDM strategy. The outstanding construct containing a 30 bp deletion 
was generated via Xover-PCR (Table 3.1). MSM strains containing this mutation have 
been isolated at the MMRU (Digby Warner, unpublished results) and in independent 
studies (Malshetty et al., 2010). MSM, via a recombination process, seems to be able to 
“loop out” this region of rpoB (Q513 – S522). This mutation is, therefore, is particularly 
interesting from a physiological point of view. The “megaprimer” method was not suited 
to production of this construct. Instead, Xover-PCR was employed, as previously 
described (Link et al., 1997). This process involves two rounds of PCR, where products on 
either side of the targeted deletion are generated and used as a template in a subsequent 
round of PCR (Figure 3.5). In the first round of PCR, two separate reactions were set up. 
Reaction A was set up to amplify the region to the up-stream from the deletion (2237 bp). 
The reverse primer used in this reaction is unique in that it contains a 3’ “tail” which is 
homologous to the 5’ side of the region that is down-stream from the deletion. The use 
of this primer introduces a sequence, which is homologous to portions of the gene down-
stream from the deletion. This facilitates homologous recombination during the second 
round of PCR. In reaction B, the region to the right of the deletion was generated using 
standard primers (1596 bp). Products from reactions A and B were used, in equimolar 
amounts, as templates in the final round of PCR (Figure 3.5). Two general primers were 
included in the reaction. Since the product of reaction A contains a region that is 
homologous to the matching end of the product of reaction B, the two products should 
recombine and the entire region should be amplified. It was important that in the final 
round of PCR, outer primers were excluded for the first 5 rounds of PCR. In this way 
products from reactions A and B were allowed to recombine, and were “filled in” by the 
DNA polymerase, and the full length product was augmented and, upon subsequent 
primer addition, amplified.  
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2027 bp
1584 bp
2027 bp
1584 bp
1 2 3 4 5
a
b
MW 
III
MW 
III
Figure 3.4(b) Gel images of final SDM and Xover PCR fragments generated cloning. 
The PCR products of the second round of SDM were separated on a 1% agarose gel. 
These fragments were purified and used for cloning into the modified p2NILAB 
vector. a) SDM fragments for single point mutations. Fragments containing specific 
mutations are in the following lanes: lane 1: S531L; lane 2: H526Y; lane 3: L521L; 
lane 5: Q513V lane 4: TH526TY b) Final Xover PCR fragments. All lanes represent this 
product. MW III denotes molecular weight marker III (Roche, Germany). Fragments 
were visualised on a 1% agarose gel. 
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After introduction of point mutations by SDM, and the 30 bp deletion by Xover-PCR, the 
resulting fragment was cloned into the p2rpoB template using Acc65I and BamHI sites, in 
effect replacing the wild-type RRDR with a fragment containing the mutation of interest. 
reverse ‘outer’ primer
forward ‘outer’ primer
BamHI
round 1
30bp 
del
inner primer with ‘tail’
forward ‘inner‘ primer
Acc65I
reaction A product reaction B product
both products used in round 2
round 2
reverse ‘outer’ primer
Acc65I
forward ‘outer’ primer
BamHI
Figure 3.5 Schematic representation of the Xover-PCR strategy used to introduce the 
30bp deletion into the rpoB gene. 
During the first stage, fragments on either side of the deletion are generated. One of 
the defining aspects of this kind of PCR is that during generation of the fragment to 
the left of the deletion, a primer is used that contains a “tail” that is homologous a 
portion of the fragment down-stream of the deletion (the tail and homologous 
regions are represented in green) (product of reaction A). The products of the initial 
rounds of PCR are used, in equimolar amounts, as template in the second round of 
PCR. Since the fragment up-stream of the deletion contains sequence which is 
homologous to the down-stream fragment, recombination should occur. Primers are 
not added to the final round of PCR for the first five cycles, to maximize 
recombination, and allow the DNA polymerase to “fill in” the fragments. 
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The successful introduction of the mutation was screened by AS-PCR and confirmed by 
sequencing the RRDR. The final allelic exchange construct was generated by cloning the 
PacI cassette from (pGOAL19) into the corresponding site. Constructs therefore 
contained: the full length rpoB gene with a RIFR-associated mutation (Table 3.1); a 
selection cassette containing lacZ, sacB, and the hygromycin resistance (HYGR) gene; KAN 
resistance gene (KANR); and E. coli OriE (Figure 3.5). These constructs were designated 
p2rpoBMT. 
 
 
 
 
 
 
 
 
3.4.5 AS-PCR to screen for mutations 
Given that the desired outcome of the SDM process was the generation of a single point 
mutation that would differentiate the mutant allele from the wild-type, standard 
screening by restriction analysis could not be used to identify those constructs containing 
BamHI
Acc65I
Figure 3.6 Representative suicide vector for allelic exchange.  
The OriE region facilitates replication in E. coli.  LacZ, and HYG and KAN resistance 
(aphC) genes facilitate selection of MSM SCOs. The sacB gene confers sucrose toxicity, 
and facilitates selection of DCO strains. Before addition of the marker cassette, Acc65I 
and BamHI sites were used to clone the final SDM product to yield a mutated version 
of rpoB. After addition of marker genes many more Acc65I and BamHI are present in 
the plasmid, however only the sites relevant for subsequent cloning are indicated in 
the figure.  Plasmid maps were prepared on Clone Manager Version 6.00 (Scientific 
and Educational Software, USA) 
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the correct mutation. This limitation would apply similarly to any subsequent attempts to 
identify MSM transformants containing the mutant alleles, and so necessitated the 
optimization of an alternative screening tool. AS-PCR was also used to screen for the 30 
bp deletion, as the sequence was different after removal of the nucleotides comprising 
the deletion.  
 
AS-PCR has been utilized previously to detect RIFR-associated mutations in clinical MTB 
isolates (Mokrousov et al., 2003). Therefore, we investigated the applicability of this 
methodology as a screening tool, initially to identify desired mutant constructs, but 
subsequently to screen for successful MSM SCO and DCO mutants (see Section 3.5). To 
this end, primers were designed that would allow screening for mutants using AS-PCR 
(Appendix 5.5). In this modification of the standard PCR technique, three primers are 
used: two outer primers that bind to the sequence of interest allow for an internal 
control which establishes that the PCR reaction is working – in this case, a 1578 bp 
product should be generated which comprises the RRDR, and regions immediately up- 
and down-stream of the RRDR – and a third primer that is either specific for the wild-type 
sequence or the mutated allele at a specific site.  
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The mutant-specific and wild-type-specific primers differ only by a single base pair at the 
3’ end (Figure 3.7). Therefore, the annealing temperature utilized for this PCR is critically 
important:  if the annealing temperature is too low, then primers will bind non-
specifically and will not differentiate between mutant and wild-type alleles; if too, high, 
no binding will occur and so no product will be generated. AS-PCR was successfully 
employed to screen for constructs containing desired point RIFR-associated mutations. A 
gradient PCR was also performed to ensure that binding of AS-primers to the cognate 
fragments was not due to low annealing temperatures and therefore non-specific (Figure 
3.8). The rpoB gene in plasmids that were confirmed via AS-PCR was sequenced to 
confirm that no unwanted mutations had been introduced during SDM. 
 
 
 
WT primerMT primerMW 
III 5’acccacaagcgtcgtctttT 3’ 5’ acccacaagcgtcgtctttC 3’
WT primerMT primerMW 
III
Template containing WT allele = extra band 
with WT specific primer
Template containing MT allele = extra band 
with MT specific primer
5’acccacaagcgtcgtctttT 3’ 5’ acccacaagcgtcgtctttC 3’
a b
Figure 3.7 Schematic of AS-PCR strategy used to screen for suicide plasmids.  
The primer sequences for both the mutant (MT) specific primer, and the wild-type 
(WT) specific primer are indicated. Allele specificity at the 3’ end of each primer is 
highlighted. a) A reaction where a WT-specific primer is used with a template 
containing a WT allele to form an additional band. b) An MT-specific primer is used 
with a MT template to form an additional band. In both cases two outer primers are 
included in the reaction, which will form a product regardless of the allele present. 
MW III, in both panels, designates molecular weight marker III (Roche, Germany).  
 
 90 
 
  
 
 
 
 
 
 
 
 
 
3.5 Allelic exchange to generate MSM strains containing RIFR-associated 
mutations 
Single point mutations in the RRDR are associated with high level RIFR in clinical MTB 
isolates (Ramaswamy & Musser, 1998, Sandgren et al., 2009). Therefore, it was important 
to develop a strategy that would allow introduction of these mutations into the 
chromosome of MSM, without any other point mutations, or the use of RIF to select for 
mutants. Such a strategy would allow for the evaluation of physiological implications of 
RIFR-associated mutations – without any other alterations that may be induced by RIF 
selection. In addition the ability of these point mutations to confer high level RIFR on their 
MW 
III
a b c d a c db
1584 bp
MT primer WT primer
1375 bp
564 bp
Figure 3.8 AS-PCR primers can detect the S531L mutation in a suicide construct.  
Two outer primers, that bind regardless the presence of the mutation, produced a 
1578 bp fragment. Reactions using the primer specific for the S531L mutant allele (MT 
primer) can be seen on the left. This primer yielded a smaller 546 bp band that was 
consistent with the presence of the mutant allele. On the right, a primer specific for 
the wild-type allele (WT primer) was used with the construct thought to contain the 
S531L mutation, and no extra bands were formed. Four different temperatures were 
used for the gradient PCR, and lanes wherein products for these temperatures are 
displayed as a) 55 °C b) 56.9 °C c) 61.1 °C d) 64.2 °C. Since the construct contained the 
mutation, the wild-type specific primer did not bind at higher temperatures and 
therefore no additional product was generated. Notably at the lowest temperature (55 
°C), a band was formed with the wild-type primer – which illustrates the importance of 
annealing temperature for AS-PCR. MW III is molecular weight marker III (Roche, 
Germany). Fragments were visualised on a 1% agarose gel. 
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own could be assessed. Allelic exchange methodology, which was pioneered in the 
MMRU in collaboration with a UK-based collaborator, Dr. Tanya Parish (Gordhan & 
Parish, 2001), has proved an invaluable technique for the genetic manipulation of 
mycobacteria including MSM and MTB and, importantly, allows the introduction of 
unmarked mutations into the mycobacterial chromosome (Gordhan & Parish, 2001, 
Parish & Stoker, 2000). 
 
3.5.1 The first step of allelic exchange: Isolation of SCOs 
The suicide vectors containing the specific rpoB mutations were delivered into MSM by 
electroporation. In a small proportion of bacilli, successful transformation is achieved 
which results in the site-specific incorporation of the suicide vector into the host 
chromosome by homologous recombination (Gordhan & Parish, 2001). The full process of 
allelic exchange, involves two selection steps, in which two distinct strains are generated, 
SCO and DCO mutants (described in Methods and Materials 2.4.2). The first of these are 
SCO mutants. As noted in Section 3.4.2, the suicide vector carries the PacI selection 
cassette which comprises KANR and HYGR genes and the lacZ gene. These enable the 
primary selection step, in which KAN- and HYG- resistant colonies that are blue on agar 
plates containing the chromogenic substrate, X-gal, are isolated. These SCOs contain two 
copies of the rpoB gene and are referred to as rpoBscoWT/MT (depending on the 
orientation, and mutation present in the strain). SCOs containing each of the relevant 
mutations (Table 3.1) were successfully generated. 
 
3.5.2 Orientation of SCOs is important for rpoB expression 
The orientation of SCO was important to determine if enough promoter sequence had 
been incorporated with the rpoB gene.  During the first step of allelic exchange, a cross 
over occurs due to homologous recombination (Gordhan & Parish, 2001). If the cross 
over occurred anywhere up-stream of the site wherein the mutation was introduced, the 
mutated rpoB gene would be introduced up-stream of native rpoB (Figure 3.9a). This is 
referred to as an up-stream SCO. Had the cross over occurred down-stream of mutation 
site, the mutant rpoB gene would be incorporated down-stream of the native wild-type 
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rpoB gene, and a down-stream SCO would have been generated. Expression of the up-
stream gene was driven by the native promoter present, regardless of whether it was the 
wild-type or mutated version of rpoB. Due to the cross over event and incorporation of 
vector sequence, the native promoter would not be present for expression of the down-
stream gene. Promoter sequence would have had to be included on the suicide vector for 
the down-stream gene to have been expressed. As discussed in Section 3.6.1, a down-
stream SCO containing an H526Y mutation (rpoBscoWT/H526Y) was resistant to high levels 
of RIF, indicating that the down-stream gene is being expressed, and therefore that 
enough promoter sequence had been included in suicide vectors.  
 
 
 
 
 
 
 
 
 
upstream  SCO
suicide vector with  
mutated rpoB
chromosomal DNAWT rpoB
a
MT
MT
downstream SCO
MT
chromosomal DNA
b
KANR
HYGR
85lacZ
sacB
a b
WT
WT
Figure 3.9 Allelic exchange can generate up- and down-stream SCOs.  
The first step of allelic exchange is represented. a) If a cross over (red crosses) had 
occurred anywhere up-stream of the site of the mutation being introduced, an up-
stream SCO was generated. b) If a cross over had occurred anywhere down-stream of 
the mutation being introduced, a down-stream SCO was generated. Vector sequence 
containing marker genes is represented in blue for both the suicide vector and in the 
SCOs. The rpoB gene is green, and promoter sequence is yellow. In this figure promoter 
is included for the down-stream gene, because RIFR of rpoBscoWT/H526Y indicates that 
the promoter present.  
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To determine the orientation of the putative SCOs identified above (Section 3.5.1), a PCR-
based strategy was designed. Primers were designed that were specific for either the up-
stream or down-stream rpoB genes (Appendix 5.5). The forward primer that was specific 
for the up-stream gene was designed to bind chromosomal sequence that occurs up-
stream of native rpoB; and the reverse primer was designed to bind chromosomal 
sequence down-stream of the native rpoB gene (Figure 3.10a). In this way primers [F1 + 
R1] should only amplify the up-stream rpoB gene, and primers [F2 + R2] should be specific 
for the down-stream gene, regardless of the origin of these alleles – that is, whether 
native wild-type or mutated (transformed) versions (Figure 3.10a). The product for 
primers [F1 + R1] was 3259 bp, while the primers [F2 + R2] yielded a product of 2770 bp 
(Figure 3.10b). Subsequently, AS-PCR was performed on these fragments to determine 
the nature of the amplified allele; that is, whether wild-type or mutated. The presence (or 
absence) of the mutation was confirmed by sequencing. Out of four S531L SCO isolates, 
two contained the mutated rpoB gene in up-stream orientation, and two in the down-
stream orientation. Both H526Y SCO isolates contained the mutated rpoB gene in the 
down-stream orientation. Therefore, from our results, there appeared to be no 
significant bias towards either up-stream or down-stream insertion of the mutated rpoB 
gene for SCO strains examined. 
 
At this point, it was decided that DCOs for only the S531L, H526Y and L521L mutations 
would be generated. The S531L and H526Y mutations are the most commonly observed 
mutations in clinical MTB isolates, and the L521L mutation is attractive as it has been 
reported to confer RIFR (Yang et al., 1998, Siddiqi et al., 2002) but does not result in an 
amino acid change. Moreover, down-stream phenotypic characterisation was only 
conducted on these mutants, and in some cases just S531L mutants. 
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3.5.3 The second step of allelic exchange: Generation of DCOs 
SCO mutants contain two copies of the rpoB gene. Loss of one copy (preferably wild-type) 
requires a second step of allelic exchange, in which the SCOs are grown in liquid medium 
that does not contain any of the selective compounds. Allelic exchange depends on 
efficient homologous recombination and DNA replication therefore it is important that 
cells are given sufficient time and nutrients for cell division to occur (Gordhan & Parish, 
2001). By removing the pressure of the selective antibiotic(s), a second cross over event 
occurs in which the marker cassette is effectively “looped out” of the chromosome 
WT/MT WT/MT 
F1 
R1 R2 
F2 
vector sequence 
5138 bp 
 3530 bp 
2027 bp 
MW 
III 
F1+R1 F2+R2 
b 
a 
Figure 3.10 Up- and down-stream specific primer sets facilitate determination of SCO 
orientation.  
a) Strategy to determine orientation of SCOs. Primer set [F1+R1] were specific for the up-
stream gene, regardless if it was the wild-type (WT) or mutated (MT) version of rpoB. 
Primer set [F2+R2] were specific for the down-stream gene. AS-PCR was then conducted on 
resultant fragment to determine the allele present in each fragment. The rpoB gene is 
represented in green, the promoter region in yellow, chromosomal region in black, and 
vector sequence in blue. b) Orientation of rpoBscoS531L/WT. Primers [F1+R1] amplify the up-
stream gene, and result in a 3539bp product. Primers [F2+R2] amplify the down-stream 
gene and yielded a 2770 bp product. MW III denotes molecular weight marker III (Roche, 
Germany). Fragments were visualised on a 1% agarose gel. 
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together with one allele. Successful DCO results in the retention of the mutated version 
of the rpoB gene in a strain referred to as a DCO mutant. However, cells may also exclude 
the marker cassette and the mutated rpoB gene, and revert to wild-type MSM. SCO cells 
grown in media without any selection compounds are likely to contain a mixed 
population of strains which include wild-type revertants, desired DCOs, and SCO strains 
which have not lost the marker cassette. The PacI cassette also contains the sacB gene, 
which confers sucrose toxicity. Therefore, to screen for DCOs, cultures of SCOs grown 
overnight in media without selective antibiotics were spread on solid media containing 
sucrose and X-gal. White colonies that were able to grow on these media were isolated, 
and DNA extracted using the colony boil protocol (see Materials and Methods 2.3.2.7).  
 
Initially the AS-PCR strategy described in Section 3.4.4 was used to screen for mutations 
in DCO strains however it failed to detect the relevant mutation – even in control strains 
containing known rpoB mutations (control strains had been previously generated at the 
MMRU by UV exposure, Digby Warner, unpublished results). Optimisation of AS-PCR 
required several rounds of trial and error, and imposed a significant delay for DCO 
generation. The only difference between wild-type and mutant strains was a single point 
mutation. This would be unlikely to provide a unique restriction site and the mutation 
incorporated into the engineered rpoB gene would not change its size. Therefore Southern 
blotting would not be feasible to differentiate between wild-type and mutant strains.The final 
protocol for this version of AS-PCR required two rounds of PCR (see Materials and 
Methods: 2.4.2.5). During the first round, a small, 311 bp fragment, containing the RRDR, 
was isolated from the rpoB gene. The product was diluted (1/100) and used as the 
template in the second PCR reaction. Two separate reactions were then set up for each 
template. In each reaction a common reverse primer was used, however, the forward 
primer in each reaction was either specific for the wild-type allele or for the mutated 
version (Appendix 5.5). The annealing temperature for both rounds of this PCR was 
increased from, 60 ⁰C in the original AS-PCR, to 62 ⁰C for this version, which greatly 
increased primer specificity. The smaller size of the template in the second reaction 
allowed for decreased annealing times (30 s for the original AS-PCR strategy vs. 15 s for 
this strategy), this minimised non-specific extension by FastStartTaq DNA PolymeraseTM 
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(Roche, Germany). Dilution to prevent excess of template also increased specificity of 
primers. Finally, for the second round of PCR, only 20 cycles were employed (whereas 30 
cycles were employed for the original AS-PCR strategy), this was also found to minimise 
non-specific annealing.  
 
If the correct primer was used with its cognate allele, a ± 170 bp product should be 
formed (the size of the band depends on the mutation being screened). Owing to the 
small size of these products, fragments were separated on a 2 % agarose gel, and the 
banding pattern indicated whether or not the mutation was present (Figure 3.11). DCOs 
containing the S531L mutation (Figure 3.11); H526Y; and L521L mutations were isolated 
in this way. In those cases where the AS-PCR indicated that there was a mutation present, 
the short fragment was sequenced to confirm the presence of the mutation, and DCO 
strains, designated rpoBMT, were carried forward for phenotypic analysis. 
 
 
 
 
 
 
 
 
MW 
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WT MT MTWT WT MT WT MT
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1 2 3 4
Figure 3.11 Colony one contains an S531L mutation in rpoB and is the rpoBS531L DCO.  
A modified version of the AS-PCR was conducted to check if these colonies contained 
the S531L mutation. In contrast to the AS-PCR strategy to screen suicide plasmids, this 
version requires two rounds of PCR. Results from the second round of this PCR are 
shown, wherein an AS-forward primer and a general reverse primer are used. 
Products from reactions which contained wild-type specific primers are denoted by 
WT, while those which contain S531L-specific primers are indicated by MT. Results 
from four putative rpoBS531L DCO colonies can be seen. Only colony one contains a 
mutant allele, revealed by the 109bp band formed by the S531L-specific primer (MT), 
and no band with the wild-type specific primer (WT). This was confirmed by 
sequencing. Colonies two – four contained a wild-type allele, and were wild-type 
revertants. Molecular weight marker V (Roche, Germany) is indicated by MW V. 
Fragments were visualised on a 1% agarose gel. 
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3.6 The impact of gene dosing for RIFR 
Approximately 95 % of RIFR clinical MTB isolates contain mutations in a well-defined 
region of the rpoB gene (Ramaswamy & Musser, 1998). Structural analyses indicate that, 
of the 12 amino acids that surround the RIF binding pocket, 11 mutate in association with 
RIFR (Campbell et al., 2001). This provides significant support for necessity of these 
mutations for RIFR. Molecular diagnostic assays have therefore been developed which 
utilize rpoB genotype as a proxy measure for RIFR. However, to our knowledge, a RIFR-
associated rpoB mutation has not been introduced into the native site in chromosome of 
a susceptible mycobacterial strain – in the absence of RIF – and shown to confer high 
levels of resistance. Such a molecular investigation is essential to verify that RIFR-
associated mutations in rpoB are both necessary, and sufficient for RIFR in mycobacteria. 
Therefore, while not the primary aim of this project, our ability to generate an rpoB point 
mutant in the absence of selection offered the opportunity of performing just such an 
investigation. That is, to compare RIF-susceptibility (RIFS) of the parental, wild-type MSM 
with its derivative rpoB mutant strains. 
 
3.6.1 RIFS of merodiploid strains: SCOs containing the S531L or H526Y mutation are 
resistant to RIF 
The key end-point of mutant generation was to isolate MSM mutants that were isogenic 
with the parental strain except for a single RIFR-associated point mutation in the rpoB 
gene. While DCO generation was underway, the RIFS of the SCO strains was evaluated. As 
noted above, these strains, contain both wild-type and mutated versions of the rpoB 
gene, and provided both genes are expressed, SCOs are essentially merodiploid. Some 
rare actinomycete species have two rpoB alleles and expression of the ‘alternative’ rpoB 
gene induces cryptic gene expression in Streptomyces livdans (Tala et al., 2009). 
Furthermore, some of the nucleic acid differences between the two S. lividans rpoB 
alleles are analogous to those found in RIFR isolates (Tala et al., 2009). 
 
If the mutated rpoB gene was in the up-stream orientation it would be expressed from 
the native promoter. However, if the mutated version of the rpoB gene was present in 
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the down-stream orientation, it would only be expressed if sufficient promoter sequence 
had been included in suicide vectors (see Section 3.5.2). Similar numbers of up- and 
down-stream SCO strains were generated. RIFS of rpoBscoS531L/WT (an up-stream SCO); 
rpoBscoWT/H526Y (a down-stream SCO) and rpoBscoL521L/WT (up-stream SCO) were 
determined on solid media. Cells from these strains were grown to logarithmic phase, 
and a dilution series was prepared. Twenty microlitres from dilutions 100 – 10-6 were 
plated on 7H10 media containing either 50 µg/ml; 100 µg/ml or 200 µg/ml (RIF50; RIF100; 
RIF200 respectively). To ensure that the strains had maintained SCO status, dilutions from 
each strain were also plated on 7H10 plates containing 20 µg/ml (KAN20); 50 µg/ml 
(HYG50) and X-gal. In all cases, blue colonies were produced on plates containing 
KAN20HYG50, confirming that these were still SCOs. The rpoBsco
S531L/WT and 
rpoBscoWT/H526Y strains were able to grow on RIF200 containing solid media (Figure 3.12). In 
contrast, rpoBscoL521L/WT and wild-type MSM were not able to grow on any of the RIF 
concentrations tested. Decreased susceptibility to RIF of rpoBscoS531L/WT and 
rpoBscoWT/H526Y mutants but not rpoBscoL521L/WT provided the first indication that missense 
mutations on their own might confer RIFR. Furthermore, decreased susceptibility of the 
rpoBscoWT/H526Y (a down-stream SCO) indicated that the mutated rpoB gene was being 
expressed when in the down-stream orientation, and provided evidence that the 
promoter region of rpoB is located in the 300 bp region up-stream of the rpoB gene.  
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3.6.2 The impact of gene dosing of rpoB on RIFS: increased copy number of rpoB does 
not confer RIFR 
SCOs containing the S531L and H526Y mutations in one rpoB allele had significantly 
decreased susceptibility to RIF in comparison with the isogenic parental strain, an 
observation which suggested that these mutations might be sufficient for RIFR. However, 
other studies have observed that for some antimicrobials over-expression of the target 
confers resistance (McMurry et al., 1998, Kurth et al., 2009). To determine whether 
increased expression of rpoB – or whether the presence of two alleles in the merodiploid 
strain – might result in increased RIFR in the S531L and H526Y SCOs, rpoB was introduced 
into MSM in additional copies. An MSM strain containing two copies of the wild-type 
rpoB gene provided a specific control for determination of SCO susceptibility phenotypes 
described in Section 3.6.1. If increased expression of rpoB was contributing to RIFR, these 
strains should have similar RIFS to rpoBscoS531L/WT and rpoBscoWT/H526Y strains. The MSM 
RIF200 RIF100 RIF50
std OADCOADC KH
RIF200 RIF100 RIF50
std OADCOADC KH
RIF200
RIF100 RIF50
std OADCOADC KH
a
c d
b
RIF200 RIF100 RIF50
std OADCOADC KH
Figure 3.12 The rpoBscoS531L/WT, and rpoBscoWT/H526Y SCO strains are resistant to RIF.  
Dilutions of these strains were spotted on 7H10 OADC containing RIF50, RIF100 or RIF200. 
Strains were diluted in un-supplemented 7H9 media. Dilutions 100 – 10-6 (left to right on 
plates) were plated. Strains were also plated on standard 7H10 OADC (std OADC) and 
7H10 OADC containing KAN20HYG50 and X-gal (OADC KH). a) rpoBsco
S531L/WT (an up-
stream SCO) b) rpoBscoWT/H526Y (a down-stream SCO) c) rpoBscoL521L/WT  (an up-stream 
SCO) d) Wild-type MSM. 
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strain containing two copies of rpoB was generated via allelic exchange, using a suicide 
plasmid containing the wild-type rpoB gene. The implications of rpoB copy number were 
also evaluated by introducing both wild-type and mutated versions on a multicopy 
episomal (pOLYG) expression vector. 
 
3.6.3 SCOs containing two copies of the wild-type rpoB gene are susceptible to RIF 
First, to determine whether the presence of two copies of the rpoB gene (whether 
mutated or not) in the chromosome conferred RIFR, a suicide vector containing wild-type 
rpoB was introduced into the MSM chromosome via electroporation as previously 
described (see Section 3.5.1). The resulting SCO mutant contained two copies of wild-
type rpoB and was designated rpoBscoWT/WT. As shown in Figure 3.13, the rpoBscoWT/WT 
mutant was as susceptible to RIF treatment as wild-type MSM. These data suggested that 
the possession of two copies of wild-type rpoB was not able to confer RIFR but that, at the 
very least, one allele must contain a point mutation. 
 
 
 
 
 
 
 
3.6.4 Expression of rpoB on pOLYG – a multicopy episomal plasmid  
To examine whether the presence rpoB in multiple copies conferred resistance to RIF in 
MSM, the rpoB gene was cloned onto the multicopy episomal plasmid, pOLYG (O'Gaora 
RIF200 RIF100 RIF50
std OADCOADC KH
Figure 3.13 The rpoBscoWT/WT mutant is as susceptible to RIF as wild-type MSM. 
Dilutions of rpoBscoWT/WT were spotted on 7H10 OADC RIF50, RIF100 or RIF200. Strains 
were diluted in un-supplemented 7H9 media. Dilutions 100 – 10-6 (left to right on plates) 
were plated. The strains was also plated on standard 7H10 OADC (std OADC) and 7H10 
OADC containing KAN20HYG50 and X-gal (OADC KH). Growth on KAN20HYG50 plates 
confirmed that rpoBscoWT/WT retained marker genes and remained SCO. 
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et al., 1997). Since SCO strains containing the S531L or H526Y mutations had exhibited 
reduced susceptibility to RIF, pOLYG constructs containing these alleles were also 
generated. These constructs – designated pGrpoBWT, pGrpoBS531L, and pGrpoBH526Y – were 
introduced into MSM via electroporation. Surprisingly, very low transformation 
efficiencies were observed (Figure 3.14 and Table 3.2) 
 
 
  
Table 3.2 Transformation efficiency of pGrpoB constructs
Construct 
a 
Electroporation efficiency (CFU/µg DNA) 
pOLYG 1 X 104 
pGrpoBWT 9 
pGrpoBS531L 4 
pGrpoBH526Y 5 
aThese experiments were conducted three times, however results from one experiment are represented in 
the table 
 
The low transformation efficiency of all three rpoB-containing pOLYG constructs 
suggested that the increased expression of rpoB was toxic in MSM (Figure 3.14). Table 3.2 
describes the relative electroporation efficiencies of pGrpoB constructs in comparison to 
pOLYG alone, in a representative electroporation. In this experiment, standard pOLYG 
was associated with an electroporation efficiency of 1 X 104 CFU/µg DNA which is similar 
to published results (Warner et al., 2006). In contrast, the pGrpoBWT construct had a 
transformation efficiency of just 9 CFU/µg DNA. The pOLYG vector exists in the cell in 
multiple copies, and although this is likely to have increased expression of rpoB, 
a
c d
b
Figure 3.14 Reduced electroporation 
efficiency of pGrpoB constructs. 
The pOLYG vector contains a HYGR gene, 
therefore MSM cells were spread on 7H10 
OADC HYG50 plates after electroporation of 
rpoB containing pOLYG constructs. a) pOLYG 
b) pGrpoBWT c) pGrpoBS531L d) pGrpoBH526Y. 
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expression analysis such as RT-PCR is required to formally show over-expression. Given 
the low number of HYGR transformants recovered from electroporations, and the 
resultant re-arrangement of plasmids within these strains (see Section 3.6.4), this kind of 
analysis was not possible. For the small number of transformed colonies that were 
obtained, RIFS was evaluated by plating on solid media containing increasing RIF 
concentrations. Those MSM strains that were recovered containing either wild-type, 
S531L, or H526Y versions of rpoB on pOLYG did not grow on any RIF concentrations 
tested (Figure 3.15).  
 
 
 
 
 
 
 
RIF200 RIF100 RIF50 RIF200 RIF100 RIF50
RIF200 RIF100
RIF50
HYG50 std OADC HYG50
HYG50
std OADC
std OADC
a
c
b
Figure 3.15. Increased copy number of rpoB on pOLYG does not confer RIFR.  
Strains containing a) pGrpoBWT b) pGrpoBS531L and c) pGrpoBH526Y were diluted 
andspotted on 7H10 OADC RIF50, RIF100 or RIF200. Strains were diluted in un-
supplemented 7H9 media. Dilutions 100 – 10-6 (left to right on plates) were plated. 
Strains were also plated on standard 7H10 OADC (std OADC) and 7H10 OADC 
containing HYG50. Plating on HYG50 verified that strains still contained the pOLYG 
construct, since this vector contains a HYG resistance gene. 
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3.6.5 Expression of rpoB from pOLYG is toxic in mycobacteria 
Previous studies have reported wholesale loss or re-arrangement of plasmids associated 
with toxicity, in mycobacteria (Stallings et al., 2009). Therefore, to investigate the 
apparent toxicity of increased copy number of rpoB, we evaluated whether plasmid 
rearrangements had occurred in those MSM transformants that were recovered. 
Plasmids were recovered from MSM transformants by electroduction into E.coli (see 
Materials and Methods: 2.4.3.1). Plasmid DNA was isolated from E. coli and the integrity 
of the different rpoB containing pOLYG constructs (pGrpoBWT; pGrpoBS531Land 
pGrpoBH526Y) evaluated by restriction analysis. Three colonies for each type of pOLYG 
construct was analysed for re-arrangement. Restriction enzymes were selected to ensure 
maximum coverage of the construct based on the sequence of the respective original 
vectors (Figure 3.16a). Results from this analysis indicated that significant rearrangement 
of plasmids had occurred upon introduction into MSM (Figure 3.16b). For example, 
digestion of the pGrpoBS531L construct with EcoRI before electroporation yielded the 
expected 5561 bp, 2306 bp, and 1515 bp fragments. In contrast, the same construct 
yielded a significantly different restriction pattern (one fragment less than 3500 bp, one ± 
2000 bp fragment, and one ± 1400 bp fragment) when recovered from a single MSM 
transformant (Figure 3.16). Similar evidence of large-scale rearrangement was observed 
with other restriction enzymes. Moreover, pGrpoBWT and pGrpoBH526Y constructs had also 
undergone significant rearrangement. This is consistent with a previous observation of 
significant instability of self-replicating plasmids expressing rpoB in MTB (Zaczek et al., 
2009). 
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Figure 3.16 Over-expression of rpoB leads to plasmid re-arrangement.  
Restriction sites for AatII, EcoRI, NaeI and NspI on standard pOLYG and pGrpoB 
constructs. The HYG resistance gene is indicated in purple, the rpoB gene is indicated in 
green, and the promoter region in yellow. Cleavage sites are represented by *. This map 
is not drawn to scale, but rather intended to give some indication of regions cleaved by 
each enzyme. b) Cleavage pattern of pGrpoBS531L constructs recovered after 
electroporation and digested with AatII, EcoRI, NaeI and NspI. i) Standard pOLYG ii) 
pGrpoBS531L before electroporation into MSM iii) pGrpoBS531L. MW III is molecular weight 
marker III from Roche (Germany). Fragments were visualised on a 1 % agarose gel. 
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3.7 RIFS of MSM mutants containing single RIFR-associated mutations 
The results of the RIFS assay of the SCO strains confirmed the importance of rpoB 
mutations for RIFR. Isolation of DCO mutants, which are isogenic to the parental strain 
except for a single RIFR-associated rpoB mutation, would allow us to assess whether these 
mutations are sufficient for high-level RIFR. In addition, DCO mutants would provide the 
means to determine the impact of rpoB mutations on MSM physiology. 
 
3.7.1 Mutants containing S531L or H526Y mutations are able to grow on solid media 
containing relatively high concentrations of RIF 
DCOs were generated which contained either the S531L, H526Y, or L521L mutation 
(rpoBS531L; rpoBH526Y; and rpoBL521L respectively). The RIFS of resultant DCO strains was 
assayed on RIF containing solid media using the same methodology as described for RIFS 
determination of SCO strains. Wild-type and SCO mutants were included in this assay 
(Figure 3.17). In addition, an S531L mutant generated previously by in vitro RIF selection 
following UV irradiation (rpoBUV_S531L; Digby Warner, unpublished results) was included to 
provide an initial indication of whether the use of RIF selection to generate RIFR mutants 
was associated with additional chromosomal or physiological changes that might impact 
RIFS. 
 
Cultures of each strain were grown to logarithmic phase and a dilution series was 
prepared in 7H10 OADC. Twenty microlitres from dilutions 100 – 10-6 were plated on 
7H10 media containing either RIF50; RIF100 or RIF200. Dilutions from each strain were also 
plated on 7H10 plates containing KAN20; HYG50and X-gal to ensure that DCOs were not 
mistaken for SCOs and to confirm SCOs maintained their SCO status. Only SCO strains 
grew on KAN20HYG50 containing plates (Figure 3.17), confirming that AS-PCR to screen for 
DCOs had not mistakenly detected a mutation in an SCO. The L521L DCO strain did not 
grow on media containing any of the concentrations of RIF tested, but displayed 
significant growth on standard, antibiotic-free media. Similarly, wild-type MSM did not 
grow on plates containing RIF. In contrast DCO strains containing an S531L or and H526Y 
mutation grew on RIF50 OADC plates until a dilution of 10
-4, and moreover displayed 
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growth until a dilution of 10-3 on RIF200 plates. The rpoB
UV_S531L mutant displayed similar 
levels of growth on RIF containing plates, which was to be expected. However growth of 
rpoBS531L and rpoBH526Y strains on RIF concentrations of up to 200 µg/ml was a significant 
result: DCO mutants were generated in the absence of RIF, to minimise the possibility of 
introducing second site mutations, therefore the ability of MSM strains containing a 
single point mutation in the rpoB gene to withstand high concentrations of RIF provides 
significant evidence for the importance of these mutations for RIFR. Initially growth up to 
RIF200 was evaluated. To obtain some indication of the maximum concentration of RIF 
that the mutants could withstand, growth was assayed on plates containing higher 
concentrations of RIF.  
 
 
 
 
 
RIF50 RIF200
std OADC OADC KH
wild-type
rpoBS531L
rpoBscoS531L/WT
rpoBUV_S531L
a b
dc
wild-type
rpoBS531L
rpoBscoS531L/WT
rpoBUV_S531L
Figure 3.17 S531L mutants are resistant to high levels of RIF.  
Dilutions of cells grown to logarithmic phase were plated on RIF containing media. 
Twenty microliters of dilutions 100 – 10-6 were plated (left to right on the 
plate).Dilutions were prepared in un-supplemented 7H9. Growth was evaluated on 
7H10 OADC plates containing RIF50 and RIF200; 7H10 OADC plates containing 
KAN20HYG50 (OADC KH) and standard 7H10 OADC plates (std OADC).  
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S531L and H526Y SCOs, and DCOs grew on RIF concentrations of up to 400 µg/ml (RIF400) 
(Figure 3.18). The rpoBUV_S531L mutant had comparable growth to DCO strains. Notably, at 
RIF200 or higher, growth of the rpoBsco
S531L/WT and rpoBscoWT/H526Y only occurred up to 
dilutions of 10-2; while rpoBS531L and rpoBH526Y DCO strains and rpoBUV_S531L grew up to 
dilutions of 10-3 at RIF200. This indicates that the wild-type version of the rpoB still present 
in SCO strains is being targeted by RIF. Conceivably RNAPs in the cell contain a mixture of 
mutated and wild-type β-subunits, and RIF is able to target the wild-type version. At high 
enough RIF concentrations, inhibition of sensitive RNAPs is probably sufficient to impede 
growth of SCO strains.   
 
 
 
 
 
 
3.7.2 MABA’s were useful for MICRIF determination and for evaluation of physiological 
effects of RIFR-associated mutations 
The use of 96-well microtitre plates for MABA allows for evaluation of growth in the 
presence of serial two-fold dilutions of RIF and therefore allows for more accurate 
definition of the MICRIF. To set up the plates (Figure 3.19), liquid medium was added to all 
wells in the plate (except for the uppermost row, which served as a no growth control). 
As per the standard protocol, the outermost column served as a positive growth control, 
in which only growth medium and cells were added. Dimethyl suphoxide (DMSO) was 
used as solvent for RIF therefore the next column contained a dilution series of DMSO 
a b c
Figure 3.18 S531L mutants can grow on RIF400.  
Dilutions of cells grown to logarithmic phase were plated on 7H10 plates containing 
RIF400. Twenty microlitres of dilutions 10
0 – 10-6 were plated (left to right on the 
plate). Dilutions were prepared in un-supplemented 7H9. a) rpoBS531L b) rpoBUV_S531L c) 
wild-type. 
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only to evaluate its effect on strain growth. RIF was added to the uppermost wells, and 
diluted ‘down’ the columns. In this way a two-fold dilution series of RIF was established. 
MSM cells from a culture that had been grown to logarithmic phase were then diluted to 
an optical density (OD600) of 0.05, and added to every well (except for the uppermost row 
which served as a contamination control). Plates were incubated at 37 ˚C for 48 hours, 
and Alamar blue added. Plates were incubated for a further 24 hours after the addition of 
Alamar blue and growth evaluated. Alamar blue is colorimetric growth indicator which 
contains resazurin. Resazurin is blue in its oxidised form (Mann & Markham, 1998). 
During bacterial growth the surrounding medium is reduced as bacteria use up oxygen. 
This drives the first step in resazurin reduction, and results in a colour change from blue 
to pink. Initial reduction of resazurin is irreversible, and produces a resofurin. Resofurin 
can undergo a reversible reduction to the form the colourless compound, 
dihydroresofurin (Mann & Markham, 1998). A change from blue to pink indicates growth, 
and wells that remain blue indicate that no growth has occurred. The MICRIF was defined 
as the concentration of RIF wherein growth was impeded. Therefore the transitional 
position on a plate where the blue to pink colour change ceased to occur was determined 
as the MICRIF (highlighted by yellow boxes in figures).  
 
RIFS determination is routinely performed using standard mycobacterial growth media, 
which contain glucose as principal carbon source. Mycobacteria possess an assortment of 
lipid metabolising enzymes (Cole et al., 1998), and there is increasing evidence that lipids 
are the predominant carbon source during MTB infection (Savvi et al., 2008, Brzostek et 
al., 2009, Pandey & Sassetti, 2008, de Carvalho et al., Marrero et al., 2010, Garton et al., 
2008, Peyron et al., 2008). During treatment with INH, a two kill step kill pattern is 
observed for MTB populations, which suggests that actively growing cells are killed 
rapidly by INH and more slowly growing cells take longer to kill (Jindani et al., 2003). 
Moreover, Xie et al. (2005) show that of seventeen antibacterial compounds tested, only 
four were active against starved MTB populations (Xie et al., 2005) and adjustment of 
carbon source can vary the types of molecules that are isolated from chemical library 
screens for activity against mycobacteria (Miller et al., 2009, Pethe et al., 2010). The 
ability to withstand antibiotic pressure is therefore intrinsically linked to physiological 
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pathways such as carbon metabolism. Therefore, the use of the MABA method to 
evaluate MICRIF facilitated the simultaneous investigation of two important questions 
raised by this project. That is, the ability of rpoB mutations to confer RIFR, and the 
implication of these mutations for carbon source utilization.  
 
3.7.3 MABA’s in 7H9 OADC media reveal increased MICRIF for rpoB
S531Land rpoBH526Y 
The MICRIF for rpoB
S531L, rpoBH526Y and rpoBL521L mutant strains, as well as the rpoBUV_S531L 
mutant and the wild-type strain, was initially determined in 7H9 OADC.  The MICRIF for the 
rpoBS531L and rpoBH526Y mutant strains was 125 – 250 µg/ml (RIF125 – RIF250 ) (Figure 3.19), 
while growth of rpoBL521L was inhibited at RIF concentrations between 0.98 µg/ml and 
1.95 µg/ml. Wild-type growth was inhibited between 1.95 µg/ml and 3.9 µg/ml. These 
values are much lower than the published MICRIF, which range from 8 μg/ml (Piddock et 
al., 2000) to 32 μg/ml (Alexander et al., 2003), and probably reflects some of the 
difficulties in evaluating RIFS in MSM (discussed in 4.4). In initial experiments, S531L and 
H526Y mutants were resistant to the highest concentration of RIF tested, namely 250 
μg/ml. These strains grew at RIF125 – RIF250, which were concentrations at the uppermost 
limit of the assay in this format. This was confirmed in subsequent experiments, which 
established an MICRIF for these mutants of 250–500 µg/ml (RIF250 – RIF500).   
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Figure 3.19 Decreased RIF-susceptibility of rpoBS531L and rpoBH526Y but not rpoBL521L 
mutants. 
 The MICRIF is indicated in yellow boxes. No cells are added to the uppermost well, which 
serves as a contamination control – blue wells in this row confirm that there is no 
contamination. The first and second outermost columns serve as positive growth 
controls, and a control for the effect of the solvent respectively. 7H9 OADC medium was 
used in this assay. MIC’s for different strains are as follows: wild-type: 1.95 – 3.9 μg/ml; 
rpoBscoS531L: 125 – 250; rpoBS531L: 125 – 250 μg/ml; rpoBUV_S531L (mutant generated by 
UV exposure and selection on RIF): 125 – 250 μg/ml; rposcoH526Y: 125 – 250 μg/ml (not 
shown in figure); rpoBH526Y: 125 – 250 μg/ml; rpoBscoL521L: 1.95 – 3.95 μg/ml (not shown 
in figure); rpoBL521L: 0.98 – 1.95 μg/ml (note, the MICRIF for wild-type in this plate is 0.98 
– 1.95 μg/ml).  
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3.7.4 The EPI’s, verapamil and reserpine, do not impact MICRIF of rpoB
S531L 
The results presented above, and those from other studies, provide convincing evidence 
for the role of RRDR mutations in RIFR. However, there are questions that surround the 
sufficiency of these mutations to confer the high levels of resistance seen in clinical 
isolates. Approximately 5 % of clinical isolates have no mutations in the RRDR (Telenti et 
al., 1993, Ramaswamy & Musser, 1998), and the question of compensatory mutation has 
never been conclusively addressed. Among various possible mechanisms, there is 
increasing interest in the role of efflux in antibiotic resistance in bacterial pathogens, 
including MTB (Louw et al., 2009). In Salmonella species, for example, fluoroquinolone 
resistance-associated gyrA mutants are more difficult to generate if efflux systems are 
inhibited (Ricci et al., 2006). Moreover, a recent mathematical model postulates that 
activated efflux systems are required to fix and maintain resistance-associated point 
mutations in a population (Fange et al., 2009). Mycobacterial genome sequences indicate 
the capacity to express efflux systems of every major class, however these systems are 
not well-characterised (Louw et al., 2009).  To evaluate the role of efflux in RIFR in our 
system, efflux pump inhibitors (EPIs) were included in MABA assays of the S531L mutant 
strains. Two compounds were used in EPI assays to increase the possibility of inhibiting 
different types of efflux systems: reserpine, which specifically inhibits ATP-dependant 
pumps, and verapamil which impedes P-glycoprotein systems (Lechner et al., 2008).  
 
In agreement with previous observations (Piddock et al., 2000), neither had significant 
impact on RIF metabolism. It is possible that MSM encodes efflux systems that are 
impervious to reserpine or verapamil, or that inhibition of one group of efflux pumps is 
offset by separate efflux systems; however, the investigation of these possibilities was 
beyond the scope of this study and, to some extent, obviated by subsequent results (see 
Section 3.7.5)  
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Table 3.3 MICRIF
EPI 
 of S531L mutant strains in the presence of EPI’s 
MICRIF (µg/ml): 
-EPI +EPI 
wild-
type 
rpoB  
S531L 
rpoBsco 
S531L/WT 
rpoB 
UV_S531L 
wild- 
type 
rpoB 
S531L 
rpoBsco 
S531L/WT 
rpoB 
UV_S531L 
resa 
  
1.95 –  
3.9 
125 – 
250 
125 – 
250 
125 – 
250 
3.9 – 
7.8 
125– 
250 
125 – 
250 
125 – 
250 
verb 1.95 – 
3.9 
125 – 
250 
125 – 
250 
125 – 
250 
0.48–
0.98 
125– 
250 
125 – 
250 
125 – 
250 
aReserpine was included in assays at 20 µg/ml. bVerapamil was included in assays at 150 µg/ml 
 
3.7.5 Restoration of the wild-type allele in rpoBS531L restores RIFS 
Inhibition of selected efflux systems had insignificant impact on RIFS in S531L mutants, so 
providing further support for the sufficiency of mutations in the RRDR for RIFR. The wild-
type allele was restored in the S531L mutant by a second round of allelic exchange. To 
this end, a suicide vector containing the wild-type rpoB allele was delivered into the 
S531L mutant strain by electroporation, and SCO strains isolated as described previously 
(see Section 3.5). The SCO mutants were then subjected to sucrose selection, and 
putative DCO strains screened by AS-PCR; in contrast to the generation of the rpoB 
mutants, in this case the opposite result, namely replacement of the mutant allele with 
the wild-type rpoB, was the desired outcome, and so the screen was conducted 
accordingly.  Restoration of the wild-type rpoB allele in rpoBS531L (strain designation 
rpoBS531L→WT) restored RIFS to levels observed with wild-type MSM (Figure 3.20). In 
combination with the observed inability of the selected EPI’s to impact RIFS, this result  
provided very strong evidence that an S531L mutation, is sufficient on its own for high 
level RIFR in MSM. However, these strains have not been subject to whole genome re-
sequencing and so it remains a formal possibility that a second site mutation – in 
combination with an rpoB mutation - is required for high-level RIFR in MSM.  
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3.7.6 Evaluation of potential carbon source specific effect on MICRIF of rpoB
S531L mutants 
Conventional antibiotic targets are essential for function, and so are often associated 
with high levels of evolutionary conservation. It follows, therefore, that mutations in 
essential genes might have significant implications for bacterial function. There is 
evidence from an array of other bacterial species that mutations in rpoB, primarily those 
occurring in the RRDR, can have profound implications for physiology (Hosaka et al., 
2009, Maughan et al., 2004, Nicholson & Maughan, 2002, Perkins & Nicholson, 2008, 
Jenkins et al., 2009, Yu et al., 2005). Notably, in B. subtilis, rpoB mutations analogous to 
those found in clinical MTB strains have been reported to confer the ability to subsist on 
carbon sources previously defined as non-utilizable (or non-nutritive) for the wild-type 
strain; for example, β-methyl-D-glucoside (Perkins & Nicholson, 2008). Moreover, as 
previously mentioned carbon source metabolism can significantly influence susceptibility 
to antibiotics (Xie et al., 2005). We therefore investigated the potential influence of 
carbon source on MICRIF, as well as the possible impact of the S531L mutation on the 
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Figure 3.20 Restoration of wild-type rpoB in rpoBS531L restores RIF-susceptibility.  
The wild-type allele was restored in the S531L mutant via allelic exchange, and strains 
were subjected to the MABA assay. The MICRIF, is indicated in yellow boxes. No cells 
are added to the uppermost well, which serves as a contamination control – blue 
wells in this row confirm that there is no contamination. The first and second 
outermost columns serve as positive growth controls, and a control for the effect of 
the solvent respectively. 7H9 OADC medium was used in this assay. Observed MICRIF 
for different strains were as follows, rpoBS531L: 125 – 250 µg/ml; wild-type: 1.95 – 3.9 
µg/ml; rpoBS531L→WT:  1.95 – 3.9 µg/ml.  
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ability of MSM to utilize different carbon sources for growth in vitro. To this end, the 
MICRIF of selected rpoB mutants strains was determined by the MABA method (as 
previously described; Section 3.6.3.2) in a limited panel of media containing defined 
carbon sources: standard 7H9 medium supplemented with either C4 (valerate) or C5 
(butyrate) lipids (Savvi et al., 2008), as well as OADC (containing both oleic acid, a C3 fatty 
acid; and dextrose, both of which could be used as carbon sources for growth) which is 
used routinely for mycobacterial growth assays (including MTB), or a GS mix which is used 
specifically for MSM in our laboratory. In some ways this study was designed to evaluate 
the feasibility of assaying the effects of single point mutations in rpoB, therefore a limited 
number of carbon sources were selected. There are several lines of evidence to indicate 
that fatty acids are the predominant carbon source during MTB infection (Brzostek et al., 
2009, Pandey & Sassetti, 2008, de Carvalho et al., 2010, Marrero et al., 2010, Garton et 
al., 2008, Peyron et al., 2008, McKinney et al., 2000), therefore MABA’s were focussed on 
fatty acid based carbon sources.  
 
The MICRIF for the wild-type strain was significantly higher in lipid-based carbon sources 
(Table 3.4). In contrast, the MICRIF for S531L mutant strains did not differ in any of the 
carbon sources evaluated (Table 3.4). As described above (Section 3.6.), mutants were 
resistant to the highest concentration of RIF tested, therefore carbon source specific 
effects may not be discernable. Therefore, this assay was repeated using a higher starting 
concentration of RIF. In these experiments, plates were set up so that the highest 
concentration of RIF in which cells would be added was 1000 µg/ml. Owing to the deep 
red colour of RIF, colorimetric analysis of growth was not possible. Instead, growth was 
evaluated using pellet size. To ensure that pellets indicated growth and not cell debris, 
cell growth was evaluated by spotting on standard 7H10 OADC plates.  The MICRIF for 
rpoBS531L and rpoBH526Y was 250 – 500 µg/ml. These results mirror those obtained on solid 
media, and provide further support for the importance of these mutations for RIFR. In 
agreement with RIFS determination on solid media (Section 3.7.1), SCO strains had slightly 
lower MICRIF values (125 – 250 µg/ml, for both rpoBsco
S531L/WT and rpoBscoWT/H526Y). This 
re-iterates that RIFS in SCO strains is likely due to the presence of wild-type rpoB. 
Although growth was slower in butyrate- and valerate-containing media, there was no 
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difference in RIFS for mutant strains. This is likely due to the very high MICRIF for mutant 
strains however, this result requires further investigation. 
 
Table 3.4 MICRIF
Growth 
medium  
of S531L mutant strains in varied carbon sources 
MICRIF (µg/ml):  
wild-type rpoBS531L rpoBscoS531L/WT rpoBUV_S531L rpoBS531L→WT 
7H9  
GS 
1.95 – 3.9  250 - 500  125 – 250  250 - 500  1.95 – 3.9  
7H9  
OADC  
1.95 – 3.9  250 - 500  125 – 250  250 - 500  1.95 – 3.9  
7H9 
Valerate 
15.6 – 31.25  250 - 500  125 – 250  250 - 500  7.8 – 15.6  
7H9 
Butyrate  
15.6 – 31.25  250 - 500  125 – 250  250 - 500  7.8 – 15.6  
 
3.8 Competition assays reveal a modest fitness defect for rpoBS531L 
Resistance-associated mutations in antibiotic targets are expected to impact physiology, 
and possibly to incur a fitness cost. Moreover, mathematical models predict that the 
spread of drug-resistant organisms is critically dependant on their relative fitness (Cohen 
and Murray, 2004). Previous studies have shown that RIFR-associated rpoB mutations 
incur heterogeneous fitness costs in mycobacteria, which depend on strain background as 
well as the assay system employed (Gagneux et al., 2006b, Mariam et al., 2004, Billington 
et al., 1999, Gillespie et al., 2002). Therefore, we evaluated the relative fitness of the 
rpoB mutants in vitro. To this end, a competition assay was employed to determine if the 
rpoBS531L mutant exhibited a growth phenotype (advantage or disadvantage) when grown 
in competition with the wild-type strain. Competition assays were set up as previously 
described (Gagneux et al., 2006b). In all cases, wild-type MSM and the rpoBS531L mutant 
were grown in axenic culture as controls.  Colony counts on RIF200 plates would allow 
enumeration of rpoBS531L strains, and subtraction of colony numbers on RIF200 plates, 
from total colonies on standard OADC plates would allow enumeration of the number of 
wild-type bacilli, thereby ensuring that the number of wild-type versus mutant baciili 
could be evaluated in the competition assay. Competition experiments were conducted 
with three separate sets of cultures and proceeded for 20 days (480 hours), until two sets 
became contaminated, and had to be discarded. At the outset, we were concerned that 
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plating on RIF may be problematic. Modelling and clinical data indicate that the likelihood 
of reversion to the wild-type allele in the absence of the antibiotic is low (Andersson & 
Levin, 1999). However, if this had occurred in our system, revertants would have 
disappeared into a population of wild-type strains, as the only way to differentiate 
between the wild-type strain and the mutant was by the RIFR phenotype. Moreover, 
spontaneous mutation in the wild-type population may lead to RIFR – especially at later 
stages of the experiment where nutrient limitation may impose a stress (Foster, 1998, 
Karunakaran & Davies, 2000, Cairns et al., 1988, Bjedov et al., 2003, Rosenberg & 
Hastings, 2004). This would bias results, and indicate falsely inflated number of rpoBS531L 
mutant strains. However, this concern was allayed since no spontaneous RIFR mutants 
were observed from axenic wild-type cultures for the duration of the experiment. This is 
in contrast to the idea that rpoB mutations increase in stationary phase (Foster, 1998, 
Karunakaran & Davies, 2000, Cairns et al., 1988, Bjedov et al., 2003, Rosenberg & 
Hastings, 2004) and differs from what was previously observed for mycobacteria 
(Karunakaran & Davies, 2000). 
 
In axenic culture, wild-type and rpoBS531L displayed very similar growth characteristics 
(Figure 3.21a) for the duration of the experiment. However, when strains are in direct 
competition, the rpoBS531L mutant has a growth defect compared to the wild-type strain, 
and there was approximately one log difference in cells numbers for most of the 
experiment (Figure 3.21b). Slightly higher numbers of wild-type were seeded in the 
experiment, but this unlikely to account for differences in growth between the wild-type 
and mutant strain. The relative fitness of the mutant to the wild-type strain was 
calculated as previously described (Gagneux et al., 2006b) and was found to be 0.87 (see 
Methods and Materials 2.4.6). This is a similar value to what was previously observed for 
the fitness of RIF-selected MTB mutants (Gagneux et al., 2006b, Mariam et al., 2004). The 
observed fitness cost is relatively low, and there were several observations which indicate 
the possibility that the number of rpoB mutants in the mixed culture may have been 
higher. 
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Figure 3.21 The rpoBS531L mutant has a fitness defect when grown in competition 
with wild-type MSM in 7H9 OADC. 
a) Growth of wild-type (–––) and rpoBS531L (–––) in axenic culture. b) Growth of wild-
type and rpoBS531L in competition. Experiments were continued for 20 days (480 
hours). Cells were enumerated by plating on standard 7H10 OADC and 7H10 OADC 
RIF200. Experiments were conducted three times, and error bars represent standard 
deviation, which indicates how much variability there is between the calculated 
average, and individual measurements at each time point. 
 
a 
b 
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3.8.1 Concerns regarding the use of RIFR to differentiate between wild-type and the 
rpoBS531L mutant  
As discussed above, there was some concern about using the RIFR phenotype to 
differentiate between wild-type and rpoBS531L strains. Observations during the 
competition experiment question the suitability of RIFR for this purpose, and moreover 
raise important physiological questions.  
 
The rpoBS531L strain was grown in axenic culture, and growth was evaluated on standard 
7H10 OADC plates, as well as 7H10 OADC RIF200 plates. Previous data indicated that the 
rpoBS531L strain was resistant to levels of RIF exceeding 200 µg/ml on solid, and in liquid, 
media (Sections 3.7.1 and 3.7.3). Similar numbers of rpoBS531L colonies should therefore 
be observed on standard OADC and RIF200 plates. We were surprised to see that the 
number of colonies on standard OADC plates was consistently higher than on RIF200 
plates (average for the entire experiment: 5.1 X 108 CFU/ml (standard OADC) vs. 2.61 X 
108 CFU/ml (RIF200)). RIF200 plates containing no colonies were observed on more than 
one occasion, and the decreased culturability of rpoBS531L appeared to decrease as the 
experiment progressed (Figure 22). These observations raised questions regarding the 
ability of growth on RIF200 to accurately represent rpoB
S531L population size. 
  
AS-PCR was performed on a selection of plates from different time points. In the 
competition culture, standard OADC plates should contain a mixture of wild-type and 
rpoBS531L strains. To determine the proportion of strains in the mixed culture, the 
genotype of a selection of colonies from standard OADC plates was determined by AS-
PCR. AS-PCR on DNA extracted from a selection of colonies would therefore give an idea 
of the proportion of strains that existed in the culture prior to plating. The genotype of 
twenty colonies from time points of 9 hours; 7 days (168 hours); 20 days (480 hours) and 
48 days (1152 hours) were determined. Only 2 sets of cultures had previously become 
contaminated, and one set was maintained until 62 days, which enabled us to 
genotypically evaluate strains composition at 48 days. At 9 hours, AS-PCR indicated that 
55 % of strains were wild-type, and 45 % were rpoBS531L (Figure 3.22a). By day 20, the 
strain composition had changed to 70 % wild-type, and 30% mutant (Figure 3.22c). The 
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corresponding RIF200 plate had no colonies on it, and the number of rpoB
S531L mutants 
had been scored as zero (Figure 3.22c). AS-PCR and observations from axenic rpoBS531L 
cultures indicate that colony numbers on RIF200 are not representative of the actual 
number of rpoBS531L mutants present in the mixed culture. This evaluation was only 
conducted once and only on a selection of plates. It is therefore plausible that this is a 
rare phenomenon, and not representative of the whole experiment.  
 
 
 
 
 
 
 
 
 
 
To evaluate the ability of rpoBS531L strains coming out of the competition assay to grow in 
the presence of RIF, a 1 ml aliquot was removed from the mixed culture. Five hundred 
microliters was added to standard 7H9 OADC liquid media, and the other 500 µl to 7H9 
RIF200
std OADC RIF200std OADC
RIF200std OADC
RIF200
std OADC
a b
c d
Figure 3.22 Growth on RIF200 plates does not represent the full extent of colonies 
present in the competition culture. 
AS-PCR was conducted on a DNA from selection of colonies from various time points of 
the competition culture to determine the relative numbers of wild-type and rpoBS531L. 
Colonies were selected from standard 7H10 OADC (std OADC plates), the 
corresponding 7H10 OADC RIF200 plates (RIF200) are shown.  Selected time points: a) 9 
hours (55 % wild-type; 45 % rpoBS531L) b) 7 days (52 % wild-type; 48 % rpoBS531L) c) 20 
days (70 % wild-type; 30 % rpoBS531L) d) 48 days (85 % wild-type; 15 % rpoBS531L). The 
numbers of rpoBS531L colonies on RIF200 plates are consistently lower than indicated by 
AS-PCR. By day 20 and 48 several RIF200 plates containing no colonies were observed, 
even though AS-PCR reveals 30 % and 15 %, respectively, of strains are rpoBS531L. 
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OADC RIF200 media. The same was done for the wild-type axenic cultures, and OD600 was 
monitored daily, for 7 days. By the time these experiments were initiated, the assay was 
in its 9th week, and few colonies were observable on RIF200 plates.  The OD600 of the 
axenic wild-type aliquot, in standard 7H9 OADC media, increased unexceptionally, by day 
2 it was 0.77 and by day 7, it was 4.8. The OD600 of cells removed from the competition 
culture and added to in standard 7H9 OADC increased similarly to the wild-type (0.67 at 
day 2, and 5.4 at day 7). In contrast in 7H9 RIF200 broth, the aliquot from the competition 
culture had only reached an OD of 0.01 at day 2, and 0.44 at day 7. There was no increase 
in OD600 for the axenic wild-type cells in RIF200 media therefore it is unlikely that the 
delayed increase in OD was due to a late mutant emerging from the wild-type population. 
This indicates that rpoBS531L mutants coming out of competition culture had difficulty 
growing in the presence from RIF, despite a MICRIF of 250 – 500 µg/ml. 
  
The implication of these observations for this experiment is that the number of rpoBS531L 
mutants represented on RIF200 plates, may have been lower than were actually present in 
the mixed culture, and results therefore may be skewed in favour of the wild-type strain. 
Perhaps more interesting though, is the question of why rpoBS531L mutant strains, that are 
resistant to high levels of RIF, have reduced culturability on RIF as they come out of 
competition culture. This issue speaks to both key questions in this project – that is the 
sufficiency of single RIFR-associated mutations to confer high level RIFR, and the 
implications of these mutations for mycobacterial physiology. 
 
4. Discussion 
New anti-TB chemotherapeutics and improved control measures are direly needed to 
curb the burgeoning drug-resistant TB epidemic. An understanding of the how drug 
resistance develops, and how resistance impacts fitness, is crucial if new control 
strategies are to be effectively maintained. The majority (approximately 95 %) of all 
clinical RIFR MTB isolates contain mutations in the rpoB gene (Ramaswamy & Musser, 
1998, Telenti et al., 1993). These mutations occur at over 25 sites in rpoB, and are 
associated with varying levels of RIFR (Sandgren et al., 2009). Notably, the same rpoB 
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allele can be associated with different levels of RIFR in different strain backgrounds 
(Gagneux et al., 2006b). This suggests that second-site mutations may be important in 
drug resistance-associated fitness, and highlights the need to introduce single, defined 
rpoB mutations into a strain in order to study the effects on drug resistance and 
physiology. For MTB, an obligate human pathogen, the ability to survive and be 
transmitted in a population is intricately dependent on physiological processes. 
Therefore, the impact of drug resistance-associated mutations on MTB physiology has 
fundamental consequences for fitness, and by association, the spread of drug-resistant 
strains. Moreover, outbreaks of multidrug-resistant (MDR)- and extensively drug-resistant 
(XDR)-TB raise significant biological questions surrounding the ability of MTB strains, 
which contain mutations in multiple essential genes, to maintain infection and 
transmission in a population.  
 
This study was designed to address two broad, but interrelated, research questions: 1. 
The impact of specific drug resistance-associated mutations on mycobacterial physiology, 
in particular their consequences for perceived fitness; and 2. The contribution of single 
point mutations to resistance levels. To this end, a panel of MSM strains containing RIFR-
associated mutations was generated via SDM (Smith & Klugman, 1997) for point 
mutations and Xover-PCR (Link et al., 1997) for the 30 bp deletion together with allelic 
exchange (Gordhan & Parish, 2001) (see Section 3.5). Observations of massively 
decreased RIF-susceptibility (RIFS) of MSM strains containing S531L or H526Y mutations 
adds to the body of evidence indicating the importance of these mutations for RIFR 
(Williams et al., 1998, Miller et al., 1994, Sandgren et al., 2009, Ramaswamy & Musser, 
1998, Telenti et al., 1993). Moreover, an increase in susceptibility after restoration of the 
wild-type allele in the rpoBS531L strain provides novel evidence to suggest an S531L 
mutation is sufficient for RIFR (described in Section 3.7.5). The rpoBS531L strain had a 
modest fitness defect when grown in competition with the wild-type strain (see Section 
3.8). However, preliminary experiments indicate that more rpoBS531L cells may have been 
present in the competition culture, than was represented by growth on RIF containing 
media. This raises the provocative possibility that the fitness of the mutant may actually 
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be higher than observed, and raises additional biological questions that require further 
investigation.  
 
4.1 Advantages (and disadvantages) of the study design for this project  
Since the study utilized MSM as research organism, an additional theme underlying this 
work was an assessment of the application of any techniques developed to MTB in future 
work. This is not a trivial point, and highlights our genuine concerns in setting up this 
project with our ability to generate rpoB point mutants in the absence of RIF selection 
and, more importantly, the type of assays that we might be apply to assess resultant 
fitness defects (or enhancements). These concerns are both physiological and 
experimental: Is it possible to generate a mutant that differs from its parent by only a 
single point mutation in a desired locus? How might an assay be designed so that it 
provides the best proxy measure of in vivo fitness? Is more than one assay required to 
approximate different stages of infection? How can the assay be set up to facilitate the 
differentiation of wild-type and mutant strains? etc. However, while the results 
presented here can therefore be considered “proof of concept” in many respects, there 
are certain key aspects of our results which we consider worth pursuing in their own right 
(in MSM) for their potential impact on our understanding of fundamental mycobacterial 
physiology. 
 
Given the large number (approximately 25) of rpoB alleles associated with RIFR in MTB, it 
was necessary to select a panel of mutants to replicate in MSM by SDM and allelic 
exchange. An analysis of the literature identified the two most common rpoB alleles 
observed in RIFR MTB strains. This was subsequently confirmed when the TB Drug 
Resistance Database (TBDReaDB) was established (Sandgren et al., 2009). The prevailing 
theory equates clinical frequency with fitness: that is, the most common mutations carry 
the least fitness cost (Gillespie et al., 2002, Mariam et al., 2004, Gagneux et al., 2006b, 
Shcherbakov et al., 2010). However, while intuitive, this impression overlooks 
fundamental uncertainties regarding the nature of the selective forces acting on clinical 
strains, both during infection (with or without antibiotic exposure) and, importantly 
during strain isolation and processing in vitro. A significant proportion of sputum bacilli, 
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for example, exist in a non-replicating state (Garton et al., 2008), and similarly do not 
grow in vitro without stimulation by a Resuscitation Promoting Factor (RPF)-mediated 
growth factor (Mukamolova et al., 2010).   
 
In addition to elucidating the relative frequencies of the multiple RIFR-associated 
mutations, our analysis of the literature also revealed previous reports indicating that a 
silent mutation, L521L, might be associated with RIFR (Siddiqi et al., 2002, Yang et al., 
1998). Structural analysis of the RNAP indicates that missense mutations in the RRDR of 
the rpoB gene decrease RIF binding efficiency (Campbell et al., 2001). It was unlikely that 
this mutation was involved in RIFR, however, if true, high level RIFR resulting from a silent 
mutation would challenge this model. If should be noted that only the RRDR of the rpoB 
gene was analysed in these studies (Siddiqi et al., 2002, Yang et al., 1998). This and MICRIF 
data obtained in this study (see Section 3.6), suggests that other mutations in rpoB (or 
elsewhere) contributed to RIFR in that strain. Nevertheless, the unusual nature of this 
mutation made it an attractive candidate for inclusion in our study together with the two 
most common mutations (Table 4.1), and  three additional alleles that had been 
identified in unrelated work at the MMRU:  an Q513V mutant that was isolated after UV-
irradiation and selection on high level RIF, and found to exhibit differential growth on 
different growth media; secondly, a mutant containing a TH526TY mutation, which arises 
from a double transition mutation (ccac → ttac), and is commonly associated with error-
prone repair of UV-induced DNA damage, by the SOS-inducible DNA polymerase III 
subunit, DnaE2 (Boshoff et al., 2003, Warner et al., 2010); and thirdly, a 30 bp deletion 
that has been isolated in MSM, in response to stress such as UV treatment and 
starvation, on multiple occasions at the MMRU (Digby Warner, unpublished results). 
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Table 4.1 Plasmid constructs and mycobacterial mutants generated in this study 
Mutationa Reason for Study Suicide 
vectorb 
SCOc  pOLYG 
vectord  
DCOe  
WT rpoB  Template for SDM and control 
for complementation and 
over-expression analyses 
 f  N/A 
S531L (tcg→ttg) Mutation most commonly 
associated with RIFR in clinical 
MTB isolates (Sandgren et al., 
2009). 
    
rpoBS531L→WT Restoration of the wild-type 
allele in the S531L mutant 
background to determine if 
this restores RIFS. 
 N/A N/A g 
H526Y (cac→tac) Another common mutation in 
clinical MTB isolates (Sandgren 
et al., 2009). 
    
L521L (ctg→ttg) Silent mutation associated 
with RIFR (Siddiqi et al., 2002, 
Yang et al., 1998). 
  X  
Q513V 
(cag→gtg) 
Preliminary research in the 
MMRU suggested that this 
mutation was associated with 
no growth phenotype in 
different media; used as a 
negative control. 
 X X X 
T-H526T-Y 
(acccac→acttac) 
Double transition mutation 
commonly associated with 
DnaE2 activity in both MTB 
and MSM; implications for 
DNA damage-induced drug 
resistance (Boshoff et al., 
2003). 
  X X 
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30 bp deletion 
(Q512 – S522) 
(cagttcatggaccag
aacaacccgctgtcg) 
During studies at the MMRU, 
this deletion was isolated in 
MSM on more than one 
occasion, in response to 
exposure to UV irradiation, 
starvation, and treatment with 
replication inhibitors (Digby 
Warner, unpublished). An 
analogous mutant was 
isolated in a recent study 
(Malshetty et al., 2010). 
  X X 
aMutations are numbered according to the system based on the E. coli genome, as per standard practice 
(Telenti et al., 1993). cSuicide vectors, containing a mutated version of rpoB, which was generated via 
targeted mutagenesis (SDM or Xover-PCR). These constructs were used to introduce mutated rpoB alleles 
into the MSM chromosome during allelic exchange. cSCO MSM strains, generated during the first step of 
allelic exchange, contain two copies of the rpoB gene – a mutated version and the wild-type version. 
dpOLYG is an episomal, multicopy vector. The wild-type, S531L and H526Y versions of rpoB were added to 
this construct and introduced into MSM to examine implications of gene dosing for RIFR. eDCO MSM strains 
generated from SCO strains, contain one copy of rpoB – the wild-type version has effectively been swapped 
for a mutated version. fThis construct contains two copies of the wild-type rpoB gene, and was used as a 
control for evaluation of RIFR in SCOs. gThe wild-type rpoB allele was restored in the S531L mutant strain. 
 
A number of studies have examined the implications of RIFR-associated mutations for the 
fitness and physiology of mycobacteria (Gagneux et al., 2006b, Mariam et al., 2004, 
Billington et al., 1999, Davies et al., 2000, Gillespie et al., 2002, Jenkins et al., 2009, 
Malshetty et al., 2010) and other organisms (O'Neill et al., 2006, Yu et al., 2005, Maughan 
et al., 2004, Perkins & Nicholson, 2008, Hosaka et al., 2009). However, these studies are 
united in their use of RIF to select for rpoB mutations, either in the laboratory, or for 
clinical isolates during patient treatment. A potential limitation of this approach is that 
second-site mutations may be introduced into the chromosome. Methodology employed 
in this study (SDM and allelic exchange) facilitated the generation RIF-naïve strains, that 
contained single point mutations commonly observed in RIFR mycobacterial strains. Other 
techniques are available to introduce point mutations into a gene. Recombineering, 
which relies on recombination proteins from phage systems, presents an alternative to 
allelic exchange for replacement of the wild-type rpoB allele with a mutated version. This 
technique has been used to generate point mutations in mycobacterial genes, in some 
cases without the need for positive selection (van Kessel & Hatfull, 2008). However, many 
of preparative and screening procedures would be similar to those for allelic exchange. 
SDM would still have been required to generate a mutated version of rpoB, and an AS-
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PCR based strategy would have been necessary to screen for resultant mutants. 
Moreover, generation of mutants by recombineering without positive selection results in 
similar transformant number to allelic exchange (van Kessel & Hatfull, 2008).  
 
Three groups have previously introduced mutated versions of rpoB, containing common 
RIFR-associated mutations, into MTB – both groups replaced a portion of a wild-type rpoB 
allele with the corresponding region from a resistant strain (Williams et al., 1998, Zaczek 
et al., 2009). In a separate study PCR-based SDM had been used to engineer mutations in 
the rpoB gene of MTB, which was then expressed in MSM (Miller et al., 1994). In all three 
studies a significant decrease of RIFS was observed upon introduction of the mutated 
rpoB allele. However, in all three cases mutants were generated which retained an intact 
wild-type rpoB gene. For an evaluation of the biology of mycobacterial strains containing 
mutated rpoB alleles, it was important that we generated strains wherein the wild-type 
allele had been removed. 
 
4.2 Was MSM a good study organism for this project? 
The fast growing, non pathogenic MSM mc2155 was used as research organism in this 
study (Snapper et al., 1990). MSM has been used extensively to investigate fundamental 
aspects of mycobacterial physiology, and often – though not in all cases – provides vital 
preliminary biological insights, as well as an indication of feasibility, prior to transferring 
the same research questions to MTB and other pathogenic mycobacterial species.  
 
The use of MSM at the research organism in this study necessitated an evaluation of 
advantages and disadvantages of this system – keeping in mind the central aims of this 
study. Investigation of RIFR in MSM is likely to yield interesting insights into mycobacterial 
biology, and is a good starting point to begin investigating drug resistance in MTB. 
However there are important physiological differences between these two species which 
must be considered. Comparative genomic studies have identified a high degree of 
evolutionary conservation among bacterial rpoB genes, which even show some 
relatedness to components of eukaryotic transcriptional machinery (Lane & Darst, 2010a, 
Lane & Darst, 2010b). At the amino acid level, the rpoB gene is 91% similar between MTB 
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and MSM, while the RRDR is fully homologous (Figure 3.2). RIFR-associated amino acid 
substitutions in the RRDR are therefore, identical in both organisms. The DNA sequence 
of the RRDR is 91% identical between MTB and MSM, moreover specific bases that would 
be mutated are exactly the same. These similarities made MSM a suitable organism for 
study in this project.  
 
Published MICRIF values for MTB (0.01 – 0.02 μg/mL) (Changsen et al., 2003) are much 
lower than for MSM (8 – 32 μg/mL) (Piddock et al., 2000, Alexander et al., 2003). 
Increased tolerance to RIF for some mycobacteria results from the activity of various RIF-
inactivating mechanisms. In MSM, for example, ribosylation of RIF by ADP 
ribosyltransferase leads to increased RIF tolerance (Quan et al., 1997, Alexander et al., 
2003), while studies of the intracellular accumulation of radio-labeled RIF indicate that 
efflux systems are expressed at low levels in MSM, thereby reducing the intracellular 
concentration of active compound (Piddock et al., 2000). Moreover, MSM contains an 
RNA binding protein (MsRbpA) that when over-expressed partially protects from the 
effects of RIF (Dey et al., 2010). The expanded complement of RIF-inactivating 
mechanisms in MSM underscores the need to repeat this work in MTB, and poses some 
challenges in working with MSM to evaluate RIFR and RIFR-associated mutations. Initial 
MICRIF determination revealed that MSM mutants containing the S531L or H526Y 
mutation were resistant to concentrations of RIF in the 125 – 250 µg/mL range. This was 
the lower bound of MICRIF for these strains – MICRIF determination using higher 
concentrations of RIF revealed rpoBS531L and rpoBH526Y could grown in concentrations of 
RIF up to 250 – 500 µg/mL (Section 3.7). Repetition of these assays in analogous MTB 
strains is unlikely to yield such high absolute MICRIF values. However, it will be interesting 
to see if RIFS decreases in MTB by the same proportion. As previously mentioned, 
important physiological and clinically relevant mycobacterial physiological features have 
been uncovered using MSM as a research organism. Even though, it will be important to 
repeat RIFR determination using MTB, the primary aim of this project was to elucidate 
physiological effects of RIFR, and MSM is a useful organism to do this in.  
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4.3 Merodiploidy and RIFR 
SCO recombinants are intermediates in the allelic exchange process and for most gene 
knock-out studies are merely a necessary step in the process of generating gene knock-
out mutants. However in the case of rpoB, SCOs are potentially interesting given that 
some Nonomuraea and Nocardia sp. encode two paralogues of the rpoB gene (Ishikawa 
et al., 2006, Vigliotta et al., 2005). Moreover, nucleotide substitutions in the alternative 
rpoB gene in Nonomuraea sp. strain ATCC 39727 occur at the H526 and S531 loci – and at 
other sites within the RRDR (Tala et al., 2009). The evaluation of RIFS of SCO strains was 
therefore a potentially interesting avenue to pursue. Moreover, this kind of analysis 
provided the opportunity to investigate the impact of gene dosing on RIFR. 
 
During initial MABA assays, the highest concentration of RIF that cells were exposed to 
was 250 µg/mL. In these assays it appeared that S531L and H526Y SCOs were resistant to 
similar levels of RIF as their derivative DCO mutants. However, when higher 
concentrations were used in RIFS assays, it became apparent that SCOs had a slightly 
lower MICRIF than DCO strains (Section 3.7.6). These results are consistent with previous 
reports that suggest that retention of the wild-type allele in a strain containing a mutated 
version of rpoB increases RIFS (Williams et al., 1998). Interestingly, Ilyina et al. (1971) 
report that, in merodipolid E. coli cells – containing both the wild-type rpoB gene and a 
RIFR variant, the susceptible phenotype dominates (Ilyina et al., 1971). The authors 
suggest that this is because the wild-type gene binds DNA more efficiently (Ilyina et al., 
1971). However, in our assays, the SCOs were associated with decreased susceptibility to 
RIF relative to wild-type MSM, thereby indicating that the mutated version of the rpoB 
was not dominated by wild-type. In addition, the observation that SCOs are more 
susceptible to RIF than DCOs suggests stochastic binding of wild-type and mutant RpoBs 
to DNA in the merodiploid strains. This conclusion is supported by the fact that the 
mutated version of rpoB is integrated at the native rpoB chromosomal site, so increasing 
the likelihood that native and mutated versions of rpoB are transcribed, and translated, 
at similar rates. The factors regulating the production and assembly of RNAP subunit 
components is not completely understood, however, β-subunit composition of 
assembled RNAP enzymes is probably a mixture – with some enzymes containing β-
 129 
 
subunit that is sensitive to RIF, and others containing a RIF-recalcitrant β-subunit. At 
relatively high concentrations of RIF, RNAP functionality is probably preserved by those 
enzymes that are made up of mutated versions of rpoB. As RIF concentrations increase, 
RNAP enzymes that contain a sensitive β-subunit are likely to be inhibited by RIF. 
However, it is not clear if this inhibition is adequate to prevent cell growth, and why 
mutated versions of rpoB can’t take over function. Recently, Kohanski et al. (2009) 
suggested that bacterial death after antibiotic treatment is a result of oxidative stress 
mechanisms induced by target inhibition (Kohanski et al., 2010, Kohanski et al., 2008). 
The precise mechanisms may differ, but inhibition of RNAP may result in off-site toxic 
stress, which may partly explain inhibition of growth of SCOs at very high RIF 
concentrations.  
 
4.4 Single S531L or H526Y point mutations in the rpoB gene drastically 
decrease RIFS: does this infer sufficiency for RIFR? 
Several aspects of the directed mutagenesis and screening strategies employed in this 
study required several rounds of optimization to increase specificity. However, 
generation of these mutants, containing RIFR-associated mutations, in the absence of RIF, 
allowed evaluation of the contribution of single point mutations in the rpoB gene – 
without second-site mutations in associated or complimentary genes – to RIFR. RIFS of 
rpoBS531L and rpoBH526Y mutants was significantly decreased in both solid and liquid media 
(wild-type: 1.95 – 3.9 μg/mL; rpoBS531L/rpoBH526Y mutant: 250 – 500 μg/mL). In contrast, 
the rpoBL521L mutant displayed susceptibility levels similar to the wild-type. Only the RRDR 
region of the clinical isolates containing the L521L mutation was sequenced (Yang et al., 
1998, Siddiqi et al., 2002), which indicates that either alternative rpoB mutations or other 
physiological mechanisms were involved in RIFR.  
 
Evaluation of the ability of mutant strains to grow on RIF containing solid media provided 
the first indication of RIFS of strain generated in this study. MABA’s were applied to 
determine a more precise MICRIF for mutant (Palomino et al., 2002, Collins & Franzblau, 
1997, Franzblau et al., 1998). The utility of this method arises from the use of 96-well 
plates which facilitate assessment of growth across a large range of antibiotic 
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concentrations (the final concentration in a plate, represents 4000-fold dilution of the 
starting antibiotic concentration). Addition of Alamar Blue aids in evaluation of growth. 
Alamar Blue contains resazurin, and as growth occurs, oxygen usage by cells allows for 
reduction of resazurin, which then changes from blue to pink (Mann & Markham, 1998). 
Wild-type MSM has a relatively high MICRIF therefore elevated concentrations of RIF were 
required to evaluate the effect of the point mutation on RIFR. The deep red colour of RIF 
made the use of Alamar Blue as a growth indicator problematic, especially in wells where 
the concentration of RIF was higher. Therefore pellet size was used as an additional 
growth measure and cell growth from selected wells was evaluated on 7H10 OADC 
(Appendix 5.2) plates to verify that growth was actually occurring.  
 
The importance of S531L and H526Y mutations for RIFR was reiterated by results of 
MABA’s (see Section 3.7.3). These assays suggest that the main contributor to RIFR was 
the single point mutation in rpoB. The fact that these strains were RIF-naïve until MIC 
determination supports this finding. To broaden the investigation of the sufficiency of 
RIFR-associated mutations for resistance, the wild-type allele was restored in the rpoBS531L 
mutant. When the leucine in the mutant RpoB was restored to the wild-type serine, RIFS 
dropped to wild-type levels (Figure 3.20). This result provides important and novel 
evidence for the sufficiency of the S531L mutation for RIFR. Experiments to restore the 
wild-type allele in the H526Y mutant are underway and it is likely that results will be 
similar. Restoration of the wild-type allele in the S531L mutant background provides good 
evidence that other mutations are not contributing to RIFR, but does not rule out the 
possibility of second-site mutations that may compensate for fitness defects.  
 
Structural evaluation of the RIF-RNAP complex shows that RIF binds to RNAP within the 
DNA/RNA channel (Campbell et al., 2001). Mutations at eleven of the twelve amino acids 
that are directly involved in RIF binding have been observed in RIFR organisms (Figure 
3.2). These mutations often result in substitution of an amino acid with a small side chain, 
with an amino acid with a more bulky group, which probably interferes with RIF binding. 
Amino acids at positions 531 and 526 are involved in hydrogen bonding with RIF, and 
changes probably disrupt this bonding (Campbell et al., 2001). Campbell et al. (2001) 
suggest that RIF impedes transcription by preventing bond formation between the 2nd 
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and 3rd trinucleotide in a growing RNA chain. Arstimovich et al. (2005) suggest an 
additional mechanism that may facilitate RIF inhibition of RNAP (Artsimovitch et al., 
2005): specifically that the tail of the RIF molecule provides an allosteric signal that 
disorders binding of the Mg2+ ion at the active site, and thereby slows catalysis. Both 
mechanisms probably play a role in RIF-mediated obstruction of transcription, and RIFR-
associated mutations at different positions in rpoB may be affecting different facets of RIF 
inhibition. Missense mutations that resulted in S531L and H526Y changes resulted in high 
level RIFR, while the silent L521L mutation had no effect on RIFR. Therefore, MICRIF 
determination during this study provide further support for the role of substituted amino 
acids – and decreased RIF binding – in RIFR.  
 
RNA transcription and DNA replication happen at the same time within a cell. Collision of 
transcriptional and replicative complexes can impact genetic stability due to replication 
stalling (Boubakri et al., 2010). It is not clear what happens to RNAP after RIF inhibition. 
Does the enzyme disassociate and re-associate somewhere else on the chromosome? Is 
the RIF bound β-subunit degraded? If RIF inhibited RNAP increase DNA replication-stalling 
this could have severe consequences for genetic stability within the cell. Interestingly a 
recent study shows that rpoB mutations (within the RRDR) reduce the need for proteins 
that resolve stalled replication complexes (Baharoglu et al., 2011). In the context of this 
study, it’s particularly important to consider how rpoB mutations impact DNA fidelity. If 
introduction of rpoB mutations affects TCR or other DNA repair mechanisms, and results 
in increased mutagenesis, isogenicity of mutant strains may be compromised. RIFR-
associated mutations examined in previous studies for their role in TCR modulation are 
not commonly observed in clinical isolates (Trautinger et al., 2002; Ganesan et al., 2007; 
Baharoglu et al., 2011). This does not, however, negate the need to consider the 
implication of RIFR-associated mutations for isogenicity of mutant strains generated in 
this study. The implications of RIFR-associated mutations on DNA repair provides an 
interesting area to explore in future studies. RIFR-associated mutations in rpoB have 
pleiotropic effects for mechanistic and regulatory aspects of transcription – from 
transcription initiation (Campbell et al., 2001) to pausing termination (Jin and Gross, 
1998; Jin and Gross, 1991; Ingham & Furneaux, 2000), and regulation (Hu et al., 2002, Xu 
et al., 2002). In addition to impacting RIF binding and RIFR, structural and mechanistic 
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implications of rpoB mutations are likely to be responsible for important physiological 
changes. 
 
4.5 Are there other contributors to RIFR? 
Up to 95 % of RIFR clinical isolates contain mutations in the RRDR (Telenti et al., 1993, 
Ramaswamy & Musser, 1998). However, the genetic basis for resistance in the remaining 
strains remains unclear. In many studies, only the region of the rpoB gene containing the 
RRDR is sequenced, despite evidence that mutations in other regions of the rpoB gene 
can be associated with RIFR. It is, therefore, possible that 5 % of RIFR strains with no 
mutations in the RRDR may have mutations in other regions of rpoB (Heep et al., 2001, 
Heep et al., 2000b).  The implications of these mutations for RNAP function, and bacterial 
physiology, are likely to be vastly different when compared to mutations found in the 
RRDR. EMB is an important first-line TB drug that is thought to interfere with cell wall 
biosynthesis (Belanger et al., 1996). Introduction of an EMBR-associated mutation into the 
MTB chromosome conferred some levels of resistance but not to the high levels seen in 
clinical isolates (Safi et al., 2010). Such evidence indicates that there may be other 
mechanisms that play a role in resistance to other clinically relevant anti-TB drugs. 
Several factors are important for the ability of a drug to execute its effects on a target, 
including the rate of passive diffusion of the drug into the cell, the operation of active 
efflux pumps which serve to reduce the intracellular concentration of toxic compounds, 
enzymatic antibiotic inactivation mechanisms, and the intracellular concentration of the 
target. These are factors important in determining drug efficacy and are also therefore 
important for the development of drug resistance (Fange et al., 2009) (Figure 4.1).  
 
We were particularly interested in the role of efflux in RIFR from a physiological 
perspective. There are several reports that indicate that active efflux systems are 
required for the development of resistance-associated mutations (Ricci et al., 2006, 
Fange et al., 2009, Lovmar et al., 2009). Evaluation of mycobacterial genomes indicates 
that there is the potential for expression of several types of efflux systems (Louw et al., 
2009). It is likely that efflux systems in mycobacteria largely play a role in maintaining 
physiological homeostasis, and protecting the bacillus from the accumulation of toxic 
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compounds (Louw et al., 2009) and extrusion of drugs may be an adaptive advantage 
conferred by some of these systems. In addition to extrusion of toxic substances – such as 
drugs – mathematical modelling (Fange et al., 2009) and results from Salmonella 
experimental systems (Ricci et al., 2006) suggest that activated efflux systems are 
absolutely required to ‘prime’ bacteria to generate and fix resistance-associated point 
mutations. In MTB, experiments indicate that inhibition of efflux decreases the mutation 
rate of EMBR, and that efflux may facilitate concurrent development of resistance to EMB 
and INH (Srivastava et al., 2010).  
 
Inclusion of EPI’s, verapamil and reserpine, in MABA plates had insignificant effects on 
RIFS of wild-type or mutant strains. Reserpine inhibits ATP-dependant pumps, while 
verapamil impedes P-glycoprotein systems (Lechner et al., 2008), and it is possible that 
mycobacterial efflux systems are recalcitrant to these compounds. Another possibility is 
that other extrusion systems compensated for inhibition of verapamil/reserpine sensitive 
efflux pumps. Reserpine and verapamil inhibit MSM efflux of ethidium bromide 2 – 4 fold 
(Lechner et al., 2008).  However, exposure to reserpine only slightly increases 
accumulation of radio-labelled RIF by MSM cells (Piddock et al., 2000). The MABA method 
may not be sensitive enough to detect a change in efflux. However, if efflux systems were 
playing a significant role in resistance, inhibition should have detectable influence on 
MIC. MICRIF determination in the presence of EPI’s indicates that efflux pumps (at least 
those inhibited by verapamil or reserpine) do not significantly contribute to RIFR in MSM. 
However, this does not exclude a role for active efflux system in generating and fixing 
drug resistance-associated point mutations in target genes and remains to be explored. 
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Figure 4.1 Factors important in drug efficacy and the development of drug 
resistance.  
This figure was adapted from (Fange et al., 2009) to reflect to the factors influencing 
the effective concentration of RIF required to inhibit bacillary growth by binding 
RNAP. Drug efficacy can be undermined at a number of levels: First, the drug needs 
to get into the cell, which often happens by passive diffusion (passive influx of the 
drug into the cell is indicated by thinker black arrows, while potential passive 
diffusion of the drug out of the cell is indicated by thinner black arrows). The efficacy 
of many drugs may be hindered at this step. The drug can be inactivated or 
degraded, a mechanism which decreases RIFS in some mycobacteria, and related 
genera (Quan et al., 1997). The drug needs to bind to the target, and the 
intracellular concentration of the drug required to inhibit all enzyme activity 
depends on the intracellular concentration of the target. Finally, intracellular drug 
concentration is likely to play a role in the development of target mutations (Fange 
et al., 2009, Gagneux, 2009), and can be lowered by activate extrusion of drug by 
active efflux systems. 
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4.6 Expression of rpoB from an episomal plasmid is toxic in MSM: Does this 
impact RNAP subunit stoichiometry? 
It has been suggested, and observed in some systems, that over-expression of an 
antibiotic target may contribute to resistance to the antibiotic (Kurth et al., 2009, Huber 
et al., 2009, McMurry et al., 1998). To investigate the effect of gene dosing on RIFR, wild-
type, S531L and H526Y versions of the rpoB gene were cloned onto pOLYG – an episomal 
plasmid (O' Gaora et al., 1997). Low electroporation efficiencies of pGrpoB constructs 
implied that expression of rpoB may from this vector may be toxic in MSM. Upon further 
investigation, significant re-arrangement was observed for pGrpoB constructs carrying 
both mutant and wild-type rpoB genes – an indication that plasmids were unstable upon 
introduction to MSM. The pOLYG vector exists in the cell in up to 23 copies (Huff et al., 
2010), and therefore expression from pOLYG is likely to confer increased expression of 
rpoB. Therefore toxicity of these plasmids may be related to over-expression of rpoB. In 
our system, electroporation efficiency was extremely low, and the plasmids recovered 
from the handful of HYGR appeared to have undergone significant rearrangement, 
therefore rpoB expression levels could not be measured in these isolates. Similar findings 
were reported by Zaczek et al. (2009) who introduced mutated versions of rpoB into MTB 
on replicating vectors. However, they also reported constitutive expression of rpoB from 
an Hsp60 promoter that was integrated at the attB site. Little detail was provided for 
these strains and it is unclear whether rpoB was expressed from Hsp60 – RIFR which may 
have indicated expression was not observed, and rpoB expression levels in these strains 
were not determined (Zaczek et al., 2009).  
 
A separate group did not observe similar toxicity when mutated versions of MTB rpoB 
gene were expressed from multi-copy episomal vectors (Williams et al., 1998). It’s 
possible therefore, that the particular episomal expression system used in ours and the 
Zaczek et al. (2009) study induces unfavourable levels of rpoB expression, while the 
system used in the Williams et al. (1998) study did not. Early reports indicate that 
expression of rpoB is regulated at the translational level. That is, if the rpoB gene were 
over-expressed without simultaneous increase of other RNAP components, translation of 
these subunits was downregulated (Passador & Linn, 1989). Subsequent studies have 
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shown regulation of rpoB expression at the transcriptional level (Dykxhoorn et al., 1996). 
The inferred toxicity of rpoB in multi-copy seems to make intuitive sense: the product of 
rpoB, the β-subunit of RNAP, is part of an essential, multi-subunit enzyme whose 
components must be present in stoichiometric amounts.  
 
4.7 Implications of RIFR-associated mutations for mycobacterial physiology 
At inception, the primary aim of this project was to generate strains containing RIFR 
associated mutations, in the absence of RIF, so that the physiology of these strains could 
be evaluated without possible bias from second-site mutations. Studies in other 
organisms indicate that rpoB mutations, analogous to those found in clinical MTB isolates 
have broad implications for bacterial biology. In B. subtilis, for example, these mutations 
had broad implications for sporulation, germination and even carbon source metabolism 
(Maughan et al., 2004, Perkins & Nicholson, 2008). In MTB, lowering the pH of a 
chemostat culture decreased the frequency with which mutants harbouring an S531L 
mutation were isolated (Jenkins et al., 2009). This is significant, given that MTB is exists in 
acidic compartments with macrophages (Vandal et al., 2009, Vandal et al., 2008). 
Moreover, mutations in the rpoB gene can induce production of novel secondary 
metabolites in Streptomyces sp. (Hosaka et al., 2009, Hu et al., 2002, Xu et al., 2002). 
Mutations in essential and highly conserved targets are expected to result in some cost to 
biological function of these proteins (Andersson & Levin, 1999, Andersson, 2006). Given 
that rpoB is highly conserved, and critical for bacterial function, it has long been 
suggested that RIFR-associated changes in this gene would alter the functioning of RNAP, 
and therefore result in a fitness cost in the absence of RIF (Gagneux, 2009, Gagneux et al., 
2006b, Andersson, 2006, Andersson & Hughes). It is impossible to uncouple fitness from 
biological processes and therefore an understanding of the biological effects of drug 
resistance mutations is important for better TB management strategies, as well as well-
informed drug discovery approaches.  
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4.7.1 Carbon source-specific effects for the MICRIF of wild-type but not mutant strains  
The use of the MABA’s allowed investigation of two central questions of this project: 
specifically, the potential physiological implications of RIFR-associated mutations and the 
contribution of single rpoB point mutations to RIFS. Antibiotic efficacy is dependent on 
the growth state of an organism (Xie et al., 2005, Jindani et al., 2003, Lipsitch & Levin, 
1997). This has proved a significant challenge for TB control, since MTB can persist in the 
host for extended periods, where altered metabolism is one of the factors that lead to 
increased antibiotic tolerance (Barry et al., 2009, Honer zu Bentrup & Russell, 2001). For 
an infectious pathogen, physiology will be affected by numerous factors including activity 
of host immune effectors, oxygen availability, and carbon source and co-factor availability 
(Warner & Mizrahi, 2007). All of these combine to form a network to increase or subvert 
antibiotic efficacy. We were particularly interested in the implications of carbon source 
metabolism for RIFR because of evidence to suggest rpoB mutations drastically alter 
carbon source metabolism in B. subtilis. Mutations in rpoB – similar to those observed in 
clinical MTB strains – confer the metabolic ability to subsist on a variety of carbon sources 
not previously considered suitable for this growth of this organism (Perkins & Nicholson, 
2008).  
 
Assay of wide-ranging carbon sources was beyond the scope of this project therefore, 
MTB-relevant carbon sources were included in MABA assays. A number of recent studies 
indicate that, during infection, MTB probably subsists on lipid based carbon sources 
(Pandey & Sassetti, 2008, Savvi et al., 2008, Brzostek et al., 2009, Marrero et al., 2010). 
Therefore MABA’s were conducted in lipid based-media and the resultant MICRIF 
compared to those obtained in standard mycobacterial growth media. Interestingly, wild-
type strains exhibited a 4-fold increase in MICRIF when grown in lipid containing media, 
while the MICRIF was lowest in GS containing media. From these assays, carbon source did 
not appear to have an effect on MICRIF for mutant strains. Further investigation is 
required, but it’s possible that due to very high MICRIF observed for these strains, carbon 
source specific effects were not discernable. Nutrient usage of MSM is not well defined, 
and although MSM contains some cholesterol catabolising genes (Uhia et al., 2011), it‘s 
not clear that MSM preferentially subsists on fatty-acids – as is suggested for MTB. It’s 
possible that in MSM carbon source composition of the growth media results in altered 
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cell wall composition, which may decrease diffusion of RIF into the cell. These two 
possibilities are not mutually exclusive, and the physiological basis of this observation 
warrants further investigation. Inclusion of a broader range of compounds will form an 
interesting part of the future of this project. The Biolog Phenotype Microarray™ system 
(http://www.biolog.com/phenoMicro.shtml) allows evaluation of thousands of different 
phenotypes in a single run and was used by Perkins and Nicholson (2008) to uncover 
rpoB-associated metabolic capabilities in  B. subtilis (Perkins & Nicholson, 2008). Although 
there are cost considerations, this system would be potentially useful to evaluate the 
effect of carbon source on MICRIF, and the physiological implications of RIF
R-associated 
mutations in mycobacteria.  
 
Discordant drug-susceptibility results have been reported despite the use of standardized 
methodology for tests (Van Deun et al., 2009).  In this study, the MICRIF of wild-type MSM 
was notably higher in lipid-based carbon sources, which demonstrate how assay 
conditions can have significant implications for MIC values. This should be considered 
when evaluating resistance levels of clinical isolates. In these experiments, only one 
condition was altered, and it is likely that the adjustment of other conditions would also 
affect susceptibility levels.  
 
4.7.2 A slight fitness defect for rpoBS531L is revealed by competitive growth experiments 
Mariam et al. (2004) observed that in three different assay systems (in axenic culture; in 
vitro competitive growth, and in macrophages), the inferred fitness of specific RIFR 
mycobacterial strains varied depending on the assay employed. For example, in 
competition with wild-type, an H526Y mutant had the lowest fitness cost when compared 
to S531LY or S522L mutants, however in axenic culture S522L mutant displayed the 
lowest fitness cost. In a highly cited study, Gagneux et al. (2006b) show that the fitness of 
RIFR strains is variable, and is dependent on the particular mutation, as well as the strain 
background. However, strains used in the aforementioned studies had been exposed to 
RIF prior to their assessment in these assays, and so it is possible that these strains had 
adapted to growth with a mutant RpoB, and perhaps even contained second-site 
mutations that could have contributed to any fitness phenotype observed. The 
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generation of RIF-naïve strains in this project, with a defined natural history (in vitro 
processing was kept to a minimum), facilitated physiological evaluation of RIFR-associated 
mutations.  
 
Fitness can be simply defined as the ability of an organism to survive and replicate 
(Andersson & Hughes, 2010), in a particular environment. Biological processes greatly 
impact the ability of the bacilli to do these things under a plethora of pressures that 
include host immune function, and antibiotic treatment (Warner & Mizrahi, 2007). 
Competition assay provided the opportunity to investigate the fitness of mutants, which 
would provide some indication of the degree of physiological effects. The use of RIF had 
been avoided at all costs during generation of rpoBMT strains. However, the high MICRIF 
for rpoBS531L (250 µg/mL – 500 µg/mL vs. 1.95 – 3.9 µg/mL for wild-type), permitted the 
use of RIF-containing plates (200 µg/mL RIF – RIF200) to differentiate between wild-type 
and mutant strains. Therefore fitness was assayed as a function of growth and measured 
by colony number. A modest relative fitness defect was observed for the rpoBS531L strain 
(Figure 21), which is similar to previous findings for MTB with the same mutation 
(Gagneux et al., 2006b, Mariam et al., 2004). However, several observations (discussed in 
the next Section) raise important questions regarding the suitability of RIFR to distinguish 
between wild-type and mutant strains. Nutrient conditions faced by MTB during 
infection, or even MSM in the soil, are likely to differ fundamentally from lab conditions. 
Other conditions which aim to simulate factors prevalent in vivo, for MSM and MTB, 
could be incorporated into the competition assay. Competition experiments between 
strains containing other RIFR-associated mutations, and the parental strain would also be 
informative. Further competition assays, using the strains generated in this project, are 
likely to yield interesting results, and have been included in design of the future of this 
project. Competition between strains containing different RIFR-associated point 
mutations, or between strains containing the same mutations but selected in different 
ways would be especially interesting. For these assays RIFR could not be used for strain 
differentiation – this underscores the need for a better strain differentiation system. It is 
anticipated that these experiments will be conducted in the near future. 
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Strain background can significantly impact observed fitness, for example an H526D 
mutation was associated with a lower fitness cost when introduced into the MTB T85 
strain, than CDC1551 (Gagneux et al., 2006b). Differences in observed fitness may be due 
to indirect biological effects of second-site mutation and these mutations may not be 
compensatory per se. Compensatory mutation, however, has important implications for 
physiology, and spread of drug-resistant strains. In S. typhimurium, direct compensation 
of functional disadvantages as result of STRR can be ameliorated by secondary mutations 
(Bjorkman et al., 1998, Bjorkman et al., 1999). Furthermore, the type of compensatory 
mutation observed was dependent on the assay system used. Whole-genome re-
sequencing of the strains generated was beyond the scope of the project, but would 
provide an interesting exploration of possible compensatory mutation after growth in 
stressful conditions. Epistatic interactions between RIFR- and STRR-associated mutations 
have been reported in E. coli (Chakrabarti and Gorini, 1977; Trindade et al., 2009). 
Moreover it was recently shown that decreased requirement for RNAP, reduced fitness 
costs associated with RIFR in P. aeruginosa (Hall et al., 2011). Treatment of RIFR strains 
with ribosome inhibitors, STR and chloramphenicol, lessened fitness costs as measured 
by growth. Treatment with ciprofloxacin, a DNA gyrase inhibitor did not have the same 
effect, which indicates that better growth of RIFR mutants was not due to generalised 
antibiotic stress, or decreased growth (Hall et al., 2011). STR and RIF are often used to 
treat MTB infected patients at the same time, and an investigation of the epistatic 
interactions between mutations associated with these drugs would be especially 
important for MDR-TB control.  
 
4.8 Complexity of fitness assay and physiological characterisation 
A core assumption of a competition assay is that strains maintain their fundamental 
identity. In other words, with regards to this study, that the rpoBS531L retained the S531L 
mutation and the wild-type retained the wild-type allele. This, therefore, allows use of a 
selective agent to differentiate between the two. One possible deviation from this is 
spontaneous mutation of wild-type to mutant. In view of studies which suggest that 
mutation rate increases during stationary phase (Foster, 1998, Karunakaran & Davies, 
2000, Cairns et al., 1988, Bjedov et al., 2003, Rosenberg & Hastings, 2004), mutation of 
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the wild-type strain was a concern for us. Many studies use rpoB mutations associated 
with RIFR to study mutation rate, and since we used RIF to differentiate between wild-
type and rpoBS531L strains, we were particularly concerned that colonies on RIF plates 
from may originate from mutated wild-type strains. To monitor this, wild-type cells from 
axenic culture were also plated on RIF200 plates. Our concerns were eliminated since no 
RIFR mutants were observed on RIF200, from axenic wild-type cultures, for the duration of 
the experiment. The “lack” of increased RIFR mutation in stationary phase has been 
separately observed at the MMRU (Sam Barichevy, unpublished results; and Digby 
Warner, unpublished results). No RIFR-specific mutation in the wild-type strain was a 
positive result – with regards to methodology for the competition assay, however, it 
contrasts to what was previously observed for MSM (Karunakaran & Davies, 2000). 
Karunakaran and Davies (1998) observed a steep increase of MSM colonies on RIF plates 
which they attributed to increased mutation rate during stationary phase. The differences 
between our study and that of Karunakaran and Davies could stem from the use of 
different MSM strains (in the Karunakaran and Davies study MSM mc26 strain was used, 
while in this project MSM mc2155 was used). Another notable difference is that our 
experiments were conducted using 7H9 OADC media, while the aforementioned group 
used Tryptic Soy Broth. Although an increase in RIFR mutants during stationary phase 
growth is often attributed to elevated mutation rates; from an elegant set of molecular 
and microbiological experiments Wrande et al. (2008) suggest that rpoB mutations 
provide an advantage during stationary growth conditions and therefore outgrow 
parental strains. Carbon source specific differential growth has been observed for UV 
induced RIFR MSM mutants (Digby Warner and Susan Puckett, unpublished results). An 
investigation of whether the differences between results generated in this study (and 
others at the MMRU), and those of Karanakarun and Davies (2008), are due to media-
specific factors and resultant physiological impact for RIFR mutants, presents an 
interesting experiment for the future. 
 
Another assumption of a competition assay is that the strains remain receptive to the 
selective compounds used to differentiate between them. That is, that the wild-type 
strain remains RIFS and that rpoBS531L strains remain resistant to RIF. AS-PCR revealed that 
by day 20 of the assay, 15 – 30 % of strains in the competition assay were of the rpoBS531L 
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genotype, even when no colonies were present on RIF200 plates (after extended 
incubation) (Figure 3.22). Only 20 colonies were examined and genotyped by AS-PCR. 
Given the low numbers of colonies examined, it is possible that there was some sampling 
bias when selecting colonies genotype. This may explain why the numbers of mutant 
colonies actually go up by 3% from the 9 hour measurement to day 7 (Figure 22). 
However, there is a total lack of colonies on RIF200 plates at 20 days and at 48 days, while 
on standard OADC, AS-PCR indicates a considerably higher number of colonies are 
present in the culture. This observation has significant implications for the observed 
fitness of the S531L mutant and suggests that sub-population rpoBS531L had lost the ability 
to grow on RIF. Additionally, an aliquot from the competition culture grew in RIF200 7H9 
OADC liquid media, albeit at a particularly slow rate (see Section 3.8.1). These 
observations require further investigation and raise important questions: If the rpoBS531L 
was resistant to high levels of RIF going into the competition experiment, why upon 
isolation from competition, did a sub-population of exhibit decreased culturability on RIF? 
Why were some rpoBS531Lcells not able to grow on solid RIF200 media, but grew in 
equivalent liquid media?  
 
Finding a better way to differentiate between strains in a competition assay will be an 
integral part of any future study. However, this will be challenging. Introducing resistance 
to a separate antibiotic as a marker is not ideal, as expression of the resistance gene may 
impact physiology in unknown ways, and introduce additional bias. Engineering of 
auxotrophy is also not perfect, and could indirectly impact fitness. A possible solution 
would be to introduce a silent point mutation, into a well characterized but non-related 
gene (“genome graffiti”). However differentiating colonies would still be cumbersome as 
sequencing or PCR characterization would be required. Fluorescently labeling one of the 
strains would make for easy and visually pleasing differentiation however colorimetric 
tags may impose some burden on the cell as they require extra resources to be produced 
and potential toxicity (Shaner et al., 2005, Rang et al., 2003). Unfortunately the issue of 
strain differentiation is a difficult one, and it is possible that all feasible options could 
influence physiology.  
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As evidenced by the preceding discussion, fitness of assay is complex and often fraught 
with possible bias. Development of an appropriate assay to measure the potential fitness 
and physiological implications of RIFR-associated mutations remains a central aim of this 
work. Other model systems could be used to evaluate relative fitness, for example, 
growth in macrophage cells or in mice (strain differentiation would still be an issue in 
these models). Moreover, a targeted evaluation of physiological implications may also 
prove useful and an investigation of the consequences for the mechanistic aspects of 
transcription, such as promoter or sigma factor binding, is another potentially interesting 
avenue of investigation. For example, MSM RNAP containing a 30 bp deletion (Table 4.1) 
was refractory to transcriptional inhibition by RIF concentrations up to 1 mg/mL 
(Malshetty et al., 2010). This mutation has been isolated on multiple occasions at the 
MMRU (Digby Warner, unpublished results) and SCOs containing this mutation have been 
generated (Table 4.1). From a physiological perspective, viability of a strain containing 
such a large deletion in RpoB raises interesting questions. MSM seems to have the ability 
to “loop out” this region of rpoB, the mechanism of mutagenesis for this kind of deletion 
is therefore potentially interesting from a DNA metabolism perspective.  
 
4.9 A pathway to clinical relevance? 
Multiple lines of evidence hint at the tantalizing possibility that drug resistance-
associated mutations in target genes might influence fundamental physiological 
processes such as metabolism and regulation of the immune system – and, furthermore, 
might even confer beneficial capabilities in the absence of antibiotic pressure (Gagneux et 
al., 2006, Maughan et al., 2004, Perkins & Nicholson, 2008, Jenkins et al., 2009, Wrande 
et al., 2008). A primary objective of this project was to investigate this possibility through 
the application of genetic tools and microbiological techniques that constitute the core 
expertise of the MMRU. The construction by allelic exchange of a panel of mutants 
comprising all known drug resistance mutations and their evaluation in phenotypic assays 
is not feasible (Hazbon et al, 2008). Moreover, as noted throughout this thesis, in vitro 
assay systems of fitness are fraught with possible bias, and the results of fitness 
assessments likely to be influenced by numerous factors including the genetic 
background of a particular mutant strain. For this reason, we were determined to 
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complement our microbiological approach with other techniques. As whole-genome 
sequencing technologies become more sophisticated, and cheaper, an ever increasing 
amount of MTB sequence data is becoming available. As previously mentioned, there 
may be pressures which act during strain isolation and processing – this is of particular 
concern when working with model strains. The ever growing collection of sequence data 
for clinical isolates offers the prospect of studying clinical isolates that have undergone 
the least possible processing, and therefore minimal selection. This provides the closest 
approximation of conditions faced within the host. To get any closer, in-host sequencing 
would be required – which presents an exciting goal for MTB genomics.  
 
Whereas classical molecular epidemiology for MTB is based primarily on DNA finger 
printing techniques, phylogenetic analyses using whole-genome sequence data are 
increasingly being utilized to supplement molecular epidemiological investigation 
(Motiwala et al., 2010, Ioerger et al., 2009, Ioerger et al., 2010). For example, in a recent 
study, Ioerger et al (2010) used whole-genome sequence from MDR-TB clinical isolates in 
the Western Cape, to show that RIFR-associated mutations appeared on multiple 
phylogenetic branches, indicating that these mutations were individually acquired. The 
information garnered from studies of this kind can be used to infer physiological 
characteristics of MTB. However, these studies are largely focused on investigating the 
transmission dynamics of MTB, the understanding of which is important for TB control. In 
contrast, our aim is to exploit sequence data to understand some of the implications of 
drug resistance mutations for mycobacterial physiology.  
 
Evolutionary analyses can offer some insight into of how an organism (or functional units 
of an organism) has adapted to – and survived – the myriad of pressures it faces during its 
existence (Toft & Andersson, 2010). For an obligate intracellular pathogen, such as MTB, 
evolutionary changes (as inferred from sequence polymorphisms) can also elucidate the 
nature of the pressures imposed by its human host and, in so doing, illuminate aspects of 
host-pathogen interactions. One technique to investigate the types of constraints on a 
gene or region of a gene is to measure the ratio of non-synonymous to synonymous 
mutations (dN/dS) at a given site (Toft & Andersson, 2010, Koonin & Wolf, 2010). The 
dN/dS ratio is commonly used to assess adaptive dynamics in protein sites, and its 
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effectiveness is born out of the redundancy of the genetic code (Koonin & Wolf, 2010). A 
greater proportion of synonymous mutations at a given site, suggests the site is subject 
to purifying selection, whereas an increased preponderance of non-synonymous 
mutations indicates positive selection (Toft & Andersson, 2010, Koonin and Wolf, 2010). 
As might be expected, an analysis of this type does not come without its own caveats 
(Toft & Andersson, 2010). Due to small population sizes, and strong biases with regards 
to nucleotide composition, constraints on protein sequence may be relaxed in obligate 
intracellular pathogens. Resulting dN/dS values may therefore be exaggerated due to 
increased fixation of slightly deleterious mutations (Toft & Andersson, 2010). Moreover, 
increased fixation of slightly deleterious mutations in mycobacteria is a concern – in 
closely related organisms these mutations are less likely to be lost due to purifying 
selection (Hershberg et al., 2008). Nevertheless, in full cognizance of the possible biases 
and confounding limitations of this approach, we have begun an evaluation of the dN/dS 
parameters at sites in rpoB that are associated with drug resistance, and those that are 
not. It is hoped that this kind of analysis will enhance and complement the conventional 
mycobacteriological techniques that comprise the bulk of this thesis. 
 
Using genome comparisons, Hershberg et al (2008) uncovered previously under-
appreciated levels of genomic diversity in MTB. Moreover, these authors concluded that 
much of the observed diversity had functional consequences and, further, that MTB was 
under reduced purifying selection, which is partially a result of the lack of horizontal gene 
transfer in MTB and extreme bottle necks during transmission (one bacilli is thought to be 
able to initiate an infection). In addition, they suggested that MTB lineages have some 
level of co-evolution with the populations they infect which, together with 
compartmentalisation within the host, leads to a highly segregated population structure. 
All of these factors function together to reduce effective population size and amplify the 
consequences of random genetic drift (Hershberg et al, 2008). A subsequent report by 
the same group suggested that regions of the MTB genome encoding known T-cell 
epitopes are more conserved than some essential genes (Comas et al., 2010). This finding 
is counter-intuitive as one would expect antigenic variation to play a role in immune 
evasion. In both investigations, dN/dS analysis provided a useful tool, and the findings of 
this group motivated our interest in these questions, and in the potential application of 
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this methodology to rpoB. This is not without precedent: the dN/dS technique formed 
part of the methodology used by Gutierrez et al. (2005) to consider ancient ancestry of 
the MTB complex.  
 
We intend to apply similar techniques to an evaluation of the emergence of drug 
resistance. Gutierezz et al. (2005) suggest that MTB emerged 35 000 years ago, 
antibiotics are therefore a relatively new selective pressure that the organism faces in its 
environment. How has MTB adapted to these new pressures, and if RIFR-associated 
mutations have additional physiological consequences, might these mutants have existed 
before the application of RIF for TB treatment? If the emergence of RIFR associated 
mutations is purely the result of antibiotic selection, one would expect regions of rpoB 
involved in RIF binding to have a higher dN/dS value than other sites. These values can be 
compared to other regions of rpoB that are functionally important and to other regions of 
the genome. In the longer term, values for rpoB can be compared to values for genes 
involved in resistance to other drugs, and to genes where selective dynamics are known. 
 
To assist us with this analysis we approached Dr Pierre Durand, who recently established 
The Evolutionary Medicine Unit at the University of the Witwatersrand (Wits). Dr Durand 
has agreed to facilitate this analysis, and has already imparted valuable conceptual and 
technical knowledge. Computation of the dN/dS ratio requires high quality rpoB 
sequence data. Professor Rob Warren, who is a senior researcher at the sister CBTBR unit 
at Stellenbosch University, kindly provided whole-gene rpoB sequence from 22 clinical 
isolates from the Western Cape. Data from the TB Diversity Sequencing Project, which 
was set up by Sebastian Gagneux and Peter Small via the Broad Institute, is publically 
available on the TBDB database and is included in our analysis. The TB Diversity 
Sequencing Project sequence data includes strains from a variety of geographical regions. 
A total of 60 strains are available for analysis. Exploitation of sequence data provides an 
opportunity to examine the biology of drug-resistant clinical MTB strains and adds an 
additional dimension of clinical relevance to this project. 
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4.10 Concluding remarks and prospective outlook 
The major motivation for this study was to gain some understanding of the physiological 
implications of RIFR-associated mutations in mycobacteria. A panel of MSM strains 
containing clinically relevant RIFR-associated mutations was generated in the absence of 
RIF. A combinatorial strategy of SDM and allelic exchange was selected so that likelihood 
of second-site mutation, which was a potential limitation in previous studies (Gagneux et 
al., 2006b, Mariam et al., 2004, Gillespie et al., 2002), was minimised. Moreover, this 
methodology also allowed us to investigate a related issue, that is, the ability of single 
rpoB mutations to confer high level RIFR, without second-site mutations. High level of RIFR 
(MICRIF = 250 – 500 µg/mL) was observed for MSM strains containing S531L and H526Y 
mutations (Section 3.7.3). Moreover this is the first study, to our knowledge, to 
demonstrate that restoration of a wild-type allele in a RIFR strain returns susceptibility to 
wild-type levels – as demonstrated for the rpoBS531L strain (see Section 3.7.5). Even 
though MSM is a useful study organism to investigate mycobacterial physiology, a 
necessary and natural follow up experiment is to introduce similar mutations in MTB and 
confirm the RIFR phenotype in this clinically relevant organism. During this project, 
established genetic manipulation techniques were optimised to introduce drug 
resistance-associated mutations into the mycobacterial chromosome in the absence of 
selection. This will greatly assist during generation of analogous MTB mutants. 
 
A moderate fitness cost was observed for the S531L mutant when compared with the 
wild-type strain. However, several observations suggest that more rpoBS531L cells were 
present in the competition assay, than was indicated by growth on RIF plates (see Section 
3.8). These results exemplify just how challenging evaluation of fitness is. A fundamental 
component of this project, in future, will be to develop a defined assay to evaluate fitness 
of strains generated using methodology developed in this project. An improved method 
for differentiation of wild-type and mutant strains is crucial but, as discussed previously, 
development of such system is likely to be tricky. A carbon-source specific effect was 
observed for MICRIF of wild-type strains (described in Section 3.7.6). MICRIF evaluation was 
conducted in a limited panel of MTB-relevant carbon sources, and it would be interesting 
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to expand the panel of carbon sources evaluated – perhaps using The Biolog Phenotype 
Microarray™ system.  
 
Every effort was undertaken to minimise second-site mutation during mutant generation. 
However, mutant strains were not re-sequenced and therefore the presence of second-
site mutations can’t be formally ruled out. In addition to re-sequencing of strains after 
mutant generation, strains could be sequenced at the start of, and at different time 
points, throughout a competition assay. Although technically demanding, this would 
allow elucidation of compensatory mutations, if present. Strain background can 
significantly impact the fitness costs of RIFR mutants (Gagneux et al., 2006b), and an 
exciting experiment, planned for the future, involves introduction of RIFR-associated 
mutations in defined clinical MTB strains, and using aforementioned assay systems to 
evaluate potential physiological effects.  
 
In this study we have taken the first step in characterising the physiological implications 
of RIFR-associated mutations. During this process, additional biological questions have 
been exposed, that will make for interesting and important further study. Moreover, 
novel evidence for the sufficiency of rpoB mutations for RIFR has been generated. Perhaps 
the most important outcome of this study, however, is that it generated a system 
whereby the physiological consequences of common drug resistance-associated 
mutations can be evaluated in a variety of strain backgrounds, including those that are 
clinically relevant.   
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5. Appendices 
5.1: RIFR-associated mutations included in this study 
 
Table 5.1.1 Literature reviewed to determine the frequency of RIFR
Paper 
-associated 
mutations in clinical and laboratory-derived MTB isolates 
Region 
Most 
common 
2nd most 
common 
3rd most 
common 
Most rare 
(Yuen et al., 
1999) 
Australia 
S531L 
tcg→ttg  
H526Y 
cac→tac  
D516Y 
gac→tac 
S522Q 
tcg→cag 
(Yang et al., 
1998) 
Western 
Japan 
S531L 
tcg→ttg 
H526Y 
cac→tac  
D516V 
gac→gtc  
L521L ctg→ ttg 
(Ramaswamy & 
Musser, 1998) 
Various 
S531L 
tcg→ttg  
H526Y 
cac→tac 
D516V 
gac→gtc  
N518H 
aac→cac 
(Mani et al., 
2001) 
India 
S531L 
tcg→ttg 
H526D 
cac→gac  
L511P 
ctg→ccg  
L533L ctg→ctt 
(Hwang et al., 
2003) 
Taiwan 
S531L 
tcg→ttg 
H526Y 
cac→tac 
D516V 
gac→gtc 
L533P ctg→ccg  
(Matsiota-
Bernard et al., 
1998) 
Greece 
S531L  
tcg→ttg 
H526D 
cac→gac 
H526Y 
cac→tac 
F508L  ttc→ttg  
(Williams et al., 
1998) 
Various 
(mostly USA) 
S531L 
tcg→ttg 
H526Y 
cac→tac 
H526Y 
cac→tac 
 
(Qian et al., 
2002) 
East Asian 
countries 
S531L 
tcg→ttg 
D516V 
gac→gtc  
H526Y 
cac→tac  
Q513L 
caa→cta 
(Pozzi et al., 
1999)  
Italy 
S531L 
tcg→ttg 
H526D 
cac→gac  
D516V 
gac→gtc 
 
(Gagneux et al., 
2006b) 
Euro-
American 
lineage 
S531L 
tcg→ttg 
H526Y 
cac→tac 
S522L 
tcg→ttg 
H526P 
cac→ccc 
East-Asian 
lineage 
S531L 
tcg→ttg 
H526D 
cac→gac 
  
(Ahmad et al., 
2002) 
Kuwait and 
Dubai 
S531L 
tcg→ttg  
H526D 
cac→gac  
H526D 
cac→gac 
D516V 
gac→gtc 
(Ahmad et al., 
2000) 
Middle east 
S531L 
tcg→ttg 
D516V 
gac→gtc 
H526P 
cac→ccc 
 
(Aristimuno et 
al., 2007) 
Venezeula 
S531L   
tcg→ttg 
D516V 
gac→gtc 
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Table 5.1.2 Frequency of mutations associated with RIFR in laboratory-derived RIFR 
Paper 
strains 
Strain Most 
common 
2nd most 
common 
3rd most 
common 
Most rare 
(Morlock et al., 
2002) 
H37Rv S531L 
tcg→ttg  
H526Y 
cac→tac 
S522L 
tcg→ttg 
D516V 
gac→gtc 
(Huitric et al., 
2006) 
Beijing (B) or 
Non- Beijing 
(NB) 
S531L 
tcg→ttg 
H526Y 
cac→tac 
H526P 
cac→ccc 
N519L 
aac→aag 
Non- Beijing S531L 
tcg→ttg 
H526Y 
cac→tac 
S522L 
tcg→ttg 
L533P 
ctg→ccg 
 
(Gagneux et al., 
2006b) 
Euro- 
American 
lineage 
H526Y 
cac→tac 
S531L tcg→ttg H526R 
cac→cgc 
Q513L 
caa→cta 
East- Asian 
lineage 
S531L   
tcg→ttg 
H526Y 
cac→tac 
  
(Mariam, 2004) Harlingen H526Y 
cac→tac 
S522  tcg→ttg NO rpoB 
MUTATION 
BUT 
RESISTANT 
TO >32ug/ml 
RIF 
37% 
S531W  
tcg→tgg 
MMRU (Warner 
et al., 
unpublished 
data) UV- 
induced (2008) 
South Africa 
(Various 
strains of 
MSM) 
H526Y 
cac→tac 
TH526TY 
acccac→acttac 
 S522L  
tcg→ttg  
(Billington et al., 
1999) 
A H526Y 
cac→tac  
   
B S531L  
tcg→ttg 
 
   
C H526R 
cac→cga 
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5.2 Bacterial growth media and supplements 
The recipes described below are for 1 L of media; where smaller amounts were required, 
amounts were adjusted accordingly. Unless otherwise described, all media were prepared using 
distilled sterile H2O (dsH2O) 
 
Table 5.2.1 Escherichia coli growth media  
Growth media Components 
Luria Bertani Broth (LB) 
(liquid medium for E. coli) 
10 g tryptone  
10 g NaCl  
5 g yeast extract  
1L distilled water 
Autoclave for 15 mins at 121 ˚Ca 
Luria Bertani Agar (LA) 
(solid medium for E. coli) 
10 g tryptone  
10 g NaCl 
5 g yeast extract 
15 g bacteriological agar  
1L distilled water 
Autoclave for 15 mins at 121 ˚C 
aAfter autoclaving, media were allowed to cool to 55 ˚C before addition of supplements 
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Table 5.2.2 Mycobacterium smegmatis growth media 
Growth media Components Rationale for use 
Liquid media 
Middlebrook 
7H9 Glucose-
NaCl (GS) 
4.7 g Middlebrook 7H9 (DifcoTM, USA) 
0.2 % glycerol (Merck, Germany) 
Autoclave for 15 min at 121 ˚Cb 
0.05 % tween80  
1 % GS 
Middlebrook 7H9 is regularly used 
for mycobacterial growth analysis. 
Common supplements include GS 
and OADC. Both of these 
supplements contain a sugar as the 
primary carbon source. Middlebrook 
7H9 Oleic-acid-
albumin-
dextrose 
(OADC) 
4.7 g Middlebrook 7H9 
0.2 % glycerol 
Autoclave for 15 min at 121 ˚C 
0.05 % tween80 
10 % OADC  
Middlebrook 
7H9 Valerate 
(Val) 
4.7 g Middlebrook 7H9 
0.085 % NaCl 
Autoclave for 15 min at 121 ˚C 
0.05 % tween80 
0.15 % Valerate  
0.5 % Albumin  
Work at the MMRU has recently 
shown that MTB and MSM are able 
survive on these compounds as the 
sole carbon source (Savvi et al., 
2008). Fatty acids are likely to be 
the prevalent carbon source during 
infection (Peyron et al., 2008, 
McKinney et al., 2000), and 
therefore the ability of rpoB 
mutants to utilize these compounds 
will be assessed. Valerate is an odd-
chained fatty acid (C3), and 
butyrate is an even-chained fatty 
acid (C4). Upon β-oxidation, 
oddchained fatty acids  yield 
propionyl CoA and acetyl CoA, 
while those with even chains only 
yield acetyl CoA (Savvi et al., 2008). 
The ability of rpoB mutants to 
utilize two different metabolic 
pathways can thereforebe 
assessed.  
Middlebrook 
7H9 Butyrate 
(But) 
4.7 g Middlebrook 7H9 
0.085 % NaCl 
Autoclave for 15 min at 121 ˚C 
0.05 % Tween80 
0.1 % Butyrate  
0.5 % Albumin 
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Solid media 
Middlebrook 
7H10 GS 
19 g 7H10 agar (DifcoTM, USA) 
0.5 % glycerol 
Autoclave for 15 min at 121˚Cc 
0.05 % tween80 
1% GS 
Middlebrook 7H9 is regularly used 
for mycobacterial growth analysis. 
Common supplements include GS 
and OADC. Both of these 
supplements contain a sugar as the 
primary carbon sourced. 
Middlebrook 
7H10 OADC 
19 g 7H10 agar  
0.5 % glycerol 
Autoclave for 15 min at 121˚C 
0.05 % tween80 
10 % OADC 
cAfter autoclaving, media were allowed to cool to 55˚C before addition of supplements 
d
Solid media supplemented with fatty acids s were not required for this study 
 
 
Table 5.2.3 Medium supplements 
Supplement Details Reason for use 
Nutritional supplements 
OADC 
(Beckton Dickinson, USA) 
 
0.05 % oleic acid-5 % albumin-2 % 
dextrose-0.004  % catalase 
Used as received from 
manufacturer  
Stored at 4 °C 
Supplementation for MSM 
growth media. The 
predominant carbon 
source for mycobacterial 
growth was derived from 
these compounds.  Glucose-NaCl Stock (100X) in distilled H2O 
20 %  glucose  
8.5 % NaCl   
distilled H2O 
Filter sterilised (0.22 mm 
membrane) 
Stored at 4 °C 
Valerate  
(Sigma Aldrich, USA) 
Used as received from 
manufacturer  
Stored at room temperature 
Butyrate  
(Sigma Aldrich, USA) 
Stock (10 mg/ml) in dsH2O  
Filter sterilised (0.22 mm 
membrane) 
Stored at 4 °C 
Polyoxyethylenesorbitan 
monooleate (Tween80) 
(Sigma-Aldrich, USA) 
 
Stock (100X) in dH2O 
25 % Tween80  
Filter sterilised (0.22 mm 
membrane) 
Stored at 4 °C 
Supplementation for MSM 
growth media to prevent 
cell clumping 
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Antibiotics 
Kanamycin (KAN) 
(Roche Applied Sciences, 
Germany) 
Stock (50 mg/ml) in dH2O 
Filter sterilised (0.22 mm 
membrane) 
Stored at 4 oC 
Selection of E. coli 
containing specific 
plasmids or for genetically 
manipulated MSM strains  
Hygromycin (HYG) 
(Roche Applied Sciences, 
Germany) 
Received at 50 mg/ml 
Stored at 4oC in the dark 
Ampicillin (AMP) 
(Roche Applied Sciences, 
Germany) 
Stock (100 mg/ml) prepared in 
50% ethanol 
Filter sterilised (0.22 mm 
membrane)  
Stored at –20 oC 
Rifampicin (RIF) 
(Sigma Aldrich, USA) 
Stock (100 mg/ml) in deionised 
dimethylformamide (DMF) (Sigma 
Aldrich, USA) 
Stored at 4 oC in the dark 
To determine RIF 
resistance levels of MSM 
strains 
Other selective compounds 
5-bromo-4-chloro-3-indolyl- 
β-galactoside (Xgal)  
(Bioline, USA) 
Stock (20 mg/ml stock) in 
deionised DMF 
Stored at 4 oC in the dark 
Selection of E. coli cells 
containing specific 
plasmids or for genetically  
manipulated MSM strains 
 
Sucrose  
 
Stock (25 %) in dH2O 
Stored at room temperature 
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5.3 DNA extraction solutions and DNA modifying enzymes 
 
Table 5.3.1 DNA Extraction solutions 
Solution Components 
Solutions for plasmid extraction from E. coli 
Solution I 50 mM glucose; 
25 mM Tris-HCl (pH 8) 
10 mM EDTA  
Autoclave for 10 min at 121 oC 
Stored at 4 oC 
Solution II 1% SDS  
0.2 M NaOH 
Autoclave for 10 min at 121 oC 
Stored at room temperature 
Solution III 3 M potassium acetate 
5 M acetic acid 
No autoclaving 
Stored at 4 oC 
RNase A  
(Sigma Aldrich, USA) 
Stock (10 mg/ml) made in distilled H2O 
Boil for 10 min 
Stored at -20 oC. 
Tris EDTA buffer (TE) 10 mM tris 
1 mM EDTA (pH 8.0) 
Solutions for chromosomal DNA extraction from MSM 
N-cetyl-N,N,N-trimethyl 
ammonium bromide 
(CTAB)/NaCl 
4.1 % NaCl 
10 % N-cetyl-N,N,N-trimethyl ammonium bromide  
Heat briefly at 65oC to dissolve 
Lysozyme 10 mg/ml 
Proteinase K 20 mg/ml 
DNA purification solutions 
Phenol-chloroform 1:1 v/v solution 
Chroloform-isoamyl alcohol 24:1 v/v solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 156 
 
Table 5.3.2 Restriction endonucleases
Enzymea 
a 
Buffer (10X) Recognition sequence and cleavage 
site 
AatII NEB buffer 4: 
20 mM Tris-acetate 
50 mM potassium acetate 
10 mM Magnesium Acetate 
1 mM Dithiothreitol 
pH 7.9 @ 25 °C 
5’ GACGT|C 3’ 
3’ C|TGCAG 5’  
AclI NEB buffer 4 
100 µg/ml BSA 
5’ AA|CGTT 3’ 
3’ TT  GCA|A 
Acc65I NEB buffer 3:  
50 mM Tris-HCl 
100 mM NaCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25 °C 
100 µg/ml BSA 
5’ G|GTACC 3’ 
3’ CCATG|G 5’ 
BamHI NEB buffer 3 
100 µg/ml BSA 
5’ G|GATCC 3’ 
3’ CCTAG|G 5’ 
EcoRI Any NEB buffer 5’ G|AATTC 3’ 
3’ CTTAA|G 5’ 
HindIII NEB buffer 2: 
10 mM Tris-HCl 
50 mM NaCl 
10 mM MgCl2 
1 mM Dithiothreitol 
pH 7.9 @ 25 °C 
100 µg/ml BSA 
5’ A|AGCTT 3’ 
3’ TTCGAA 5’ 
NaeI NEB buffer 4 5’ GCC|GGC 3’ 
3’ CGG|CCG 5’ 
NspI NEB buffer 2  
100 µg/ml BSA 
5’ RCATG|Y 3’ 
3’ Y|GTACR 5’ 
ScaI NEB buffer 3 5’ AGT|ACT 3’ 
3’ TCA|TGA 5’ 
aAll restriction endonucleases were obtained from New England Biolabs, USA 
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Table 5.3.3 Other DNA modifying enzymes 
Enzyme Buffer (10X) Functionality 
Antarctic Phosphatase 
(New England Biolabs, 
USA) 
Antarctic Phosphatase buffer: 
50 mM Bis-Tris-Propane-HCl 
1 mM MgCl2 
0.1 mM ZnCl2 
pH 6.0 @ 25 °C 
Removal of 5’ phosphate groups 
during cloning 
T4 DNA ligase  
(Roche Applied 
Sciences, Germany) 
Ligation buffer: 
660 mM Tris-HCl 
50 mM MgCl2 
10 mM dithioerythritol 
10 mM ATP  
pH 7.5 @ 20 ° C 
Catalyst for covalent bond formation 
between fragments during cloning 
DNA large fragment I  
(Klenow) 
NEB buffer 2 ‘Fill-in’ of overhangs generated by 
restriction digestion 
 
 
Table 5.3.4 DNA polymerases 
PCR kit Buffer  Reason for use 
FastStart Taq DNA 
PolymeraseTM  
(Roche Applied 
 Sciences, Germany) 
PCR reaction bufferTM (10X): 
500 mM Tris/HCl 
100 mM KC 
50 mM (NH4)2SO4 
20 mM MgCl2 
pH 8.3/ 25 °C 
 
GC solutionTM is useful when 
amplifying high GC content DNA 
Taq DNA polymerase does not 
have 3’ → 5’ proofreading ability, 
and therefore has an error rate of 
approximately 1.3 per 105 bases. 
This system was used for 
screening large numbers of 
colonies.  
Phusion High Fidelity 
DNA PolymeraseTM 
(New England Biolabs, 
USA) 
Phusion High Fidelity PCR bufferTM 
contains 7.5 mM MgCl2 
 
GC solutionTM is useful when 
amplifying high GC content DNA 
This polymerase has a 
significantly lower error rate of 
4.3 per 107 bases, and was 
therefore used when fidelity was 
paramount. 
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5.4 Agarose gel electrophoresis  
 
Table 5.4.1 Agarose gel electrophoresis components 
Component Details 
Agarose (Invitrogen, 
USA) 
0.3 g agarose in 30 ml TAE buffer makes a 1 % agarose gel 
Ethidium bromide 
(Invitrogen, USA ) 
Stock (10 mg/ml) made in dsH2O 
Stored at  4˚C in the dark 
Loading dye 0.3 g Bromophenol blue 
0.3 g Xylenol 
93.6 ml 80 % glycerol 
3 ml 0.5 M EDTA 
Made up to 250 ml with dsH2O 
Stored at 4 ˚C 
tris-acetate-EDTA (TAE) 
buffer 
Stock (50X) prepared as follows: 
24.2 % Tris  
5.71 % glacial acetic acid 
0.05 M EDTA (pH 8.0)  
50 X stock stored at room temperature 
1 X electrophoresis running buffer stored at  4 ˚C 
 
 
 
                      
 
 
 
 
 
 
Figure 5.1 Molecular weight marker III and V (MW III and MW V).  
MW III was used as standard marker. MW V was used to analyse small 
fragments generated during allele specific PCR. Both were supplied by Roche 
Applied Sciences (Germany). 
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5.5. Primers used in this study 
Table 5.5.1 Primers used in this study 
Name Primer seq. (5’→3’) Description 
Isolation of MSM rpoB and SDM 
WholerpoBF cccccaccaaaaagcttgtt Primers used to isolate the wild-type rpoB gene 
from the MSM chromosome. Underlined regions 
represent HindIII site in WholerpoBF and a ScaI site 
WholerpoBR.  
WholerpoBR aacttgagtactgaggcggt 
SDM outer R ttccataccggtacccacca Outer general primers used in SDM 
SDM outer F Tccttctcggatccgcgct 
S531L mut F cgtcgtcttttggcgctgggc Mutagenic primers used to introduce specified 
mutations into the megaprimer during  the first 
round of SDM 
H526Y mut F gggtctgacctacaagcgtcgt 
L521L mut F gaacaacccgttgtcgggtct  
Q513V mut F ccagctgtcggtgttcatggacca  
TH526TY mut F cgggtctgacttacaagcgtcgt 
Xover-PCR 
SDM outer R ttccataccggtacccacca Outer general primers used in Xover-PCR 
SDM outer F Tccttctcggatccgcgct 
Xover F inner Ggtctgacccacaagcgt Primers used in the first round of Xover-PCR. Xover 
F inner is used in reaction B, while Xover R inner is 
used in reaction A. The region that is homologous 
to the region down-stream from the deletion is 
underlined. 
Xover R inner acgcttgtgggtcagacc 
cgacagctggctggtgcc 
Allele-specific PCR 
AS WILD S531L acccacaagcgtcgtctttc Allele specific primers for differentiation between 
specified mutations, and the wild-type allele at 
that site. These primers differed by a single base 
pair at the 3’ end.  
AS MT S531L acccacaagcgtcgtctttt 
AS WILD H526Y Cgctgtcgggtctgaccc 
AS MT H526Y Cgctgtcgggtctgacct 
AS WILD L521L catggaccagaacaacccgc 
AS MT L521L catggaccagaacaacccgt 
AS WILD Q513V Caccagccagctgtcgca 
AS MT Q513V Caccagccagctgtcggt 
AS WILD 
TH526TY 
Cgctgtcgggtctgaccc 
AS MT TH526TY Cgctgtcgggtctgactt 
AS WT 30 bp del  
AS MT 30 bp del  
Seq F RRDR tgagctgatccagaaccaga Outer primers for standard AS-PCR (section 3.3.4); 
and primers used to isolate a smaller fragment for 
the modified version of AS-PCR (section 3.4.3). 
These primers were also used for sequencing. 
Whole R3 Tcgggcacatgcggccg 
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Sequencing primers 
Whole F Gctgggtggcgggtgga Primers used to sequence the p2rpoB template, 
and S531L and H526Y suicide vectors to check for 
any unwanted point mutations. 
Whole F1 Tcgccgagctttccccca 
Whole F2 aacaagaagctgggcctgaa 
Whole F3 caccgaggaccgcgtcat 
Whole F4 Gcgcggcatcgtccgca 
Whole F5 Ccgtacccggtgacggtt 
Whole F6 agaagatcttcggaccgact 
Whole R aagttgacgtctagcacgtaa 
Whole R1 Tggacgcccagtccggca 
Whole R2 atgatcgccacgagcaggt 
Seq R RRDR cgatgaagccgaacgggtt 
Whole R4 Ttgtaacggcccacacgg 
Whole R5 Tctcctcgccgcggtcg 
Whole R6 Ttccggccggcaccgtc 
SCO orientation 
UpOri F cccgcaacgattttcgctaa Primers set 1 (F1 and R1) used to isolate the 
upstream rpoB gene in the SCO – regardless of 
whether the mutation is present 
UpOri R  aagatcctgcccgtcgagga 
DownOri F  ctgcacgagggtcagactt Primers set 2 (F2 and R2) used to isolate the 
downstream rpoB gene in the SCO – regardless of 
whether the mutation is present 
DownOri F aagtacaagcgtgtccgctt 
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